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Organocatalysis has emerged as a powerful tool to synthesize chiral 
pharmaceutical important natural products because of its advantages in comparison 
with transition metal catalysis. Among different modes of organocatalysis, 
hydrogen-bond-mediated asymmetric catalysis has made astounding advances in the 
synthetic chemistry in the past few decades. Urea and thiourea catalysts have paved 
the way for the development of hydrogen-bonding catalysis mode in asymmetric 
organocatalysis. Although huge contributions have been made by various chiral 
scaffold based urea/thiourea catalysts, it is still highly desirable to discover novel and 
simple chiral structure scaffolds. The aim of this dissertation was to develop some 
novel and easily synthesized bifunctional indane amine-thiourea catalysts to promote 
unique enantioselective cascade reactions, resulting in assembling some densely 
functionalized privileged medicinal scaffolds. 
Chapter 1 gave a brief introduction of the enantioselective hydrogen bonding 
catalysis mediated by urea and thiourea derivatives. Various chiral scaffolds based 
urea/thiourea derivatives were successfully applied in a wide range of novel and 
particularly interesting enantioselective transformations, such as Strecker reaction, 
Michael reaction, Mannich reaction, Henry reaction, acyl-Pictect Spenger reaction, 
Morita-Baylis-Hillman (MBH) reaction, petasis-type reaction and so on.  
Chapter 2 described a surprising example of enantioselective cascade Michael–
oxa-Michael–tautomerization reaction of malononitrile and benzylidenechromanones. 
In this case, malononitrile functioned as both nucleophile and electrophile. Meanwhile, 
a simple bifunctional indane amine–thiourea catalyst was discovered to promote this 
process to afford high yields (up to 99%) and high to excellent enantiomeric excesses 
(81–99% ee). 




Chapter 3 disclosed a novel and highly stereoselective Michael–enolation–
cyclization cascade reaction catalyzed by a chiral bifunctional indane amine-thiourea 
catalyst. A broad substrate scope of chiral dihydro-2H-pyran complexes that 
contained two stereogenic centers were obtained in one-pot manner in good to 
excellent yields (72–97%) and high to excellent stereoselectivities (92–97% ee). 
Chapter 4 presented an enantioselective cascade Mannich–Intramolecular ring 
cyclization–tautomerization reaction of malononitrile with 2-hydroxyl 
N-protected-amido sulfones, which provided a novel route to the synthesis of 
privileged scaffold 2-amino-4H-chromene in high yields (up to 94%) and with good 
to high enantiomeric excesses (74–89% ee). 
Chapter 5 documented a highly efficient catalytic decarboxylative [1,2]-addition 
strategy based on readily available isatins and α-functionalized acetic acids, using a 
catalytic amount of weak base. This catalytic protocol was utilized to efficiently 
assemble important pharmaceutical 3-hydroxyoxindole natural products, such as 
(±)-flustraminol B, (±)-convolutamydine A, (±)-alline, donaxaridine, 
(±)-convolutamydine E, (±)-convolutamydine B and (±)-CPC-1.  
Chapter 6 showed a direct enantioselective decarboxylation of readily accessible 
α,β-unsaturated carbonyls and malonic acid half thioesters to furnish chiral saturated 
δ-lactones, ubiquitous bioactive o-heterocycles in nature, in high yields and high to 
excellent enantioselectivities. The synthetic utility of this strategy was demonstrated 
by the versatile ready modifications of the thiophenyl group and the applicability of 
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Chapter 1 Enantioselective Hydrogen Bonding Catalysis Mediated by 
Urea and Thiourea Derivatives 
 
1.1 Introduction of Hydrogen Bonding Catalysis 
Organocatalysis refers to the utilization of precisely designed catalysts consisting 
of carbon, hydrogen, nitrogen and other nonmetal elements to enormously accelerate 
reaction rates and effectively control various organic transformations.1,2 Because of 
its relative stability, environment friendliness, relative nontoxicity, high functional 
group tolerance, operational simplicity and ready availability, as compared with 
conventional transition metal catalysis,1,2 it has emerged as a practical and powerful 
synthetic methodology to synthesize divergent attractive biologically active building 
blocks in the past few decades. A number of novel and unprecedented organic 
transformations have been discovered in this explosively growing field of 
enantioselective organocatalysis.1,2,3 In the synthesis of natural and pharmaceutical 
products, organocatalysis can be categorized into several activation modes: amino 
catalysis, phase transfer catalysis, hydrogen-bonding catalysis, and so on. 
                                                              
1  For selected books on organocatalysis, see: a) Berkessel, A.; Groger, H. in Asymmetric Organocatalysis, Wiley, 
Weinheim 2005; b) Dalko, P. I. in Enantioselective Organocatalysis, Wiley, Weinheim, 2007; c) Reetz, M. T.; List, 
B.; Jaroch, S.; Weinmann, H. in Organocatalysis, Springer, 2007; d) List, B. in Asymmetric Organocatalysis, 
Springer, 2009. 
2  For selected reviews of asymmetric organocatalysis, see: a) Dalko, P. I.; Moisan, L. Angew. Chem. Int. Ed. 2001, 
40, 3726; b) Dalko, P. I.; Maison, L. Angew. Chem. Int. Ed. 2004, 43, 5138; c) Enders, D.; Grondal, C.; Hüttl, M. R. 
M. Angew. Chem. Int. Ed. 2007, 46, 1570; d) List, B. Chem. Rev. 2007, 107, 5413; e) Gaunt, M. J.; Johansson, C. 
C. C.; McNally, A.; Vo, N. T. Drug Discovery Today 2007, 12, 8; f) Walji, A. M.; MacMillan, D. W. C. Synlett. 
2007, 1477; g) Dondoni, A.; Massi, A. Angew. Chem. Int. Ed. 2008, 47, 4638; h) Bertelsen, S.; Jørgensen, K. A. 
Chem. Soc. Rev. 2009, 38, 2178; i) Hegedus, L. S. J. Am. Chem. Soc. 2009, 131, 17995; j) Grondal, C.; Jeanty, M.; 
Enders, D. Nat. Chem. 2010, 2, 167; k) Albrecht, Ł.; Jiang, H.; Jørgensen, K. A. Angew. Chem. Int. Ed. 2011, 50, 
8492. 
3  For selected examples of asymmetric organocatalysis, see: a) Dudding, T.; Hafez, A. M.; Taggi, A. E.; Wagerle, 
T. R.; Lectka, T. Org. Lett. 2002, 4, 387; b) Yamamoto, Y.; Momiyama, N.; Yamamoto, H. J. Am. Chem. Soc. 2004, 
126, 5962; c) Huang, Y.; Walji, A. M.; Larsen, C. H.; MacMillan, D. W. C. J. Am. Chem. Soc. 2005, 127, 15051; d) 
Yang, J. W.; Fonseca, M. T. H.; List, B. J. Am. Chem. Soc. 2005, 127, 15036; e) Marigo, M.; Schulte, T.; Franzen, 
J.; Jørgensen, K. A. J. Am. Chem. Soc. 2005, 127, 15710; f) Enders, D.; Hüttl, M. R. M.; Grondal, C.; Raabe, G. 
Nature 2006, 441, 861; g) Wang, Y.; Liu, X. F.; Deng, L. J. Am. Chem. Soc. 2006, 128, 3928; h) Wang, W.; Li, H.; 
Wang, J.; Zu, L. J. Am. Chem. Soc. 2006, 128, 10354; i) Sunden, H.; Ibrahem, I.; Zhao, G. L.; Eriksson, L.; 
Córdova, A. Chem. –Eur. J. 2007, 12, 574; j) Li, H.; Zu, L.; Xie, H.; Wang, J.; Jiang, W.; Wang, W. Angew. Chem. 
Int. Ed. 2007, 46, 3732; k) Hayashi, Y.; Okano, T.; Aratake, S.; Hazelard, D. Angew. Chem. Int. Ed. 2007, 46, 4922. 
 




Remarkably, amino catalysis has received immeasurable attention in the 
synthetic community for the past few years.4,11 The origin of amino catalysis was 
ascribable to the research studies of Emil Knoevenagel, who utilized primary and 
secondary amines to promote the aldol condensation.5 However, after the discovery 
of the important Knoevenagel reaction, the amino catalysis was not fully explored in 
the following decades. The significance of amino catalysis was not discovered until 
List and Barbas published the seminal investigations of intermolecular enamine 
catalysis in the presence of the fairly general and efficient L-proline (Scheme 1.1a).6 
The formation of nucleophilic reactive enamine, in situ generated from carbonyl 
compounds, elevated the overall energy of the highest occupied molecular orbital 
(HOMO). Almost simultaneously, MacMillan et al. reported the first enantioselective 
example of iminium catalysis strategy.7 The activated iminium ion from enal and 
imidazolidinone reacted with suitable coupling partners (nucleophiles), by lowering 
the energy of the lowest unoccupied molecular orbital (LUMO) (Scheme 1.1b). 
Subsequently, MacMillan’s research group described a novel enantioselective 
α-functionalization of aldehydes via singly occupied molecular orbital (SOMO) 
acitivation mode (Scheme 1.1c). 8  The first organocatalytic enantioselective 
γ-functionalization of α, β-unsaturated aldehydes was directly conducted through the 
formation of the dienamine intermediate (Scheme 1.1d).9a Since then, a rapid growth 
in asymmetric synthesis was witnessed based on the dienamine 9  and similar 
                                                              
4  a) List, B. Acc. Chem. Res. 2004, 37, 548; b) List, B. Chem. Commun. 2006, 819; c) see Ref. 2e; d) List, B. 
Angew. Chem. Int. Ed. 2010, 49, 1730; e) Renzi, P.; Bella, M. Chem. Commun. 2012, 48, 6881. 
5  a) Knoevenagel, E. Ber. Dtsch. Chem. Ges. 1896, 29, 172; b) Knoevenagel, E. Ber. Dtsch. Chem. Ges. 1898, 31, 
738; c) Knoevenagel, E. Ber. Dtsch. Chem. Ges. 1898, 31, 2585; d) Knoevenagel, E. Ber. Dtsch. Chem. Ges. 1898, 
31, 2596. 
6  a) List, B.; Lerner, R. A.; Barbas, C. F., III J. Am. Chem. Soc. 2000, 122, 2395. Also see: b) Notz, W.; List, B. J. 
Am. Chem. Soc. 2000, 122, 7386; c) List, B.; Pojarliev, P.; Castello, C. Org. Lett. 2001, 3, 573; d) Notz, W.; Tanaka, 
F.; Barbas, C. F., III Acc. Chem. Res. 2004, 37, 580; e) Mukherjee, S.; Yang, J. W.; Hoffmann, S.; List, B. Chem. 
Rev. 2007, 107, 5471. 
7  a) Ahrendt, K. A.; Borths, C. J.; MacMillan, D. W. C. J. Am. Chem. Soc. 2000, 122, 4243. Also see: b) Northrup, 
A. B.; MacMillan, D. W. C. J. Am. Chem. Soc. 2002, 124, 2458; c) Wilson, R. M.; Jenand, W. S.; MacMillan, D. W. 
C. J. Am. Chem. Soc. 2005, 127, 11616; d) Lelais, G.; MacMillan, D. W. C. Aldrichim. Acta. 2006, 39, 79; e) 
Erkkilä, A.; Majander, I.; Pihko, P. M. Chem. Rev. 2007, 107, 5416. 
8  Beeson, T. D.; Mastracchio, A.; Hong, J.; Ashton, K.; MacMillan, D. W. C. Science 2007, 316, 582. 
9  a) Bertelsen, S.; Marigo, M.; Brandes, S.; Dinér, P.; Jørgensen, K. A. J. Am. Chem. Soc. 2006, 128, 12973; b) 
Han, B.; He, Z. Q.; Li, J. L.; Li, R.; Jiang, K.; Liu, T. Y.; Chen, Y. C. Angew. Chem. Int. Ed. 2009, 48, 5474; c) Han, 
B.; Xiao, Y. C.; He, Z. Q.; Chen, Y. C. Org. Lett. 2009, 11, 4660; d) Bencivenni, G.; Galzerano, P.; Mazzanti, A.; 
Bartoli, G.; Melchiorre, P. PNAS, 2010, 107, 20642; e) Li, J. L.; Kang, T. R.; Zhou, S. L.; Li, R.; Wu, L.; Chen, Y. 




trienamine 10  organocatalysis. Recently, a facile and efficient oxidative enamine 
catalysis was developed independently by Wang11 and Hayashi12 (Scheme 1.1e). 
 
Scheme 1.1 Amino catalysis:11 a) enamine catalysis; b) iminium catalysis; c) SOMO 
catalysis ; d) di- and tri-enamine catalysis; e)oxidative enamine catalysis. 
                                                                                                                                                                                  
C. Angew. Chem. Int. Ed. 2010, 49, 6418; f) Ramachary, D. B.; Ramakumar, K. Eur. J. Org. Chem. 2011, 14, 2599; 
g) Parra, A.; Reboredo, S.; Alemán, José Angew. Chem. Int. Ed. 2012, 51, 9734; h) Ramachary, D. B.; Reddy, Y. V. 
Eur. J. Org. Chem. 2012, 865; i) Albrecht, Ł.; Dickmeiss, G., Acosta, F. C., Rodríguez-Escrich, C.; Davis, R. L.; 
Jørgensen, K. A. J. Am. Chem. Soc. 2012, 134, 2543; j) Li, J. L.; Zhou, S. L.; Chen, P. Q.; Dong, L.; Liu, T. Y.; 
Chen, Y. C. Chem. Sci. 2012, 3, 1879; k) Albrecht,  Ł.; Dickmeiss,  G.; Weise, C. F.; Rodríguez-Escrich,  C.; 
Jørgensen, K. A. Angew. Chem. Int. Ed. 2012, 51, 1. 
10  a) Jia, Z. J.; Jiang, H.; Li, J. L.; Gschwend, B.; Li, Q. Z.; Yin, X.; Grouleff, J.; Chen, Y. C.; Jørgensen, K. A. J. 
Am. Chem. Soc. 2011, 133, 5053; b) Jia, Z. J.; Zhou, Q.; Zhou, Q. Q.; Chen, P. Q.; Chen, Y. C. Angew. Chem. Int. 
Ed. 2011, 50, 8638; c) Jiang, H.; Gschwend, B.; Albrecht, Ł.; Hansen, A. G.; Jørgensen, K. A. Chem. Eur. J. 2011, 
17, 9032; d) Xiong, X. F.; Zhou, Q.; Gu, J.; Dong, L.; Liu, T. Y.; Chen, Y. C. Angew. Chem. Int. Ed. 2012, 51, 4401; 
e) Albrecht, Ł.; Acosta, F. C.; Fraile, A.; Albrecht, A.; Christensen, J.; Jørgensen, K. A. Angew. Chem. Int. Ed. 2012, 
51, 9088; f) Halskov, K. S.; Johansen, T. K.; Davis, R. L.; Steurer, M.; Jensen, F.; Jørgensen, K. A. J. Am. Chem. 
Soc. 2012, 134, 12943. 
11  Zhang, S. L.; Xie, H. X.; Zhu, J.; Li, H; Zhang, X. S; Li, J.; Wang, W. Nat. Commun. 2011, 2, 211. 
12  Hayashi, Y.; Itoh, T.; Ishikawa, H. Angew. Chem. Int. Ed. 2011, 50, 3920. 




In contrast to typical covalent organocatalysis (amino catalysis) which requires 
high catalyst loading, non-covalent organocatalysis just needs low catalyst loading to 
promote C–C and C–heteroatom bond formation reactions. Remarkably, hydrogen 
bond organocatalysis is considered as a broadly applicable type of non-covalent 
organocatalysis that relies on the function of explicit hydrogen bonding interactions to 
accelerate and control a wide range of chemical processes. In a hydrogen bond 
-mediated chemical reaction, weakly acidic small organic molecule incorporating 
distinct hydrogen bond motif could decrease the electron density of electrophile to 
decrease the energy of LUMO and stabilize the transition state (TS) of reaction 
intermediate resulting in lowering the energy barrier of the reaction and formation of a 
well-defined chiral environment.  
Actually, the design of small hydrogen bond donors as organocatalysts originates 
from the biological catalytic systems, such as enzymes, antibodies and 
ribonucleases.13 It is widely known that hydrogen bond donors of enzyme’s active 
sites could selectively coordinate and activate the embedded electrophiles in the wide 
range of biochemical transformations. The most notable example of electrophile 
activation by hydrogen bonding in biological processes is the serine protease that is 
responsible for the enzymatic hydrolysis of amide bonds.14 The mechanistic study of 
action of this class of enzymes has shed light on the key feature of highly active-site 
nucleophilic serine residue, which activates the amide carbonyl group by the serine 
protease “oxyanion hole” composed of double hydrogen bonding. Simultaneously, the 
serine hydroxyl group was effectively activated by a general basic histidine/aspartate 
proton shuttle system.  
                                                              
13 Schramm, V. L. Chem. Rev. 2006, 106, 3029. 
14  Wharton, C. W. In Comprehensive Biological Catalysis, vol. 1 (Ed. M. L. Sinnott), Academic Press, London, 1998. 





Scheme 1.2 Serine protease: Biological amide hydrolysis with the assistance of double 
H-bonding, multiple non-covalent catalyst-substrate interactions and bifunctional catalysis.14 
Inspired by the crucial role of hydrogen bonding in biochemical electrophilic 
activation, small well-defined H-bond donors have been developed as organocatalysts 
to accelerate reaction rates and stereocontrol the organic transformations since the 
seminal studies were performed by Hine and co-workers.15 They proposed that the 
reaction between phenyl glycidyl ether 1-2 with diethylamine 1-3 was enormously 
enhanced by 1,8-biphenylenediol 1-1 capable of synergetic donation of two identical 
strong hydrogen bonds to the oxygen atom of the electrophile compared with phenol 
(Scheme 1.3).  
 
Scheme 1.3 Epoxide opening reaction promoted by 1,8-biphenylenediol 1-1 
                                                              
15 a) Hine, J.; Ahn, K.; Gallucci, J. C.; Linden, S. M. J. Am. Chem. Soc. 1984, 106, 7980; b) Hine, J.; Linden, S. 
M.; Kanagasabapathy, V. M. J. Am. Chem. Soc. 1985, 107, 1082; c) Hine, J.; Hahn, S.; Miles, D. E.; Ahn, K. J. 
Org. Chem. 1985, 50, 5092; d) Hine, J.; Linden, S. M.; Kanagasabapathy, V. M. J. Org. Chem. 1985, 50, 5096; e) 
Hine, J.; Hahn, S.; Miles, D. E. J. Org. Chem. 1986, 51, 577; f) Hine, J.; Ahn, K. J. Org. Chem. 1987, 52, 2083; g) 
Hine, J.; Ahn, K. J. Org. Chem. 1987, 52, 2089.  




In the recent few decades, significant advances have been made in 
hydrogen-bond-mediated asymmetric catalysis. Many small H-bond donor catalysts 
have been reported which consist of various structural and functional frameworks and 
differ widely in acidities of the hydrogen donor motif spanning over 20 pKa units 
(Figure 1.1).16 According to the distinction of activation mode in the transition state, 
these catalysts could be categorized into two classes: single H-bond donors and 
double H-bond donors.16 Single H-bond donors providing only a single hydrogen 
bond, such as diols, biphenols, hydroxyl acids and phosphoric acids, are engaged to 
assemble the well-defined multidimensional catalyst-substrate complexes. However, 
compared with single H-bond donors, dual H-bond donors capable of simultaneous 
donation of two hydrogen bonds to the electrophiles, such as ureas/thioureas, 
guanidinium and amidinium ions, induce increased strength and directionality.16 They 
have emerged as a class of widely applicable and privileged organocatalysts in many 
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Figure 1.1 Approximate pKas of H-bond donor motifs in small-molecule catalysis16 
Among these double H-bond donors, urea and thiourea derivatives have been 
                                                              
16  a) Doyle, A. G.; Jacobsen, E. N. Chem. Rev. 2007, 107, 5713; Thiourea and urea: b) Bordwell, F. G.; Algrim, D. 
J.; Harrelson, J. A. J. Am. Chem. Soc. 1988, 110, 5903; Guanidinium: c) Angyal, S. J.; Warburton, W. K. J. Chem. 
Soc. 1951, 2492; Triflamide: d) Zhuang, W.; Poulsen, T. B.; Jørgensen, K. A. Org. Biomol. Chem. 2005, 3, 3284; 
Amidinium: e) Hess, A. S.; Yoder, R. A.; Johnston, J. N. Synlett 2006, 147; Alcohols: f) Olmstead, W. N.; 
Margolin, Z.; Bordwell, F. G. J. Org. Chem. 1980, 45, 3295; g) Bordwell, F. G.; McCallum, R. J.; Olmstead, W. N. 
J. Org. Chem. 1984, 49, 1424; Phosphoric acid: h) Quin, L. D. A Guide to Organophosphorus Chemistry; John 
Wiley & Sons: New York, 2000; Chapter 5, p 133. i) Nakashima, D.; Yamamoto, H. J. Am. Chem. Soc. 2006, 128, 
9626; j) Taylor, M. S.; Jacobsen, E. N. Angew. Chem. Int. Ed. 2006, 45, 1520. 




intensively investigated in the area of biological molecular recognition through 
binding to carboxylic acids, sulfonic acids, nitrates and other hydrogen-bonding 
acceptors.17 Furthermore, urea and thiourea organocatalysts play a crucial role in 
various catalytic transformations through stabilization of the electrophiles, tetrahedral 
intermediates and anionic fragments by explicit double H-bond interactions, owing to 
their advantages, no product inhibition, high Turn-Over-Frequency (TOF), low 
catalyst loading, relative stability, acid-labile substrate tolerance, operational 
simplicity and ready availability.18 So many groups have paid huge attention to the 
utilization of properly developed urea and thiourea derivatives in many 
non-asymmetric and enantioselective reactions. Among these studies, seminal 
investigations by Kelly and Etter inspired the impressive development of achiral urea 
catalysts. Kelly and co-workers reported that acidic bisphenol 1-5 could accelerate 
Diels-Alder reactions.19 Subsequently, Etter and co-workers recognized the ability of 
electron-deficient diaryl ureas 1-6 to form cocrystals with a variety of proton 
acceptors such as carbonyl compouds.20 In 1994, the first example of achiral urea 
catalyst was reported by Curran and Kuo that a Lewis acid, diarylurea 1-7 could alter 
the rate and stereochemical outcome of the allylation reactions of cyclic sulfinyl 
radicals with allyltributylstannane.21 Since then, Many groups have reported the 
utilization of various effective chiral scaffolds based urea and thiourea catalysts in 
diverse enantioselective transformations. 
 
Figure 1.2 Seminal investigations of urea derivatives19,20,21 
                                                              
17  Takemoto, Y. Org. Biomol. Chem. 2005, 3, 4299. 
18 Kotke, M.; Schreiner, P. R. Synthesis 2007, 5, 779. 
19  Kelly, T. R.; Meehani, P.; Ekkundi, V. S. Tetrahedron Lett. 1990, 31, 3381. 
20  a) Etter, M. C. Acc. Chem. Res., 1990, 23, 120; b) Etter, M. C.; Urbanzyk-Lipkowska, Z.; Zia-Ebrahimi, M.; 
Panunto, T. W. J. Am. Chem. Soc., 1990, 112, 8415. 
21  Curran, D. P.; Kuo, L. H. J. Org. Chem. 1994, 59, 3259. 




The following sections of this chapter will reveal the applications of different 
chiral scaffold-based urea and thiourea catalysts in diverse fantastic enantioselective 
transformations to afford densely functionalized and synthetically useful chiral 
building blocks. Focus will be given to various classic well-known reactions, such as 
Strecker reaction, Michael reaction, Mannich reaction, Morita-Baylis-Hillman (MBH) 
reaction, Friedel-Craft alkylation, Henry reaction, as well as dynamic kinetic 
resolution. Furthermore, some novel cascade reactions will also be depicted under the 
catalysis of bifunctional urea/thiourea derivatives, incorporating Lewis base 
functionalities on chiral scaffolds, which are responsible for creating a well-defined 
chiral environment for both the acceptors and donors. Non-stereoselective 
urea/thiourea catalysis is beyond the scope of this thesis owing to the absence of 
optical activity of the final products. 
 
1.2 Enantioselective Reactions Catalyzed by (Thio)Urea Derivatives 
1.2.1 The Strecker Reaction 
The Strecker reaction, firstly documented by the German chemist Adolph 
Strecker in 1850, is a series of well-known economical chemical reactions which 
combine an aldehyde, ammonium chloride and potassium cyanide to form an 
α-aminonitrile.22 Subsequently, α-aminonitriles could be hydrolyzed to obtain the 
privileged α-amino acids. Although the arguments for the mechanism of the Strecker 
reaction arose between the cyanohydrin pathway and the imine pathway around early 
20th century,23 control experiments and kinetic studies proved the rate-determining 
step (RDS) is imine formation.24 Firstly, protonation of the carbonyl oxygen is 
followed by a nucleophilic attack of ammonia to afford the ammonium salt 1-10. 
Subsequently, proton transfer and dehydration could synthesize the iminium ion 
                                                              
22 a) Strecker, A. Ann. Chem. Pharm. 1850, 75, 27; b) Strecker, A. Ann. Chem. Pharm. 1854, 91, 349. 
23 a) Stadnikoff, G. Ber. 1907, 40, 1014; b) Stadnikoff, G. J. Russ. Phys. Chem. Soc. 1914, 46, 1201; c) Snyesarev, 
A. P. J. Russ. Phys. Chem. Soc. 1914, 46, 217. 
24  a) Ogata, Y.; Kawasaki, A. J. Chem. Soc. B 1971, 325; b) Taillade, J.; Commeyras, A. Tetrahedron 1974, 30, 
2493. 




intermediate 1-12, which acts as a reactive electrophile to react with the cyanide anion 
yielding the α-aminonitrile 1-13 (Scheme 1.4). Since the pioneering studies, the 
Strecker reaction gradually captured much attention of many research groups in both 
organic and biological chemistry, because it could afford a facile, robust and powerful 
method to synthesize various natural and non-natural α-amino acids from easily 
available simple starting materials. 25  Besides, α-aminonitriles also could be 
functionalized as valuable iminium ion equivalents after elimination of a cyanide 
anion to afford a series of natural pharmaceutical products.26  
 
Scheme 1.4 Mechanism of the typical Strecker reaction. 
Inspired by the initial nonasymmetric methodologies, in recent decades, 
considerable progress has been achieved in the development of asymmetric versions 
of the Strecker reaction to obtain enantiomerically pure α-aminonitriles assisted by 
stoichiometric amounts of chiral auxiliaries or chiral catalysts.27 Among these various 
methodologies, urea and thiourea derivatives provide a concise and powerful 
approach which serves as an essential complement to other chiral transition-metal 
complex catalysts and organocatalysts.27 
In 1998, the Jacobsen group demonstrated the first Schiff-base thiourea catalyst 
promoted enantioselective Strecker reaction.28 Actually, this landmark work paved 
the way for the rapid development of organocatalysis mediated by urea/thiourea 
derivatives in a wide range of biological enantioselective transformations. In the 
                                                              
25  a) Najera, C.; Sansano, J. M. Chem. Rev. 2007, 107, 4584; b) Soloshonok, V. A.; Izawa, K.; Eds. Asymmetric 
Synthesis and Application of R-Amino Acids; American Chemical Society: Washington, DC, 2009. 
26  a) Enders, D.; Shilvock, J. P. Chem. Soc. Rev. 2000, 29, 359; b) Opatz, T. Synthesis 2009, 1941.  
27  a) Merino, P.; Marques-Lopez, E.; Tejero, T.; Herrera, R. P. Tetrahedron 2009, 65, 1219; b) Wang, J.; Liu, X. H.; 
Feng, X. M. Chem. Rev. 2011, 111, 6947. 
28  Sigman, M. S.; Jacobsen, E. N. J. Am. Chem. Soc. 1998, 120, 4901.  




presence of Schiff base thiourea catalyst 1-14, N-allyl aldimines 1-15, derived from 
both aromatic and aliphatic aldehydes, reacted with HCN 1-16 in toluene to construct 
the respective trifluoroacetylated Strecker adducts 1-17 in good yields (65-92 %) and 
enantioselectivities (70-91 %) (Scheme 1.5).  
 
Scheme 1.5 Thiourea-catalyzed asymmetric Strecker reaction (First-Generation Catalyst) 
The concept of the catalyst design originated from the initial research object to 
develop a potential tridentate chiral ligand for organometallic catalysis.28,29 Based on 
the results of parallel screening and conventional linear optimization, 
polystyrene-bound 1-18 was identified as the optimal catalyst in terms of best 
enantioselectivity which was higher than metal-containing alternatives evaluated 
under otherwise identical conditions. On the basis of the core structural features of 
polystyrene-bound 1-18, the Jacobsen group incorporated three important components 
into this practical Schiff base thiourea derivative 1-14, (1R, 2R)-diaminocyclohexane 
unit as a chiral backbone, α-amino acid unit (L-tert-Leucin) as a chiral diverse 
function, salicylaldimine unit as a sterically demanding function. Experimental results 
conceived these components as crucial elements for the formation of precise chiral 
environment in the transition state.  
 
Figure 1.3 The key features of Schiff base thiourea catalyst 1-14 and polystyrene-bound 1-18.  
                                                              
29  Yu, X. H.; Wang, W. Chem. Asian J. 2008, 3, 516. 




Four years later, this assumption was proved by a mechanistic study based on 
NMR, structure-activity, kinetic and theoretical analysis. This study revealed that high 
catalytic activity could be ascribed to the thiourea group which coordinated and 
activated the imine (Z)-isomer via an explicit dual H-bond interaction with the lone 
pair of imine nitrogen. This well-defined chiral environment could largely minimize 
the steric interactions between the large imine substitute and the thiourea moiety 
(Figure 1.4).30 
                           
Figure 1.4 Dual H-bond interaction in the thiourea-catalyzed enantioselective Strecker 
reaction 
In view of the vital structure of catalyst 1-18, further optimization of a new 
parallel library revealed that both the polymer-bound catalyst 1-19a and 
non-immobilized urea analogue 1-19b could be employed for the direct construction 
of diverse unnatural aromatic and aliphatic substituted α-aminonitriles 1-17 in high 
yields and enantiomeric excesses (Scheme 1.6). Remarkably, the utilization of 
resin-bound catalyst 1-19a could simplify the purification process by simple filtration 
and solvent removal. Moreover, the catalytic activity and enantio induction of 1-19a 
still remained even after over ten times recycles.31  
Scheme 1.6 Asymmetric Strecker reaction catalyzed by Schiff base thiourea catalysts 1-19 
In addition to the successful applications of Schiff base thiourea catalysts in the 
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Strecker reaction of N-aldimines, Jacobsen and co-workers also expanded this 
reaction substrate scope to ketoimines. The first highly enantioselective Strecker 
reaction of HCN to ketoimines 1-20 was described to construct α-quaternary α-amino 
acid precusors 1-21 in the presence of readily available and recyclable Schiff base 
catalyst 1-19b in quantitative isolated yields and up to 95% enantioselectivities 
(Scheme 1.7).31 Furthermore, the authors documented a concise and effective 
formylation/hydrolysis sequence to convert the α-quaternary α-aminonitrile adducts 
1-21 to the respective α-quaternary α-amino acids in high yields (for example, 
α-methyl phenylglycine 1-25, Scheme 1.8).32  
 
Scheme 1.7 Asymmetric Strecker reaction of HCN to ketoimines 1-20. 
Scheme 1.8 The synthesis of α-methyl phenylglycine 1-25. 
Due to the extremely high toxicity and volatility of the problematic HCN, List 
and coworkers replaced it with commercially available liquid reagent acetyl cyanide 
1-28 as the cyanide source in the highly enantioselective acyl-Strecker reaction.33 
The Jacobsen catalyst 1-26 turned out to be an efficient and practical organocatalyst to 
promote the acetylcyanation of diverse N-benzyl aliphatic and aromatic aldimines 
1-27 in moderate to high yields and excellent enantioselectivities (Scheme 1.9). 
Furthermore, the desired N-protected α-aminonitriles 1-29 could be readily converted 
into the corresponding α-amino acid salts without erosion of enantioselectivities 
through acid-mediated hydrolysis and hydrogenolysis. Subsequently, the List group 
                                                              
32  Vachal, P.; Jacobsen, E. N. Org. Lett. 2000, 2, 867. 
33  Pan, S. C.; Zhou, J.; List, B. Angew. Chem. Int. Ed. 2007, 46, 612. 




further developed this methodology to the first asymmetric variant of 
three-component Strecker reaction in the presence of the same Jacobsen thiourea 
catalyst 1-26. This one-pot highly economic reaction of aldehydes, amines, and acyl 
cyanides actually provided an attractive approach to construct different α-amino acid 
precusors.34  
Scheme 1.9 Catalytic asymmetric acylcyanation of aldimines 1-27. 
In the same year, Kunz et al. designed and synthesized an efficient organic 
thiourea catalyst 1-30 incorporating a readily accessible chiral monosaccharidic 
backbone for the efficient asymmetric Strecker and Mannich reactions (Scheme 
1.10).35 In the presence of this catalyst, the Strecker reactions of a variety of aromatic 
N-allyl aldimines 1-15 and TMSCN 1-31 as cyanide source were accomplished in 
good to excellent yields (72-98%) and moderate to excellent enantioselectivities 
(69-95%). The powerful enantioinduction of catalyst 1-30 was considered to be 
ascribed to the restriction on the conformational flexibility of the common 
monosaccharidic backbone. 
Scheme 1.10 Catalytic asymmetric acylcyanation of aldimines 1-15. 
Another significant progress in the urea/thiourea derivatives catalyzed Strecker 
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reactions was reported by the Jacobsen group in 2009.36 The authors designed and 
synthesized a simple and robust chiral amido-thiourea catalyst 1-32 without sensitive 
functional groups, which was compatible with safer and cheaper aqueous KCN salts 
compared with other hazardous cyanide sources. This catalyst was proved to be 
effective in the hydrocyanation of N-protected imines 1-33 derived from aryl, 
heteroaryl, alkyl and alkenyl aldehydes affording excellent enantioselectivities in the 
presence of 0.5 mol% catalyst loading under mild reaction conditions. The 
particularly attractive point of this methodology was its adaptability to large-scale 
synthesis of highly enantiomerically enriched natural and non-natural α-amino acids 
in one or two steps. The tert-butoxycarbonyl protected α-amino acids 1-35 were 
afforded from corresponding α-aminonitriles 1-34 through a two-step sequence 
involving H2SO4/HCl mediated hydrolysis and treatment with di-tert-butyl 
dicarbonate (Boc2O). 
 
Scheme 1.11 Potassium cyanide-mediated Strecker synthesis catalyzed by chiral 
amido-thiourea catalyst 1-32. 
Authors also studied the detailed mechanism of this Strecker reaction through 
spectroscopic, labeling, kinetic and computational experiments.37 The study of these 
experiments had shed light on a novel and unexpected mechanism involving 
formation of an iminium/cyanide ion pair that coordinated the catalyst through 
multiple non-covalent interactions rather than direct activation of the aldimine’s 
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nitrogen through explicit double hydrogen bonding interactions. The proposed 
mechanism began with the coordinating of HNC, existing in equilibrium with HCN, 
to the thiourea moiety of the catalyst, followed by protonation of aldimine to form the 
key iminium-cyanide ion pair. In this catalyst-iminium-cyanide complex 1-37, the 
amide carbonyl also provided one H-bond interaction to stabilize the iminium 
component. Subsequently, rotated cyanide anion attacked the iminium to yield the 
final α-aminonitrile 1-34 with concurrent release of the elegant organocatalyst 1-32 
(Scheme 1.12).  
 
Scheme 1.12 Proposed mechanism of the Strecker reaction catalyzed by amino-thiourea 
catalyst 1-32.  
1.2.2 The Michael Reaction 
As a powerful and efficient catalytic C–C or C–X bond formation reaction, the 
Michael reaction represents one of the most interesting and challenging fields in 
organic synthesis. It represents an important and atom-economic nucleophilic addition 
of enolate equivalents to Michael acceptors resulting in increasing complexity and 
structural diversity of the final products’ carbon skeletons. A number of asymmetric 




Michael additions to α,β-unsaturated carbonyl compounds have been reported in the 
presence of chiral organocatalysts.38 It is noteworthy that a variety of compounds 
could operate as Michael donors, such as 1,3-diketones, β-ketoesters, malonates, 
malononitrile, α-nitro esters. These active methylenes are usually adjacent to 
electron-withdrawing groups which could increase the methylenes’ acidity and 
stabilize the carbanion derived from the deprotonation of methylenes by base. 
Moreover, many activated alkenes constantly act as acceptors in typical Michael 
reactions, such as nitroalkenes, enones, enals, unsaturated imides, ynones, chalcones, 
maleimides, quinones and so on.  
The first asymmetric Michael addition catalyzed by thiourea derivatives was 
documented by Takemoto group in 2003.39 By the catalysis of the bifunctional amine 
thiourea organocatalyst 1-39, a range of aromatic and aliphatic nitroalkenes 1-40 
reacted with diethyl malonate 1-41 to afford the addition product nitroalkanes 1-42, 
which possessed the versatility in further synthetic manipulation to other important 
organic functional groups, in yields ranging from 74-95% and with 81-93% ee values 
(Scheme 1.13).  
Scheme 1.13 First enantioselective Michael addition catalyzed by Takemoto’s bifunctional 
thiourea catalyst 1-39.   
Remarkably, it was the pioneering report about the design and synthesis of the 
bifunctional organocatalyst 1-39, which bore a tertiary amine group, a thiourea moiety 
and a 1,2-trans diamine chiral scaffold. Actually, the concept of bifunctionality 
principle originated from highly catalytic natural enzymic systems, for example, 
serine protease. Furthermore, inspired by the catalyst design principles in the seminal 
work of Curran, Jacobsen and Schreiner, the Takemoto group utilized the key features 
                                                              
38  a) see Ref. 1a; b) see Ref. 1b. 
39  Okino, T.; Hoashi, Y.; Takemoto, Y. J. Am. Chem. Soc. 2003, 125, 12672. 




of biological H-bonding organocatalysis to develop a novel bifunctional thiourea 
catalyst. Through mimicking the “oxyanion hole” and histidine/aspartate proton 
shuttle system, the bifunctional organocatalyst respectively incorporated the 
corresponding thiourea moiety and base functionality into the chiral scaffold (1R, 
2R)-diaminocyclohexane (Figure 1.5). The thiourea moiety donated explicit double 
H-bond to coordinate and activate the electrophile component, whereas the Brønsted 
basic functionality simultaneously activated the nucleophile resulting in higher rate 
enhancement and stereoinduction, in contrast with comparable monofunctional 
thiourea organocatalyst.39, 40  The synthesis of this excellent Takemoto catalyst 
(bifunctional amine thiourea derivative 1-39) triggered the rapid development of 










































b) Bifunctional activation mode of Takemoto
thiourea organocatalyst
Figure 1.5 Comparison of activation modes between H-bond biocatalysis and bifunctional 
organocatalysis.  
Subsequently, in 2005, the Takemoto group elucidated the plausible reaction 
mechanism according to the results of kinetic and catalyst modification studies 
(Scheme 1.14).41 The six-membered enol form of diethyl malonate 1-41a was firstly 
stabilized through H-bond interaction with the amino moiety of Takemoto catalyst 
1-39. Subsequently, the Michael acceptor trans-β-nitrostyrene 1-40a reacted with the 
thiourea moiety of complex 1-43 through explicit double H-bond interactions 
resulting in the formation of a new ternary complex 1-44. On the basis of the elegant 
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steric organization and proper relative organization of the reaction components, 
diethyl malonate 1-41a attacked the β position of trans-β-nitrostyrene 1-40a in a 
(R)-favored mode to form the nitronate complex 1-44. This nitronate complex 1-44 
was effectively stabilized through explicit dual H-bonds between the two amide 
protons and the two negatively charged oxygens of the nitro group. Finally, proton 
transfer from the ammonium group of the catalyst to the nitronate afforded the final 
Michael adduct. This study also demonstrated that various β-ketoesters and 
α-substituted β-ketoesters were compatible with this methodology with good to 
excellent diastereoselectivities and enantioselectivities. Furthermore, the synthetic 
utility of this protocol was shown by the vital step of the total synthesis of 
(R)-(–)-baclofen (Scheme 1.15), a widely acceptable antispastic agent.  
 
Scheme 1.14 Proposed mechanism of the first enantioselective Michael addition catalyzed by 
Takemoto’s bifunctional amine thiourea organocatalyst 1-39. 
Scheme 1.15 Total synthesis of (R)-(–)-baclofen. 
Compared with the Takemoto proposed dual activation mode, Papai et al. 
elucidated an alternative mechanistic insight of this reaction by using the in silico 




study.42 In their proposed dual activation mode 1-48 (Scheme 1.16), the Michael 
acceptor trans-β-nitrostyrene 1-40a preferred to coordinate the generated ammonium 
group through single H-bonding interaction, while the enolate was H-bonded to the 
thiourea moiety of the catalyst. Although the activation mode was distinct from the 
above mentioned activation mechanism, both of them predicted the same 
stereochemistry. 
 
Scheme 1.16 DFT-calculated dual activation mode 1-48.  
In order to expand the synthetic utility of the Takemoto amine thiourea catalyst 
1-39, the Takemoto group further demonstrated the first enantioselective Michael 
addition of the highly acidic malonitrile 1-50 to α,β-unsaturated imides 1-49.43 As 
depicted in Scheme 1.17, the pyrrolidinone moiety of α,β-unsaturated imides 1-49 
played a crucial role in the formation of explicit dual H-bond interaction in the ternary 
complex 1-52. In addition, the lability of pyrrolidinone moiety revealed the feasibility 
of the general transformation of Michael adducts 1-51 to esters, aldehydes and 
carboxylic acids.  
 
Scheme 1.17 Asymmetric Michael reaction of malononitrile to α,β-unsaturated imides 1-49. 
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Apart from malonates and malonitrile, α-substituted cyanoacetates 1-54 
incapable of providing two strong H-bond binding sites were still demonstrated by the 
Chen group to be applied in the Takemoto bifunctional amine thiourea catalyzed 
enantioselective Michael addition.44 A wide range of α-aryl or alkyl cyanoacetates 
1-54 reacted with vinyl ketones 1-53 resulting in constructing multifunctional 
compounds α,α-disubstituted cyanoacetates 1-55 with a configurationally stable 
quaternary stereocenter in moderate to excellent yields (61-99%) and 
enantioselectivities (82-97% ee). The enantiopure α,α-disubstituted cyanoacetates 
1-55 could be smoothly converted to various optical pure β2,2-amino acids, which 
were important unique pharmacological entities in natural products. Based on the 
experimental and computational studies, the authors proposed an interesting reaction 
model 1-56 that tertiary amine thiourea catalyst 1-39 synergistically activated the 
nucleophile and electrophile through multiple hydrogen-bonding interactions. 
 
Scheme 1.18 Asymmetric Michael reaction of α-substituted cyanoacetates 1-54 to vinyl 
ketones 1-53.  
To expand the scope of Michael donors, Huang and Jacobsen further modified 
the monofunctional Jacobsen thiourea catalyst to develop a novel bifunctional primary 
amine thiourea catalyst 1-57, which incorporated a primary amine moiety to replace 
the Schiff base unit. This highly enantioselective catalyst was particularly efficient for 
the conjugate addition of various aromatic or aliphatic nitroalkenes 1-40 to a wide 
variety of ketones 1-58 with up to 99% ee values and good-to-excellent 
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diastereoselectivities. In this reaction, the bifunctional organocatalyst synergetically 
activated both the electrophile, by H-bonding interaction between thiourea moiety and 
nitro group, and the nucleophile by forming a Z-enamine intermediate (Scheme 
1.19).45 
 
Scheme 1.19 Direct Michael addition of ketones 1-58 to nitroalkenes 1-40 catalyzed by 
primary amine thiourea catalyst 1-57.  
Scheme 1.20 Direct Michael addition of α,α-disubstituted aldehydes 1-62 to nitroalkenes 1-40 
catalyzed by primary amine thiourea 1-61. 
In addition to the above mentioned ketones, α,α-disubstituted aldehydes 1-62 
were also compatible with direct and most appealing approach to afford versatile 
multifunctional nitroalkanes 1-63 in high yields, excellent enantioselectivities and 
syn-favored diastereoselectivities in the presence of the primary amine thiourea 
catalyst 1-61.46 In the author’s proposed mechanism, the thermodynamically favored 
(E)-enamine was responsible for syn-favored diastereoselectivity. The explicit double 
H-bonding interaction between thiourea motif and only a single oxygen atom of 
nitroalkenes facilitated the close proximity of the enamine to a variety of aromatic and 
aliphatic nitroalkenes 1-40. The addition of 5 equiv. water accelerated the final imine 
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hydrolysis and effected the initial imine formation.  
Since impressive progress has been made by tertiary amine and primary amine 
thiourea organocatalysts, the Tang group paid attention to develop a novel 
bifunctional secondary amine thiourea organocatalyst 1-65, combining the pyrrolidine 
and thiourea functionalities in the well-designed chiral skeleton.47 In the presence of 
20 mol % of catalyst 1-65 and 10 mol % of n-butyric acid, cyclohexanone 1-66 
reacted with both aryl and alkyl nitroolefins 1-40 to furnish Michael adducts 1-67 
with high enantio- and diastereoselectivities (Scheme 1.21). As shown in the proposed 
stereochemical model 1-68, the pyrrolidine moiety firstly reacted with the carbonyl 
group of cyclohexanone 1-66 to form an enamine, while the thiourea motif of the 
catalyst donated the explicit double H-bond to activate the nitroolefin. The generated 
enamine attacked the activated nitroolefin from the re-face in a rigid chiral 
environment, which accounted for the stereochemistry of the final adduct 1-67, as 
well as high enantioselectivity and high diastereoselectivity. 
 
Scheme 1.21 Asymmetric Michael reaction promoted by chiral pyrrolidine thiourea 1-65 and 
the stereochemical model 1-68.   
Cinchona alkaloids isolated from the bark of trees in the cinchona genus could 
act as especially useful pharmaceutical agents in the treatment of various diseases. 
They combine a secondary hydroxyl group at C-9 position and a basic quinuclidine 
moiety in a well-defined chiral environment. On the basis of their structural tunability 
and ready availability, a series of natural cinchona alkaloids (Figure 1.6) and their 
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analogues have been applied in a broad range of organic transformations as chiral 
auxiliaries, as chiral ligands in transition metal mediated processes, and as phase 
transfer catalysts and organocatalysts.48  
 
Figure 1.6 Various natural cinchona alkaloids.  
The pioneering work of cinchona alkaloids’ asymmetric induction, reported by 
Wynberg and coworkers in 1981, demonstrated that the sulfa-Michael addition 
reactions of aromatic thiols to cycloalkenones could be promoted by catalytic amount 
of unmodified natural QN, QD, CD, CN. 49  The rate enhancements and 
enantioselectivities conducted by natural cinchona alkaloids were higher than those of 
C9-OH acylated cinchona alkaloid derivatives, which implied the potential 
application of cinchona alkaloids as bifunctional catalysts. They provided a plausible 
dual activation mode through H-bonding from the C-9 OH group and deprotonation 
from the basic quinuclidine motif.  
In view of the dual activation mode of natural cinchona alkaloids, four groups 
independently modified and developed these catalysts by incorporating privileged 
urea/thiourea moieties, better H-bond donors, to substitute the C-9 hydroxy group 
with or without inversion of C9 configuration. In addition, the C'-6 position could also 
be modified by combining a rigid 3,5-bis(trifluoromethyl)phenyl-thiourea component, 
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while the C9-OH group was revised to an ether or ester. These variable modifications 
enhanced the catalytic activity and influenced the relative stereochemistry between 
Brønsted acidic and Brønsted basic groups. On account of these advantages benefited 
from modifications on chiral scaffolds, (thio)urea-substituted cinchona alkaloid 
derivatives have emerged in the last eight years as elegant, robust and tunable 
bifunctional organocatalysts in extensive synthetically useful transformations.50  
The first synthesis and application of thiourea-substituted cinchona alkaloids 
were reported by Chen and co-workers. They revealed that the thiourea substituted 
cinchonidine and cinchonine-derived bifunctional catalysts 1-69 and 1-70 respectively 
catalyzed the sulfa-Michael addition of thiophenol 1-72 to α,β-unsaturated imide 1-71 
with high efficiency (99% yield/2h), but low enantioselectivity (7% or -17% ee) 
(Scheme 1.22).51 
 
Scheme 1.22 The first report of thiourea-substituted cinchona alkaloid catalyzed 
sulfa-Michael addition. 
Subsequently, a significant breakthrough in this field was made by Soós and 
co-workers in the same year. 52  They developed a suite of thiourea-substituted 
quinine/quinidine-derived cinchona alkaloid catalysts 1-74 – 1-77 (Scheme 1.23) in 
the nitro-Michael addition of nitromethane 1-79 to chalcone 1-78. Surprisingly, the 
bifunctional thiourea derivative with natural stereochemistry at C-9 (i.e. 1-74) showed 
no catalytic activity, while its epimers (1-75) exhibited high activity (71% yield) and 
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excellent enantioselectivity (95% ee). So the relative orientation of thiourea and 
quinuclidine moiety played a crucial role in the catalysis. It was notable that the 
system operated via a bifunctional synergistic activation mechanism. 
 
Scheme 1.23 Organocatalysis of the nitro-Michael addition of nitromethane to chalcone. 
Subsequently, the Connon group53 and Dixon group54 demonstrated that the 
typical asymmetric Michael reaction of dimethyl malonate 1-41b to nitroalkenes 1-40 
could be promoted by their independently developed similar (thio)urea 
organocatalysts derived from by the corresponding DHQ/DHQD (Scheme 1.24) or 
CN (Scheme 1.25) backbones with excellent catalytic activities and 
enantioselectivities.  
 
Scheme 1.24 The typical Michael addition catalyzed by thiourea-substituted DHQ 1-76. 
 
Scheme 1.25 The typical Michael addition catalyzed by cinchonine-derived thiourea 1-70. 
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Based on the catalytically privileged axially chiral binaphthyl scaffold55, Wang et 
al. designed a new class of bifunctional tertiary amine thiourea catalysts prepared 
from commercially available (R)-binaphthyl amine.56 In the presence of binaphthyl 
thiourea catalyst 1-81, the asymmetric typical Michael reactions between 1,3-diketone 
1-82 and nitroolefins 1-40 bearing electron-donating and electron-withdrawing 
substituents on aryl group were carried out at room temperature to furnish the desired 
Michael adducts 1-83 (Scheme 1.26). It was worth noting that a synthetically useful 
protocol was developed with the Michael adducts 1-83 as starting materials to form 
valuable α-substituted-β-amino acids 1-86. Similar with Takemoto catalyst’s 
activation mode, binaphthyl thiourea catalyst was expected to simultaneously 
coordinate and stabilize both the enolized 2,4-pentandione and nitroolefins through 
the basic amine moiety and thiourea motif.  
 
Scheme 1.26 The typical Michael reactions catalyzed by binaphthyl-derived thiourea 1-81. 
 
Scheme 1.27 The synthetic utility of 1-81 catalyzed Michael reaction.  
Apart from the typical Michael addition for C–C bond formation, aza-, sulfa- and 
oxa- Michael addition for new C–N, C–S and C–O bond formation also captured 
much attention of many research groups to construct particularly useful heteroatom 
compounds. Particularly, the aza-Michael addition was considered as the most direct 
and atom-economic approach to access valuable nitrogen-containing compounds with 
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broad synthetic utility and application in organic and medicinal chemistry. In the 
presence of catalytic amount of quinine-derived thiourea 1-75, enantioselective 
aza-Michael reaction of 1H-benzotriazole 1-88 as a nitrogen source was accomplished 
(Scheme 1.28).57 A variety of α,β-unsaturated ketones 1-87 were well tolerated in this 
protocol to form the desired products in moderate to good yields (51-85%) and 
moderate enantioselectivities (55-64%). The quinine-derived thiourea 1-75 
simultaneously activated the enones 1-87 through double hydrogen-bonding and 
1H-benzotriazoles 1-88 by amine-group mediated deprotonation.  
 
Scheme 1.28 The aza-Michael addition catalyzed by quinine-derived thiourea 1-75. 
Although the sulfa-Michael addition reaction catalyzed by the cinchonidine/ 
cinchonine thiourea derivatives failed to demonstrate good catalytic activities and 
enantioselectivities, Chen and co-workers reported that the Takemoto catalyst 1-39 
based on a more rigid skeleton of chiral 1,2-cyclohexanediamine could efficiently 
promote the asymmetric sulfa-Michael addition of arenethiols 1-72 to 
2-cycloalkenones 1-90 and α,β-unsaturated N-benzoyl imides 1-71 with up to 85% ee 
value.58  
 
Scheme 1.29 The sulfa-Michael addition catalyzed by Takemoto catalyst 1-39. 
                                                              
57  Wang, J.; Zu, L.; Li, H.; Xie, H.; Wang, W. Synthesis, 2007, 2576. 
58  Li, B. J.; Jiang, L.; Liu, M.; Chen, Y. C.; Ding, Li. S.; Wu, Y. Synlett 2005, 4, 603. 




The enantioselective oxa-Michael reaction 59  of functionalized aliphatic 
nitroalkenes 1-40 with ethyl glyoxylate oxime 1-92 as oxygen source was conducted 
as well in the presence of 5 mol% quinine-derived thiourea catalyst 1-75 to obtain the 
final optically active aliphatic nitro- or aminoalcohols 1-93 (Scheme 1.30).60 In the 
plausible transition model, the oxime was activated by single hydrogen-bonding with 
basic quinuclidine nitrogen atom, while the Michael acceptor was coordinated and 
activated by double hydrogen-bonding with the C9-thiourea motif. The synthetic 
utility of this approach was demonstrated by selective cleavage of O-N bond to 
furnish the corresponding enantiopure N-Boc protected amino alcohol (1. H2/Pd/C; 2. 
(Boc)2O) or (R)-configured β-hydroxy nitroalcohol (ZrCl4/NaBH4/THF). 
 
Scheme 1.30 The oxa-Michael addition catalyzed by quinine-derived thiourea 1-75.  
Furthermore, an unprecedented intramolecular oxa-Michael addition reaction 
was described by the Flack group to accomplish the β-hydroxylation of 
hydroxyl-enone substrates 1-94.61 Under the catalysis of a push/pull bifunctional 
quinine-derived thiourea 1-75, a variety of γ-hydroxy-α,β-enones and 
δ-hydroxy-α,β-enones 1-94 reacted with phenylboronic acid 1-95 to generate boronic 
acid hemiesters 1-97 in situ, which attacked the β-position of enones to furnish the 
chiral target diols 1-96 after mild oxidative work-up with high yields and excellent 
enantioselectivities. As depicted in Scheme 1.31, the complexation between the 
tertiary nitrogen with boron atom (push effect) and the hydrogen-bonding 
coordination between the carbonyl group with the thiourea motif (pull effect) 
synergistically increased the nucleophilicity of the boronate oxygen and created a 
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well-defined chiral environment, which accounted for the excellent enantioselectivity 
of this intramolecular oxa-Michael reaction. 
 
Scheme 1.31 The intramolecular oxa-Michael addition of hydroxyl-enone substrates 1-94. 
 
1.2.3 The Mannich Reaction 
The Mannich reaction, named after chemist Carl Mannich62, has presented as a 
classic and particularly powerful carbon–carbon bond-forming reaction in organic 
chemistry. This reaction consists of an amino alkylation of α-proton adjacent to a 
carbonyl functional group with aldehydes/ketones and amines with the generation of 
β-amino carbonyl compounds. In addition to α-CH-acidic compounds, activated 
phenyl substitutes and several electron-rich heterocycles, such as furan, pyrrole, 
thiophene and indole could be compatible with this protocol. Due to functional and 
structural diversity of final products, the mannich reaction has always emerged as a 
key step in medicinal chemistry. Up to now, significant advances have been made in 
the development of catalytic enantioselective Mannich reactions.63  
In 2002, Wenzel and Jacobsen utilized a Schiff base thiourea derivative 1-99 to 
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induce the asymmetric Mannich addition of N-Boc protected aldimines 1-100 with 
silyl ketene acetal 1-101. 64 Both aryl and heteroaryl derivatives were consistent with 
this methodology to afford β-amino ester products 1-102 with nearly quantitative 
yields and up to 98% enantioselectivities (Scheme 1.32). 
Scheme 1.32 The Mannich reaction of N-Boc-protected aldimines 1-100 and silyl ketene 
acetal 1-101. 
Subsequently, Jacobsen group revealed that in the above-mentioned Mannich 
reaction the diaminocyclohexane-derived Schiff base portion of the typical Jacobsen 
monofunctional thiourea catalyst was not crucial for the catalytic activity and 
enantioinduction. The remarkably simpler catalyst 1-103 incorporating a phenyl group 
instead of diaminocyclohexane-derived Schiff base moiety exhibited improved 
activity (> 99% conv.) and high enantioselectivity (94% ee) (Scheme 1.33).65 
Scheme 1.33 The Mannich reaction catalyzed by simple amino acid derived organocatalyst 
1-103. 
Although attractive progress has been made by classic Jacobsen Schiff base 
thiourea catalysis in many enantioselective transformations, it is necessary to further 
develop some novel thiourea catalysts in catalytic enantioselective methodologies 
engaging aromatic π systems as starting materials. In 2005, Taylor and Jacobsen 
reported asymmetric acyl-Mannich reactions of substituted isoquinoline substrates 
1-105 and silyl ketene acetal 1-101 to furnish a number of dihydroisoquinolines 1-106 
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in good yields and excellent enantioselectivities in the presence of a pyrrole-derived 
thiourea catalyst 1-104.66 Moreover, the synthetic utility of this methodology was 
demonstrated by the conversion of acyl-Mannich adduct dihydroisoquinolines 1-106 
to the corresponding enantioenriched 1-substituted tetrahydroisoquinoline derivatives 
through hydrogenation of the enamide moiety (Et3SiH/TFA) and reductive cleavage 
of the trichloroethyl carbamate group (Zn/AcOH).  
Scheme 1.34 Acyl-Mannich reaction of substituted isoquinolines 1-105. 
Although several organocatalytic asymmetric nitro-Mannich reactions have been 
reported to afford excellent enantioselectivity and high antiselectivity,67 it was not 
until 2008 that Wang et al. described the best result for enantioselective 
organocatalytic nitro-Mannich reaction in the presence of a new class of bifunctional 
amine-thiourea catalyst 1-107.68 This bifunctional catalyst bearing multiple hydrogen 
bonding donors (an extra hydrogen bonding donor in sulphonamide moiety) showed 
enormously enhanced reaction rates, good to excellent yields (85-99%), high 
anti-selectivities (93:7-99:1) and excellent enantioselectivities (96-99%) (Scheme 
1.35).   
 
Scheme 1.35 Nitro-Mannich (aza-Henry) reactions catalyzed by multiple hydrogen bonding 
donors 1-107.  
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In order to further expand the applications of cinchona alkaloids derived amine 
thiourea catalysts, Deng’s group described the first direct efficient enantioselective 
Mannich reactions of malonates 1-41 and N-Boc aryl and alkyl imines 1-100 in the 
presence of quinidine-derived amine thiourea organocatalyst 1-77 under mild, 
moisture and air-compatible conditions (Scheme 1.36). 69 Furthermore, this highly 
attractive and convergent approach was also applicable to β-keto esters. The synthetic 
utility of this methodology was demonstrated by providing a wide variety of 
biological interesting β-amino acids. 
 
Scheme 1.36 Enantioselective Mannich reaction of malonates 1-41 to N-Boc-imines 1-100 
catalyzed by quinidine-derived thiourea catalyst 1-77.  
 
Scheme 1.37 Quinidine-derived thiourea 1-77 catalyzed Friedel-Crafts reactions of indoles 
1-112 with aldimines 1-111.  
Subsequently, the same group further employed the quinidine derived thiourea 
catalyst 1-77 to catalyze the first highly enantioselective Friedel-Crafts reaction of 
indoles 1-112 with imines 1-111 to construct the 3-indolyl methanamine structural 
motif 1-113,70 which displayed the potential application in the synthesis of numerous 
indole alkaloids (Scheme 1.37).71 This direct, versatile and unprecedented protocol 
was sustainable for a wide range of indoles and aldimines bearing aromatic and 
aliphatic substituents. It was also found that the high enantioselectivities were 
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independent of the electronic properties of indole rings and the N-protected groups of 
aldimines.  
As a modern variation of the Mannich reaction72, the Petasis reaction was firstly 
developed by Petasis and co-workers.73 The Petasis reaction involves an amine, an 
aldehyde and a vinyl or aryl boronic acid to furnish a highly substituted amine. In 
2007, Takemoto and co-works developed an enantioselective Petasis reaction of 
various quinolines 1-115, phenylvinyl boronic acids 1-116 and phenyl chloroformate 
in the presence of a novel bifunctional aminol thiourea catalyst 1-114. 74 This new 
catalyst was modified from the classic Takemoto thiourea catalyst through 
mono-hydroxy alkylation of the ternary amine motif. In the proposed mechanism, the 
hydroxyl group moiety activated vinylboronic acids 1-116 with formation of a 
five-membered ring. Subsequently, the activated alkyl vinyl unit attacked the 
hydrogen-bonded N-acetylated quinolinium ions 1-118 in this well-defined chiral 
environment to effectively afford useful 1,2-dihydroquinoline adducts 1-117 in 
relatively low to high yields (28-78%) and high to excellent enantioselectivities 
(89-97%) (Scheme 1.38). H2O/NaHCO3 as the additive system regenerated the active 
catalyst structure by removal of the final boronic acid side product and the proton 
source to facilitate product formation.  
 
Scheme 1.38 Asymmetric Petasis reaction catalyzed by aminol thiourea organocatalyst 1-114.  
The Pictet-Spengler reaction, discovered in 1911 by Amé Pictet and Theodor 
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Spengler, is considered as a special class of the Mannich reaction in which 
β-arylethylamine undergoes ring closure after the formation of an imine or iminium 
ion from an aldehyde or ketone.75 Usually, indole or pyrrole nucleophilic aromatic 
rings could afford better results under mild conditions compared with less 
nucleophilic phenyl rings. Since the seminal work, the development of asymmetric 
Pictect-Spenger reaction has attracted much attention because of its particular 
importance in the fields of alkaloid and pharmaceutical synthesis. In 2007, Jacobsen 
group utilized a novel bifunctional thiourea pyrrole derivative 1-119 to induce the 
enantioselective N-acyl-Pictet-Spengler cyclization of β-indolyl ethyl hydroxylactams 
1-120 to furnish highly enantioenriched cyclization products 1-121 with excellent ee 
values ranging from 90% to 99% (Scheme 1.39)76. On the basis of the results of 
various NMR studies, the mechanism of this reaction was considered as anion-binding 
catalysis. Firstly, β-indolyl ethyl hydroxylactams 1-120 reacted with TMSCl as a 
dehydrating agent resulting in rapid and irreversible formation of chlorolactams 1-122. 
Subsequently, the catalyst abstracted a chloride counterion and then closely bounded 
to the activated iminium ion as a result of a chiral N-acyliminium–chloride–thiourea 
complex 1-123, which underwent the final intramolecular cyclization step in this 
well-defined chiral environment. 
 
Scheme 1.39 Pyrrole thiourea-catalyzed N-acyl-Pictet-Spengler cyclization. 
Scheme 1.40 Proposed mechanism for pyrrole thiourea-catalyzed N-acyl-Pictet-Spengler 
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Inspired by the previously described N-acyl-Pictet-Spengler reaction, the 
Jacobsen group further applied this thiourea organocatalysis by anion binding to the 
intermolecular enantioselective additions to oxocarbenium ions.77 A new thiourea 
derivative 1-124 bearing a tertiary benzylic amide group was developed to catalyze 
the substitution of silyl ketene acetals 1-126 onto oxocarbenium ions, which act as 
important reaction components in the synthesis of complex natural products and 
carbohydrates. It was shown that the starting chloroethers 1-125 could epimerize 
under the optimal reaction conditions and the thiourea firstly abstracted the chloride to 
afford a closely associated ion pair in the form of the oxocarbenium–thiourea–
chloride complex 1-128. Finally, the enol silane nucleophile attacked the asymmetric 
ion pair to generate the final alkylated isochromans 1-127 with excellent 
enatioselectivities.  
Scheme 1.41 Enantioselective addition of silyl ketene acetals 1-126 to oxocarbenium ions.  
 
1.2.4 The Morita-Baylis-Hillman (MBH) reaction  
As one of the most important and superior atom-enocomic carbon-carbon bond 
formation reactions, the Morita-Baylis-Hillman (MBH) reaction, firstly reported by 
Morita78  in tertiary phosphine catalysis and Baylis-Hillman79  in tertiary amine 
catalysis, has gradually attracted huge attention in modern catalytic synthesis.80 The 
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MBH reaction represents as a condensation of electron-deficient alkenes and sp2 
hybridized carbon electrophiles, such as aldehydes, ketones and aldimines, to 
construct allylic alcohols or allylic amines in the presence of Lewis bases (amine or 
phosphine).  
In 2005, the Wang group demonstrated the first bifunctional amine thiourea 
catalyzed Morita-Baylis-Hillman reaction.81 The newly developed binaphthyl derived 
amine thiourea 1-81 conducted the reaction of cyclic enones 1-90 and a broad range 
of aromatic and linear aliphatic aldehydes 1-129 to furnish allylic alcohols 1-130 in 
yields ranging from 55% to 84% and with ee values ranging from 60% to 94%. In the 
proposed catalytic cycle, the explicit double hydrogen bonding interaction between 
thiourea moiety and cyclic enone could facilitate the initial Michael reaction of the 
tertiary amine motif to the β-position of enone. The subsequent aldol reaction formed 
the bifunctional catalyst-zwitterionic ion complex 1-132, which was converted to the 
final allylic alcohols 1-130 by the rate-determing deprotonation of the α-hydrogen.  
 
Scheme 1.42 Asymmetric MBH reaction catalyzed by bifunctional organocatalyst 1-81.  
 
Scheme 1.43 Proposed catalytic cycle for the binaphthyl amine thiourea 1-81 promoted MBH 
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However, it is well known that aromatic tertiary amines are much weaker 
nucleophiles than phosphines. Modification of the binaphthyl derived amine thiourea 
catalyst 1-81 with replacement of the amine motif with stronger phosphine 
nucleophiles resulted in a novel bifunctional phosphine thiourea catalyst 1-133. The 
aza-MBH reaction of N-Tos aldimines 1-134 and methyl vinyl ketones 1-53 under the 
catalysis of 1-133 furnished the N-protected allylic amines 1-135 in high yields and 
excellent enantioselectivities (Scheme 1.44).82 
Scheme 1.44 Asymmetric MBH reaction catalyzed by binaphthyl derived phosphine thiourea 
catalyst 1-133.  
In addition to binaphthyl derived thiourea catalysts, C2-symmetric chiral 
1,2-diaminocyclohexane-derived bisthiourea 1-136, prepared by Nagasawa and 
co-workers, 83  was employed in the Morita-Baylis-Hillman (MBH) reaction to 
simultaneously activate the aldehydes 1-129 and cyclohexenone 1-90 in a spatially 
restricted chiral environment. With the aid of Lewis base DMAP, this method 
provided access to various allylic alcohols 1-130 bearing both aromatic and aliphatic 
groups with high catalytic activities and up to 90% ee in the case of 
cyclohexanecarboxaldehyde.  
 
Scheme 1.45 Asymmetric MBH reactions promoted by C2-symmetric bisthiourea 1-136.  
Another important development in enantioselective MBH reaction was disclosed 
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by Berkessel et al.84 A new and efficient bisthiourea catalyst 1-137 was designed and 
synthesized from readily available isophoronediamine (IPDA) in one step. In 
combination with a nucleophilic base (N,N,N',N'-tetramethylisophoronediamine 
TMIPDA or DABCO) the bisthiourea catalyst 1-137 controlled the relative orientation 
of enone 1-90 and a series of aldehydes 1-129 to obtain good to excellent yields and 
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Scheme 1.46 Asymmetric MBH reactions promoted by bisthiourea 1-137.  
Despite the important advance has been made in asymmetric aza-Baylis-Hillman 
(ABH) reaction with enone substrates as pre-nucleophiles85, Raheem and Jacobsen 
further expanded the substrate scope of the ABH reaction to simple acrylate 
devivatives.86 In the presence of catalytic amount of Jacobsen catalyst 1-99 and 1.0 
equiv. of 1,4-diazabicyclo[2.2.2]octane (DABCO), this unprecedented protocol was 
well applicable to a wide range of aromatic imines 1-138 to construct highly 
functionalized nosyl-protected amines 1-140 with high to excellent 
enantioselectivities (87-99% ee), albeit in low to moderate yields (25-49%). The vital 
synthetic utility of this methodology was well revealed through some representative 
synthetic transformations, such as dihydroxylation, hydrogenation, alkalation, 
epoxidation, [3+2] cycloaddition and so on. Besides, this report also depicted the first 
isolation or characterization of zwitterionic ion and its dihydrochloride salt in MBH or 
ABH reactions. 
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Scheme 1.47 Jacobsen thiourea catalyst 1-99 promoted aza-Baylis-Hillman reactions. 
 
1.2.5 Decarboxylative Reactions  
As one of the oldest organic reactions, decarboxylation commonly plays a 
particularly vital role in biological and synthetic chemistry. It is a chemical process 
that removes a carbonyl group (COOH) with concurrent release of CO2. The first 
decarboxylative Claisen condensation was conducted by Kobuke under enzyme-free 
conditions with magnesium acetate as catalyst in 1978.87 Subsequently, the Shair88 
and Cozzi 89  group independently developed Cu(II)-catalyzed enantioselective 
decarboxylative Aldol reactions of malonic acid half-thioesters (MAHTs) to 
aldehydes under mild reaction conditions. Since then, organocatalytic decarboxylation 
has gradually attracted a great deal of interest.  
In 2007, the Wennemers90 group made a major breakthrough in asymmetric 
organocatalytic decarboxylative synthesis. By mimicking the active site of polyketide 
synthases, a quinine derivative 1-141 incorporating both a basic quinuclidine site and 
a urea moiety was utilized to conduct the enantioselective decarboxylative reaction of 
various aromatic and aliphatic nitroolefins 1-40 and malonic acid half-thioesters 
(MAHTs) 1-142 served as thioester enolate equivalents. The final high yields and 
good enantioselectivities were ascribed to the simultaneous activation of substrates 
through explicit double hydrogen-bond interactions and deprotonation. Furthermore, 
the resulting γ-nitrothioesters 1-143 were readily converted to versatile building 
blocks by reduction of the nitro group and intramolecular cyclization, such as 
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antidepressant rolipram. Subsequently, another considerable achievement was made 
by the Ricci91 group. They employed the quinidine-derived alkaloid β-isocupreidine 
(β-ICD) in asymmetric organocatalytic decarboxylative Mannich reactions via 
hydrogen bonding catalysis.  
 
Scheme 1.48 Quinine derived urea catalyst 1-141 promoted decarboxylative addition of 
MAHT to nitroolefins. 
However, the previous pioneering works’ catalytic activity and enantioselectivity 
were insufficient for further synthetic utility. In order to address this problem, the 
Song group employed a superior quinine-based ternary amine squaramide 1-144 to 
promote the biomimetic decarboxylative Michael addition of MATHs 1-142 to a 
variety of nitroolefins 1-40, resulting in the formation of the optically active γ-amino 
acid precursors 1-143. 92 In comparison to thiourea motifs, chiral squaramides93 
could serve as more efficient hydrogen bond donors in many enantioselective organic 
transformations due to the higher Brønsted acidity of the NH protons of the 
squaramides94 and spatial fixed anti/anti-orientation of the NH protons relative to the 
carbonyl groups 95 . Remarkably, it was shown that this protocol proceeded 
enantioconvergently to provide high catalytic activity and excellent enantioselectivity. 
The authors also presented the synthetic utility of this methodology of the conversion 
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to pharmaceutically important γ-amino acids through simple reduction and 
intramolecular cyclization steps.  
 
Scheme 1.49 Quinine derived squaramide catalyst 1-144 promoted decarboxylative addition 
of MAHT to nitroolefins.  
In recent reports, enantioselective organocatalytic decarboxylation was proved as 
a particularly powerful and effective process in many reactions, such as protonations96, 
Aldol reactions97 and Mannich reactions98. All of these decarboxylative processes 
were promoted by cinchona-based tertiary amines or chiral guanidines.  
 
Scheme 1.50 Enantioselective decarboxylative protonation mediated by pseudoenantiomers 
1-75 and 1-77. 
The Rouden group firstly applied the cinchona alkaloids based thiourea 
derivatives to the asymmetric decarboxylative protonation of acyclic, cyclic or 
bicyclic α-aminomalonate hemiesters 1-145, affording optically active aminoesters 
1-146 in high yields and up to 93% enantiomeric excess under mild conditions 
(Scheme 1.50).96d Both the quinidine-based thiourea derivative 1-77 and its 
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pseudoenantiomer 1-75 could afford the conformational rigidity to anchor the chiral 
protonating agent and the prochiral enolate in a well-defined chiral environment.  
The Shibata group firstly demonstrated the organocatalytic decarboxylative aldol 
addition of malonic acids half thioesters to ketones in the presence of quinine-derived 
squaramide catalyst.97a Under optimal conditions, a series of isatins 1-147 reacted 
with MAHTs 1-148 to afford chiral 3-substituted 3-hydroxy-2-oxindole derivatives 
1-149 in excellent yields (88-99%) and good enantiomeric excesses (86-92%) 
(Scheme 1.51). The final products could act as key intermediates in the synthesis of 
various biologically active compounds, such as convolutamydines, CPC-1, 
(-)-flustraminol B. Remarkably, this work showed the first report on the 
enantioselective synthesis of optically active (-)-flustraminol B 1-151 (Scheme 1.52). 
Based on the results of preliminary experiments, the authors also elucidated the 
mechanism of this reaction. The activation of MAHT by squaramide functionality’s 
double hydrogen bonding and deprotonation of carboxylic acid would facilitate the 
decarboxylation of MAHT to generate a thioester enolate. Simultaneously, the 
protonated catalyst coordinated the two carbonyl oxygen from isatin through 
hydrogen bonding. Finally, the in situ generated thioester enolate attacked the 
carbonyl group of the isatins 1-147 from the Si-face as a result of the preferable 
formation of (R)-isomer. 
 
Scheme 1.51 Enantioselective decarboxylative aldol reactions of isatins 1-147 with MAHT.  
Scheme 1.52 Synthesis of optically active (-)-flustraminol B. 




Subsequently, the Lu group also demonstrated a facile and important protocol for 
the synthesis of biologically crucial 3-substituted 3-hydroxy oxindole derivatives 
through decarboxylative additions.97b As synthetic equivalents of aryl/alkyl methyl 
ketone enolates, a wide range of β-ketoacids 1-153 reacted with isatins 1-152 bearing 
different substituents on the aromatic ring to afford good yields and excellent 
enantioselectivities. On the basis of the results of experimental study in the 
mechanism, the authors proposed a decarboxylation–nucleophilic addition pathway in 
this reaction. However, some other catalytic systems fully support the alternative 
nucleophilic addition–decarboxylation reaction sequence. Further investigations 
toward the deep understanding of the mechanism in the decarboxylation are still 
highly desirable.  
  
Scheme 1.53 Enantioselective decarboxylative aldol reactions of isatins 1-152 with 
β-ketoacids 1-153.  
 
1.2.6 Miscellaneous Reactions  
In the following section, some elegant and crucial transformations are described. 
These particularly efficient reactions have emerged as powerful and promising 
strategies for the synthesis of some natural and pharmacologically important structural 
motifs. 
The Henry reaction (nitro-aldol reaction), discovered in 1895 by L. Henry,99 is 
an efficient and classic C–C bond formation reaction in organic chemistry. It involves 
the base-catalyzed condensation of a nitroalkane bearing an α-hydrogen atom and a 
carbonyl compound (aldehyde or ketone) resulting in the formation of β-nitroalcohol. 
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The synthetic utility of this well-known reaction is demonstrated by the conversions 
of the final β-nitroalcohol products to other particularly useful synthetic intermediates, 
such as nitroalkenes by dehydration, α-nitro ketones by oxidation of the secondary 
alcohol and β-amino alcohols by reduction of the nitro group. Although many 
efficient catalytic asymmetric Henry reactions have been described, it is not until 
2006 that Hiemstra et al. reported a highly enantioselective organic reaction between 
activated aromatic aldehydes 1-129 and nitromethane 1-79 in the presence of 
cinchona derivatives. On the cinchona alkaloid backbone, the C9 position was not the 
sole position where thiourea functionality could be installed.100 So they modified the 
chiral cinchona scaffold through replacement of the 6’-OMe group with a thiourea 
moiety to furnish a novel and powerful bifunctional catalyst 1-155. 101 As illustrated 
in Scheme 1-54, this catalyst activated the aldehyde by the thiourea unit and 
simultaneously deprotonated the nitromethane by the basic quinuclidine ring. A 
variety of aldehydes 1-129 bearing aryl and heteroaryl substituents were compatible 
with this protocol to afford high yields (87-99%) and excellent enantiomeric excesses 
(85-93%). 
 
Scheme 1.54 Asymmetric Henry reactions catalyzed by 1-155 and proposed activation mode.  
The Diels-Alder reaction has attained a preeminent position in organic chemistry 
for the convenient construction of synthetically valuable six-membered cyclohexene 
rings due to requirement of very little energy.102 So far, many strategies have been 
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reported to realize this reaction.102 In 2007, Deng et al. demonstrated the first example 
of cinchona alkaloid based thiourea derivative as an efficient bifunctional catalyst for 
a highly diastereoselective and enantioselective Diels-Alder reaction with 2-pyrones 
1-158. 103  The amine and thiourea moiety of catalyst not only activated the 
HOMO-LUMO, but also controlled the rearrangement of the dienes and dienophiles 
in a spatial conformational rigid environment. Remarkably, many dienophiles 
including fumaronitrile, maleonitrile, acrylonitrile as well as α-acrylonitrile 1-159 
were compatible with this protocol to afford excellent yields and enantioselectivities, 
especially with high endo/exo selectivities (Scheme 1.55).  
 
Scheme 1.55 Exo-selective cinchona-based thiourea deviratives 1-75 or 1-77 promoted 
Diels-Alder reaction.  
The Friedel-Crafts reaction, developed by Charles Friedel and James Crafts in 
1877104, has emerged as a key reaction in synthetic organic chemistry resulting in the 
formation of new C-C bonds.105 It could be generally classified into two main types, 
alkylation reaction and acylation reaction. The nucleophilic addition of aromatic 
substrates to electron-deficient alkenes is usually considered as a Friedel-Crafts type 
alkylation. The first catalytic enantioselective Friedel-Crafts alkylation of indoles with 
nitroalkenes was developed by Ricci and coworkers in the presence of a novel chiral 
indane-based hydroxyl thiourea catalyst 1-161.106 This methodology was consistent 
with various indoles 1-162 and a wide range of nitroalkenes 1-40 bearing aryl and 
alkyl substituents with fairly good yields and excellent enantioselectivities (Scheme 
1.56). This asymmetric Friedel-Crafts alkylation facilely provided the enantioenriched 
2-indolyl-1-nitro derivatives 1-163, which could be easily converted into particularly 
                                                              
103  Wang, Y.; Li, H.; Wang, Y. O.; Liu, Y.; Foxman, B.M.; Deng, L. J. Am. Chem. Soc. 2007, 129, 6364. 
104  Friedel, C.; Crafts, J. M. Compt. Rend. 1877, 84, 1392.  
105 Olah, G. A. Friedel–Crafts and Related Reactions, Vol. II, part 1, Wiley-Interscience, New York, 1964. 
106  Herrera, R. P.; Sgarzani, V.; Bernardi, L.; Ricci, A. Angew. Chem. Int. Ed. 2005, 44, 6576. 




valuable biological compounds, such as tryptamines or 
1,2,3,4-tetrahydro-β-carbolines (Scheme 1.57). In the proposed mechanism mode, the 
nitroalkene was activated by two thiourea hydrogen atoms, whereas the free alcoholic 
function of catalyst interacted with the indolic proton by a simple hydrogen bond. The 
activated indole nucleophile attacked the Si face of the nitroolefin.  
Scheme 1.56 Asymmetric Friedel-Crafts alkylations catalyzed by chiral hydroxyl-thiourea 
1-161.  
 
Scheme 1.57 The synthetic utility of the optically active 2-indolyl-1-nitro derivatives 1-163. 
To date, only few catalysts based on chiral indane scaffold have been developed 
in organic chemistry. The above mentioned work revealed that the particularly 
privileged indane scaffold could induce a well-defined chiral environment for the 
reaction substrates. On the basis of these initial results, our group firstly designed and 
synthesized a series of indane amine-thiourea catalysts that have been confirmed to be 
especially effective in many asymmetric cascade transformations. 
In comparison with standard kinetic resolution in the maximum yield of 50%, 
dynamic kinetic resolution has emerged as a particularly practical methodology to 
access the highly enantiomerically pure compounds in theoretically quantitative yield 




from cheap and easily available racemic precursors. In order to increase the 
enantioselectivity of organocatalyzed DKRs of azlactone, Berkessel and co-workers 
employed bifunctional amine urea/thiourea organocatalysts in this strategy.107 Based 
on the NMR spectroscopic studies, the authors proposed a plausible mechanism that 
the thiourea motif activated the azlactone by explicit hydrogen bonding (Scheme 
1.58). The Brønsted basic tertiary amine activated the alcohol nucleophile through 
deprotonation. Besides, the H1 and C13 spectra of the catalyst-azlatone complex 
indicated that one of two possible diastereomers of this complex was preferentially 
formed as a result of rapid interconversion of the azlactone enantiomers.107a Under 
optimized conditions, both Takemoto catalyst analogue 1-167 and Jacobsen catalyst 
analogue 1-168 could promote the alcoholytic ring opening of various racemic 
azlactones 1-169 to generate the desired optically active N,C-doubly protected 
α-amino acid derivatives 1-171 with high conversions and excellent 
enantioselectivities. It was noteworthy that the products could be readily transformed 
to enantiopure natural and non-natural α-amino acids which possessed a huge 
application in the synthesis of many valuable pharmaceuticals and catalysts.107  
 
Scheme 1.58 The mechanism of alcoholytic dynamic kinetic resolution.  
 
Scheme 1.59 Asymmetric alcoholytic dynamic kinetic resolution of azlactones 1-169. 
                                                              
107  a) Berkessel, A.; Cleemann, F.; Mukherjee, S.; Müller T. N.; Lex, J. Angew. Chem. Int. Ed. 2005, 44, 807; b) 
Berkessel, A.; Mukherjee, S.; Cleemann, F.; Müller T. N.; Lex, J. Chem. Commun. 2005, 1898.  




Cascade synthetic strategy is of considerable significance in both academic and 
industrial chemistry, because it provides an elegant and efficient protocol to construct 
complex molecular architectures in atom and step economic processes. So the 
development in the asymmetric versions of cascade reactions caught enormous 
interest of chemists in recent years. In 2007, Wang et al. disclosed a highly effective, 
enantio- and diastereoselective cascade Michael-aldol reaction in the presence of a 
quinine based thiourea organocatalyst 1-75. 108  The synergistic non-covalent 
H-bonding activation of 2-mercaptobenzaldehydes 1-172 and various α,β-unsaturated 
oxazolidinones 1-173 facilitated the construction of versatile synthetically useful and 
medicinally important chiral thiochromanes 1-174 with three stereogenic centers in 
good to excellent yields (75-95%), excellent enantiomeric excesses (91-99%) as well 
as excellent distereoselectivities (>20:1) (Scheme 1.60).  
 
Scheme 1.60 Asymmetric cascade Michael-aldol reaction catalyzed by quinine-based 
thiourea organocatalyst 1-75. 
To expand the scope of the electrophiles and nucleophiles in cascade synthetic 
strategies, the Wang group also described highly enantio- and diastereoselective 
hydrogen-bond-mediated tandem Michael-Aldol and Michael-Michael reactions, 
respectively, utilizing maleimides 1-176 or trans-3-(2-mercaptophenyl)-2-propenoic 
acid ethyl esters 1-178 as substrates, to incorporate three adjacent stereogenic centers 
in the particularly privileged biological scaffolds.109  
                                                              
108  Zu, L. S.; Wang, J.; Li, H.; Xie, H. X.; Jiang, W.; Wang, W. J. Am. Chem. Soc. 2007, 129, 1036.  
109  a) Zu, L. S.; Xie, H. X.; Li, H.; Wang, J.; Jiang, W.; Wang, W. Adv. Synth. Catal. 2007, 349, 1882; b) Wang, J.; 
Xie, H. X.; Li, H. Zu, L. S.; Wang, W. Angew. Chem. Int. Ed. 2008, 47, 4177.  






Scheme 1.61 Hydrogen-bond mediated asymmetric cascade reactions: a) domino 
Michael-Aldol sequence; b) domino Michael-Michael sequence.  
 
1.3 Project Objectives 
As shown in previous sections, hydrogen-bond-mediated catalysis has emerged 
as a powerful and practical tool in organic synthesis. It is noteworthy that the 
discovery of a variety of mono- and bifunctional urea/thiourea catalysts has triggered 
the rapid development of the application of urea/thiourea activation mode in 
asymmetric organocatalysis. In the past few decades, these elegant powerful 
urea/thiourea catalysts based on various crucial scaffolds have proven to be 
specifically efficient implements to afford biologically and pharmaceutically 
important molecules in many novel and interesting enantioselective reactions, such as 
Strecker reaction, Michael reaction, Mannich reaction, Henry reaction, 
acyl-Pictet-Spengler reaction, Morita-Baylis-Hillman (MBH) reaction, Petasis-type 
reaction and so on.  
Although great advances have been made in urea/thiourea catalyzed organic 
transformations, it is still highly desired to develop novel and versatile urea/thiourea 
catalysts due to limited chiral structural scaffolds. Moreover, the previously 
mentioned urea/thiourea catalysts would lose or decrease their catalytic activities and 
chiral inductions in some specific reactions. Therefore, how to enlarge the reaction 
scope still remains one challenge in urea/thiourea-mediated catalysis.  
The main objective of this project is to: 




 design and develop a small library of novel and easily synthesized bifunctional 
indane amine-thiourea catalysts.  
 apply these powerful catalysts to many unique enantioselective cascade 
reactions.  
 expeditiously assemble versatile synthetically useful and densely functionalized 
privileged medicinal scaffolds in both organic and biological chemistry. 
The study of this project could provide a facile and concise strategy to synthesize 
a series of bifunctional indane amine-thiourea catalysts from various readily available 
and cheap starting materials. These powerful catalysts could serve as an essential 
complement to other chiral scaffold-based urea/thiourea catalysts to catalyze many 
useful enantioselective cascade transformations.  
Furthermore, this project will mainly focus on some unanticipated cascade 
sequences because of their advantages, such as simple operation, environmental 
friendliness, and rapid one-pot entries to molecular complexity. These cascade 
synthetic protocols would construct some interesting, potential biological and 
pharmaceutical molecules in the presence of the bifunctional indane amine-thiourea 
catalysts. Many typical and important named reactions are outside the scope of this 
project because excellent enantioselectivities have been achieved in these reactions 
catalyzed by previously mentioned classic scaffold-based (thio)urea catalysts. In 
Chapter 2, a Michael–Oxa-Michael–tautomerization reaction will be described. 
Chapter 3 will demonstrate the highly stereoselective cascade Michael–enolation–
cyclization reaction catalyzed by chiral indane-based thiourea. Furthermore, Chapter 
4 will depict these catalysts’ practical application in enantioselective Mannich–
intramolecular ring cyclization–tautomeriztion cascade sequence. Subsequently, a 
highly efficient catalytic decarboxylative [1,2]-addition strategy to quickly assemble 
3-hydroxy-2-oxindole scaffolds would be demonstrated in Chapter 5. Finally, Chapter 
6 will disclose a direct enantioselective decarboxylation of α,β-unsaturated carbonyls 
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Cascade synthetic strategy has been developed as a uniquely powerful tool for 
forging synthetic connections and plays a pivotal role in modern organic synthesis.110 
Given its widespread use, the development of new synthetic cascade reactions for the 
construction of complex molecules is an important goal of research carried in both 
academic and industrial laboratories.111 In particular, asymmetric organocatalytic 
cascade processes112 are even more appealing because of their advantages, such as 
operational simplicity, environment friendliness, and rapid one-pot entries to 
molecular complexity via atom, step and redox economic or protecting-group-free 
protocols.  
The catalytic asymmetric C–C bond formation represents one of the most 
interesting and challenging fields in organic chemistry. A number of asymmetric 
Michael additions to α,β-unsaturated carbonyl acceptors catalyzed by chiral 
organocatalysts have been reported.113 However, the nucleophiles employed in the 
asymmetric Michael addition reactions are restricted to malonate esters, 114 
diketones,115 ketoesters116 and nitroalkanes117. Extending the scope of either the 
                                                              
110 For selected reviews, see: a) Nicolaou, K. C.; Edmonds, D. J.; Bulger, P. G. Angew. Chem. Int. Ed. 2006, 45, 
7134; b) Nicolaou, K. C.; Montagnon, T. Molecules that Changed the World: A Brief History of the Art and 
Science of Synthesis and its Impact on Society, Wiley-VCH, 2008; c) Nicolaou, K. C.; Chen, J. S. Chem. Soc. Rev. 
2009, 38, 2993.  
111  For book reviews, see: a) Nicolaou, K. C.; Sorensen, E. J. Wiley-VCH, 1995; b) Nicolaou, K. C.; Snyder, S. A. 
Wiley-VCH, 2003. 
112  For selected reviews of organocatalytic cascade reactions, see: a) see Ref. 3a; b) see Ref. 3b; c) Yang, J. W.; 
Hechavarria Fonseca, M. T.; List, B. J Am Chem Soc 2005, 127, 15036; d) Marigo, M.; Schulte, T.; Franzen, J.; 
Jørgensen, K. A. J. Am. Chem. Soc. 2005, 125, 15710; e) see Ref. 3f; f) see Ref. 3g; g) Sunden, H.; Ibrahem, I.; 
Zhao, G. L.; Eriksson, L. Chem. –Eur. J. 2007, 13, 574; h) Wang, W.; Li, H.; Wang, J.; Zu, L. J. Am. Chem. Soc. 
2006, 128, 10345; i) Galzerano, P.; Pesciaioli, F.; Mazzanti, A.; Bartoli, G.; Melchiorre, P. Angew. Chem. Int. Ed. 
2009, 48, 7892. 
113  For book reviews, see: a) see Ref. 1a; b) see Ref. 1b. 
114  For selected examples of organocatalytic conjugation addition of malonlate esters, see:  a) Halland, N.; 
Aburel, P. S.; Jørgensen, K. A. Angew. Chem. Int. Ed. 2003, 42, 661; b) Ye, J. X.; Dixon, D. J.; Hynes, P. S. Chem. 
Commun. 2005, 35, 4481; c) Li, H. M.; Wang, Y.; Tang, L.; Deng, L. J. Am. Chem. Soc. 2004, 126, 9906; d) see 
Ref. 41; e) see Ref. 53; f) Terada, M.; Ube, H.; Yaguchi, Y. J. Am. Chem. Soc. 2006, 128, 1454; g) Wang, J.; Li, H.; 
Zu, L. S.; Jiang, W.; Xie, H. X.; Duan, W. H.; Wang, W. J. Am. Chem. Soc. 2006, 128, 12652. 
115  For selected examples of asymmetric conjugate additions of diketones, see: a) Uraguchi, D.; Terada, M. J. Am. 
Chem. Soc. 2004, 126, 5356; b) Tillman, A. L.; Ye, J. X.; Dixon, D. J. Chem. Commun. 2006, 1191; c) Hatano, M.; 
Maki, T.; Moriyama, K.; Arinobe, M.; Ishihara, K. J. Am. Chem. Soc. 2008, 130, 16858; d) Jiang, X. X.; Zhang, Y. 
F.; Liu, X.; Zhang, G.; Lai, L. H.; Wu, L. P.; Zhang, J. N.; Wang, R. J. Org. Chem. 2009, 74, 5562; e) see Ref. 93a; 
f) see Ref. 56. 
116  For the conjugate addition of ketoesters, see: a) Wu, F.; Li, H.; Hong, R.; Deng, L. Angew. Chem. Int. Ed. 2006, 
45, 947; b) Elsner, P.; Bernardi, L.; Dela, S. G.; Overgaard, J.; Jørgensen, K. A. J. Am. Chem. Soc 2008, 130, 4897; 
c) Li, H.; Zhang, S. L.; Yu, C. G.; Song, X. X.; Wang, W. Chem. Commun. 2009, 2136; d) Murai, K.; Fukushima, 




acceptors or the donors employable in the asymmetric Michael addition is an 
important advance in order to have access to diversely functionalized and 
synthetically useful chiral building blocks. The utilization of malononitrile as 
nucleophile in Michael additions has received much less attention, although the nitrile 
group can undergo further transformations to 1,3-dicarbonyl derivatives, or imines. 
Quite recently, the Jacobsen and Kanemasa groups independently reported the 
enantioselective Michael additions of malononitrile to α,β-unsaturated imides 
catalyzed by metal catalysts.118 Later on, the Takemoto group reported the first 
example of enantioselective Michael reactions of malonontrile to α,β-unsaturated 
imides in the presence of a chiral organocatalyst (Scheme 2.1).119 More recently, the 
Deng,120 and Lattanzi121 groups also independently reported a cinchona alkaloid 
catalyzed enantioselective Michael addition of malononitrile to enones (Scheme 2.1). 
Furthermore, the Zhao group also successfully incorporated malononitrile into a 
three-component reaction for the synthesis of pyranopyrazoles.122  However, all 
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Scheme 2.1 Organocatalyst promoted cascade reactions of malononitrile with α,β-unsaturated 
ketones. 
To extend the synthetic utility of malononitrile as electrophile or both 
electrophile and nucleophile in asymmetric catalysis, we wish to undertake an 
investigation of new protocols. We hypothesized that the novel Michael reaction 
based process might facilitate a new synthetic pathway to construct a complex 
molecule instead of a simple Michael adduct. Surprisingly, the results of our novel 
reaction exploration envisioned that the change of common enones to 
benzylidenechromanones efficiently drove the reaction to interact with malononitrile 
to generate novel chiral pyrano–chromene complexes (Scheme 2.1). Herein, 
malononitrile worked as both electrophile and nucleophile. Notably, these pyrano–
chromene complexes might possess a broad application in medicinal chemistry.123 
Herein, we disclose a new enantioselective organocatalytic cascade reaction with a 
Michael–Oxa-Michael–Tautomerization sequence that generates highly 
functionalized chiral pyrano–chromene complexes in a concise manner. Notably, the 
features of the strategy include (1) the cascade process efficiently catalyzed by a new 
indane amine-thiourea catalyst via hydrogen-bonding catalysis in good to excellent 
yields (up to 99%); (2) the first utilization of malononitrile as both nucleophile and 
electrophile in asymmetric organocatalytic Michael addition; (3) the efficient 
assembly of highly functionalized pyrano–chromene complexes with high to excellent 
enantioselectivities (up to 99% ee) in a one-pot reaction.  
 
2.2 Results and Discussion 
2.2.1 Catalyst Screening 
                                                              
123   For book review, see: Ellis, G. P.; Lockhart, I. M.; Meeder-Nycz, D.; Schweizer, E. E. Chromenes, 
Chromanones and Chromones, Viley, New York, 1977. 




To explore the feasibility of the proposed catalytic cascade Michael–
Oxa-Michael–Tautomerization process, reactions of (E)-3-benzylidenechroman-4-one 
(2-5a) with malononitrile (2-6) were performed in CH2Cl2 at room temperature in the 
presence of a cinchona alkaloid amine-thiourea catalyst 2-1, independently developed 
by Connon53 and Soós124 groups (Figure 2.1). As shown in Table 2.1, the major 
Michael adduct 2-7a was afforded by catalyst 2-1 with 65% yield and 0.7:1 d.r. 
(Table 2.1, entry 1). Interestingly, a small amount of unpredicted complex 2-8a was 
also formed by a 21% yield and a moderate 65% ee. The 1H and 13C NMR results of 
complex 2-8a demonstrated that it has an absolutely different structure in comparison 
with Michael adduct 2-7a. This phenomenon envisioned that malononitrile could be 
utilized both as nucleophile and electrophile, especially in asymmetric organocatalysis. 
Inspired by this discovery, we then devoted to discover a proportionate powerful 
chiral organocatalyst which could efficiently promote the reaction to selectively 
synthesize 2-8a and also highly control the stereochemistry of 2-8a. 
 
Figure 2.1 Evaluated bifunctional chiral organocatalysts. 
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Yield [%]b d.r.[%]c Yield [%]b ee [%]d 
1 2-1 65 0.7:1 21 65 
2 2-2a 41 1.5:1 12 65 
3 2-2b 78 1.3:1 16 45 
4 2-2c 72 1.9:1 18 67 
5 2-3 72 1.5:1 26 –72 
6 2-4 21 0.4:1 72 79 
a Reaction was conducted on 0.1 mmol scale in DCM (0.1 mL) at r.t. for 3 d, and the ratio of 
2-5a/2-6 was 1:1.5. b Yield of isolated product. c Determined by 1H NMR analysis of the crude 
product. d Enantiomeric excess (ee) was determined by HPLC analysis. 
Recently, our group developed a series of novel bifunctional indane 
amine-thiourea catalysts which were approved to be efficient chiral catalysts for 
Michael-type reactions.125 Based on these results, we discovered indane catalysts 
exhibited a number of amazing properties, such as high reactivity and excellent 
stereo-control in many cases. Thereby, a test of our indane catalysts’ superiority in this 
reaction was investigated. To this end, a small library of indane catalysts synthesized 
by our group 2-2–2-4 (Figure 2.1) was applied to this reaction. The library includes (1) 
catalyst 2-2a, 2-2b and 2-2c with modifications on the conformation of the amine 
functional group; (2) catalyst 2-3 with a specific alternation on the relative orientation 
of the amine and thiourea functional groups in comparison with catalyst 2-2c; (3) 
catalyst 2-4 with an adjustment of the relative positions of the amine and thiourea 
functional groups in contrast with catalyst 2-3. To the best of our knowledge, we 
believe the dihedral angle between two functional groups is one of the key issues for 
stereo-control. We envision that the change of dihedral angel between the functional 
groups of the amine and thiourea might introduce an ideal and stable transition state to 
assist excellent stereocontrol. Eventually, the novel catalyst 2-4 was discovered as a 
relatively ideal promoter to catalyze this cascade process under the same condition we 
stated above (Table 2.1, entry 6, 72% and 79% ee for 2-8a). In catalyst screening, we 
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observed that the geometry and the relative positions of the amine and thiourea 
functional groups played a critical role in promoting reaction and controlling the 
enantioselectivity. If there was anti-geometry between the amine and thiourea 
functional groups, the reactivity of catalysts (2-2a-c) was relative weak and the major 
product was Michael adduct 2-7a (entries, 2–4, 41%, 78% and 72%, respectively). 
Nevertheless, catalyst 2-4 manifested a relatively higher level of catalyst efficiency 
and stereo-control with a formation of desired product 2-8a. In terms of catalyst 2-4’s 
structure, we found that a syn-geometry between the amine and thiourea functional 
groups in catalyst 2-4 was a significant factor. Surprisingly, a slight interchange of the 
relative positions of the amine and thiourea functional groups (from 2-4 to 2-3) 
definitely caused the loss of desired compound 2-8a (entry 5, 72% yield for major 
Michael adduct 2-7a and only 26% yield for 2-8a). In contrast to other catalysts, we 
envisioned that catalyst 2-4 could further reduce the activation energy of the 
oxa-Michael step for promoting this cascade sequence.  
 
2.2.2 Reaction Optimization 
In view of high enantioselectivity, further optimization efforts were performed by 
examining other parameters, such as solvents, temperatures and reaction 
concentrations (Table 2.2). In contrast to other solvents, toluene was revealed as the 
best media (Table 2.2, entry 9, 95% and 87% ee, 3 d). In the hope of higher 
enantioselectivity, we decreased the reaction concentration from 1.0 M to 0.5 M. As a 
result, an excellent enantiomeric excess was achieved (entry 13, 95%, 92% ee) 
without much time penalty (entry 13, reaction completed in 4 d). If concentration was 
down to 0.2 M, 95% ee was achieved, but with a consumption of 9 d (entry 14). 
Table 2.2 Influence of solvent and concentration on the enantioselective reaction.a 
 






Yield [%]b d.r.[%]c Yield [%]b ee [%]d 
1 CH2Cl2 21 0.4:1 72 79 
2 CHCl3 13 0.8:1 83 75 
3 DCE 9 0.7:1 86 77 
4 Et2O 10 0.9:1 81 67 
5 THF 23 2.6:1 56 62 
6 Dioxane 35 3.0:1 61 67 
7 MeOH 25 1.8:1 73 6 
8 i-PrOH 25 2.2:1 68 34 
9 Toluene <5 n.d. 95 87 
10 Xylenes <5 n.d. 92 88 
11 DMF 59 1.9:1 33 7 
12 Cyclohexane 10 1.1:1 34 85 
13e Toluene <5 n.d. 95 92 
14f Toluene <5 n.d. 90 95 
a Unless specified, see the Experimental section for reaction conditions. b Yield of isolated product. 
c Determined by 1H NMR analysis of the crude mixture. d Enantiomeric excess (ee) was 
determined by HPLC analysis. e 0.5 M, 4 d. f 0.2 M, 9 d. 
 
2.2.3 Substrate Scope 
Having established the optimal reaction conditions, we next examined the 
generality of this catalytic process. Remarkably, this enantioselective cascade reaction 
served as a reliable synthetic process for the preparation of densely functionalized 
pyrano–chromenes (Table 2.3). Significantly, the new stereogenetic center was 
efficiently created in good to excellent enantioselectivities in a one-pot manner. 
Moreover, the process not only afforded a pyrano–chromene complex, and also bore a 
diversely structural variation of (E)-3-benzylidenechroman-4-ones 2-5 (Table 2.3, 
entries 1–17, when R = aryl; entries 18 and 19, when R = alkyl). The process also 
bore the replacement of “O” by “S” and “CH2” to introduce different heterocycles 




(entries 16 and 17). For example, the catalyst 2-4-promoted cascade process smoothly 
afforded moderate to excellent yields (60–99%) and high to excellent 
enantioselectivities (80–99% ee). The efficiency of catalyst 2-4 allowed the reaction 
to bear a diverse structure of benzylidenechroman-4-one substrates which possess 
neutral functional groups (entries 1, 14–17, 60–95%, 80–94% ee), electron-donating 
groups (entries 2–7, 72–99%, 82–93% ee) and electron-withdrawing groups (entries 
8–12, 85–91%, 87–99% ee) in the backbone. Noticeably, the bulky alkyl group 
involved in benzylidenechroman-4-ones also worked to afford the desired product 
with good yields (86% and 75% respectively, entries 18 and 19) and high 
enantioselectivities (86% and 87% ee, entries 18 and 19). When a heterocyclic 
thiophene was introduced to benzylidenechroman-4-one backbone, the reaction still 
provided a good enantioselectivity (entry 13, 86%, 81% ee). The absolute 
configuration of the pyrano–chromene 2-8f was unequivocally determined by 
single-crystal X-ray diffraction analysis (Figure 2.2).126 
 
Table 2.3 Substrate scope of the reaction. a 
 
Entry X Y R Yield [%]b ee [%]c 
1f O H Ph(2-8a) 95 92 
2e O H 3-ClC6H4(2-8b) 93 88 
3e O H 4-ClC6H4(2-8c) 92 90 
4e O H 3,4-Cl2C6H3(2-8d) 88 92 
5e O H 2-F-4-ClC6H3(2-8e) 83 87 
6e O H 2-BrC6H4(2-8f) 99 86 
                                                              
126  CCDC 790340 (2-8f) contains the supplementary crystallographic data for this paper. These data can be 
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7d O H 4-NO2C6H4(2-8g) 72 93 
8g O H 4-MeOC6H4(2-8h) 90 99 
9g O H 4-allyloxyC6H4(2-8i) 85 90 
10e O H 2-allyloxyC6H4(2-8j) 91 92 
11e O H 3-PhOC6H4(2-8k) 90 87 
12f O H 4-i-PrC6H4(2-8l) 88 88 
13g O H 2-thiophenyl(2-8m) 86 81 
14e O 6-Cl Ph(2-8n) 88 92 
15e O 6-Me Ph(2-8o) 91 94 
16g CH2 H Ph(2-8p) 60 80 
17g S H Ph(2-8q) 85 81 
18g O H Cyclohexyl(2-8r) 86 86 
19g O H i-Pr(2-8s) 75 87 
a Unless specified, see the Experimental section for reaction conditions. b yield of isolated product. c 
Enantiomeric excess (ee) was determined by HPLC analysis. d Reaction time: 2 d. e 3 d. f 4 d. g 5 d. 
 
 
Figure 2.2 X-ray crystal structure of compound 2-8f. 
 
 





In conclusion, this study has developed a small library of novel and easily 
accessible chiral bifunctional indane amine-thiourea catalysts and applied them to a 
cascade Michael–Oxa-Michael–Tautomerization reaction of malononitrile to enones. 
The densely functionalized chiral pyrano–chromenes were obtained in a one-pot 
manner in good to high yields (up to 99%) and high to excellent enantioselectivities 
(up to 99% ee). Moreover, this catalytic system also tolerated many synthetically 
useful functional groups, such as nitrile, nitro, amino groups which might be 
manipulated for accessing more sophisticated heterocyclic compounds. This study is 
of considerable importance since it provides a facile and concise way to synthesize a 
series of bifunctional indane amine-thiourea catalysts from different available starting 
materials. These powerful catalysts serve as essential complements to other chiral 
scaffolds based urea/thiourea catalysts to catalyze this interesting Michael–
Oxa-Michael–Tautomerization reaction. Further application of the catalytic system to 
other new reactions is under investigation. 
 
2.4 Experimental Section 
2.4.1 General Information 
Chemicals and solvents were purchased from commercial suppliers and used as 
received. 1H and 13C NMR spectra were recorded on a Bruker ACF300 (300 MHz) or 
AMX500 (500 MHz) spectrometer. Chemical shifts were reported in parts per million 
(ppm), and the residual solvent peak was used as an internal reference: proton 
(chloroform δ 7.26), carbon (chloroform δ 77.0) or tetramethylsilane (TMS δ 0.00) 
was used as a reference. Multiplicity was indicated as follows: s (singlet), d (doublet), 
t (triplet), q (quartet), m (multiplet), dd (doublet of doublet), bs (broad singlet). 
Coupling constants were reported in Hertz (Hz). Low resolution mass spectra were 




obtained on a Finnigan/MAT LCQ spectrometer in ESI mode, and a Finnigan/MAT 
95XL-T mass spectrometer in EI mode. All high resolution mass spectra were 
obtained on a Finnigan/MAT 95XL-T spectrometer. For thin layer chromatography 
(TLC), Merck pre-coated TLC plates (Merck 60 F254) were used, and compounds 
were visualized with a UV light at 254 nm. Further visualization was achieved by 
staining with iodine, or ninhydrin followed by heating using a heat gun. Flash 
chromatography separations were performed on Merck 60 (0.040-0.063 mm) mesh 
silica gel. The enantiomeric excesses of products were determined by chiral phase 
HPLC analysis. Optical rotations were recorded on Jasco DIP-1000 polarimeter. 
 
2.4.2 Preparation of Catalysts 
Preparation of indane catalysts 2-2a/2b/2c 








A solution of (Boc)2O (2.4 g, 11 mmol) in THF (5 ml) was added to the mixture 
of the amino alcohol a (1.5 g, 10 mmol) and sodium carbonate (2.12 g, 20 mmol) in 
THF/H2O (1:1, 60 ml) at 0°C. The mixture was stirred at 0°C for 1h and then at room 
temperature for another two 2h (TLC was used to monitor the reaction). Water (30 ml) 
was added to the mixture upon completion. The organic layer was separated and the 
aqueous layer was extracted with ethyl acetate (3 x 50 ml). The combined organic 
layers was washed with brine (60 ml) and dried with anhydrous MgSO4 for 1h. It was 
then filtered and the solvent was removed under vacuum to give the product (2.5 g) 
with quantitative yield. It was sufficiently pure for the next step. The pure product 
was obtained by purification with silica gel chromatography. 1H NMR (500 MHz, 
CDCl3): δ = 7.3-7.29 (m, 1H), 7.24-7.22 (m, 3H), 5.11 (d, J = 28.7 Hz, 2H), 4.60 (s, 
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1H), 3.13 (dd, J = 16.6, 5.2 Hz, 1H), 2.93 (dd, J = 16.6, 1.7 Hz, 1H), 1.96 (s, 1H), 
1.51 (s, 9H); 13C NMR (125 MHz, CDCl3): δ = 156.30, 140.82, 139.82, 128.18, 
127.12, 125.33, 124.47, 79.88, 73.65, 58.89, 39.41, 28.39; HRMS (ESI) calcd for 
C14H19NO3 (M + H+) 249.1365, found 249.1367. 
 
tert-Butyl (1S,2S)-2-amino-2,3-dihydro-1H-inden-1-ylcarbamate c128 
 
Diisopropyl azodicarboxylate (3.0 g, 15 mmol) was added to a stirred solution of 
compound b (2.5 g, 10 mmol) and triphenylphosphane (3.15 g, 12 mmol) in THF (50 
mL) at 0 °C via syringe under nitrogen atmosphere. After 10 min, diphenylphosphoryl 
azide (DPPA) (4.1 g, 15 mmol) was added dropwise by syringe. The solution was 
stirred overnight at room temperature. After that, triphenylphosphane (5.3 g, 20 mmol) 
was added in one portion, and the solution was stirred at room temperature for 2 hours. 
Water (5 mL) was then added and the solution was heated at 50°C for 6 h. The 
reaction mixture was concentrated and the residue was purified by silica gel 
chromatography (eluting with 1:1 EtOAc-DCM then 1:10 methanol-DCM) to obtain 
the white solid product (1.57 g, 63% yield, two steps). 1H NMR (300 MHz, CDCl3): δ 
= 7.20-7.19 (d, J = 5.9 Hz, 4H), 4.85-4.63 (m, 2H), 3.42 (dd, J = 14.8, 7.5 Hz, 1H), 
3.19 (dd, J = 15.6, 7.4 Hz, 1H), 2.63 (dd, J = 15.6, 8.2 Hz, 1H), 1.75 (s, 2H), 1.49 (s, 
9H); 13C NMR (75 MHz, CDCl3): δ = 156.29, 141.55, 140.60, 128.07, 126.94, 124.78, 
123.80, 79.65, 64.52, 62.39, 39.25, 28.37; HRMS (ESI) calcd for C14H21N2O2 (M + 
H+) 249.1603, found 249.1601. 
 
tert-Butyl (1S,2S)-2-(dimethylamino)-2,3-dihydro-1H-inden-1-ylcarbamate d129 
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To a solution of compound c (0.75 g, 3 mmol) in 15 mL CH3CN was added 
aqueous formaldehyde (37% w/w, 1.2 mL, 15 mmol), the solution was stirred at room 
temperature for 15 minutes. After that, NaBH3CN (0.38 g, 6 mmol) was added, 
followed 15 minutes stirring later by AcOH (1 mL). After 1 hour, the reaction mixture 
was dilute with 2% methanol-DCM (40 mL), washed with 1.0 M NaOH (3 x 30), 
dried by MgSO4, and concentrated. The resulting residue was purified by silica gel 
chromatography (eluting with 1: 20 methanol-DCM) to afford the pure product (0.79 
g, 95% yield). 1H NMR (500 MHz, CDCl3): δ = 7.26-7.15 (m, 4H), 5.20 (t, J = 8.4 Hz, 
1H), 4.77 (d, J = 8.8 Hz, 1H), 3.03 (m, 2H), 2.87 (dd, J = 14.0, 7.4 Hz, 1H), 2.40 (s, 
6H), 1.49 (s, 9H); 13C NMR (125 MHz, CDCl3): δ = 155.49, 142.61, 139.71, 127.90, 
126.96, 124.59, 124.13, 79.49, 74.59, 57.25, 42.94, 33.68, 28.43; HRMS (ESI) calcd 




To a solution of compound d (0.7 g, 2.5 mmol) in 3 mL methanol was added 3 
mL concentrated HCl solution. The mixture was stirred at room temperature for 5 hrs, 
then 40% NaOH solution was added until pH of mixture was 14. After extraction by 
DCM (5 x 10 mL), the organic layer was combined and dried by MgSO4, then 
concentrated. The pure product (0.41 g, 93% yield) was obtained by silica gel 
chromatography (very short column, eluting with 1:10 to 1:5 methanol-DCM). 1H 
NMR (500 MHz, CDCl3): δ = 7.30 (d, J = 7.3 Hz, 1H), 7.23-7.16 (m, 3H), 4.23 (d, J 
= 7.3 Hz, 1H), 2.95 (dd, J = 13.4, 6.1 Hz, 1H), 2.89-2.80 (m, 2H), 2.40 (s, 6H), 1.81 (s, 




2H); 13C NMR (125 MHz, CDCl3): δ = 145.30, 139.71, 127.30, 126.68, 124.59, 
123.42, 77.76, 59.07, 43.02, 31.17; HRMS (ESI) calcd for C11H17N2 (M + H+) 





To a solution of compound g (0.4 g, 2.27 mmol) in 10 mL DCM was added 
1-isothiocyanato-3,5-bis(trifluoromethyl)benzene (0.59 g, 2.16 mmol) dropwise. The 
mixture was stirred at room temperature for 30 min, reaction completed. The solvent 
was removed by rotary evaporation and pure product 2-2a (1.0 g, 98% yield) was 
obtained by silica gel chromatography (eluting with 1:5 EtOAc-hexane then 1: 10 
methanol-DCM). 1H NMR (500 MHz, CDCl3): δ = 12.84 (s, 1H), 8.10 (s, 2H), 7.61 (s, 
1H), 7.42-7.28 (m, 4H), 6.86 (d, J = 3.2 Hz, 1H), 5.22 (m, 1H), 3.75 (q, J = 8.5 Hz, 
1H), 3.08 (ddd, J = 44.1, 15.9, 9.0 Hz, 2H), 2.52 (s, 6H); 13C NMR (125 MHz, CDCl3): 
δ = 182.25, 141.95, 139.83, 137.38, 133.15, 132.06, 131.80, 131.53, 131.26, 129.35, 
127.86, 125.57, 124.18, 123.46, 122.73, 122.01, 117.60, 74.45, 62.57, 40.75, 25.39; 
HRMS (ESI) calcd for C20H20F6N3S (M + H+) 448.1282, found 448.1277. 
 
tert-Butyl (1S,2S)-2-(pyrrolidin-1-yl)-2,3-dihydro-1H-inden-1-ylcarbamate e130 
 
Compound c (0.75 g, 3 mmol), 1,4-dibromobutane (0.78 g, 3.6 mmol), potassium 
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carbonate (1.08 g, 7.8 mmol), potassium iodide (0.1 g, 0.6 mmol) and 10 mL 
iso-propanol were added into a sealed tube. The mixture was heated at 80 °C for 48 
hrs and then allowed to cool to room temperature. The mixture was filtered and 
washed with DCM, the filtrate was concentrated and the resulting residue was 
purified by silica gel chromatography (eluting with 1:5 EtOAc-hexane then 1:10 
methanol-DCM) to obtain the product e (0.64 g, 70% yield). 1H NMR (500 MHz, 
CDCl3): δ = 7.26-7.16 (m, 4H), 5.25-5.22 (m, 1H), 4.81 (d, J = 9.1 Hz, 1H), 3.17 (dd, 
J = 18.9, 11.0 Hz, 1H), 3.01-2.98 (m, 2H), 2.80-2.75 (m, 4H), 1.85 (s, 4H), 1.49 (s, 
9H); 13C NMR (75 MHz, CDCl3): δ = 155.44, 142.25, 139.68, 128.06, 127.05, 124.56, 
124.08, 79.61, 72.61, 59.61, 52.34, 36.24, 28.41, 23.36; HRMS (ESI) calcd for 




To a solution of compound e (0.6 g, 2.0 mmol) in 3 mL methanol was added 3 
mL concentrated HCl solution. The mixture was stirred at room temperature for 5 hrs, 
then 40% NaOH solution was added until pH of mixture was 14. After extraction by 
DCM (5 x 10 mL), the organic layer was combined and dried by MgSO4, then 
concentrated. The pure product (0.36 g, 90% yield) was obtained by silica gel 
chromatography (very short column, eluting with 1:10 to 1:5 methanol-DCM). 1H 
NMR (500 MHz, CDCl3): δ = 7.31-7.16 (m, 4H), 4.35 (d, J = 7.3 Hz, 1H), 3.10 (dd, J 
= 15.3, 7.7 Hz, 1H), 2.94 (dd, J = 15.3, 9.0 Hz, 1H), 2.86-2.81 (m, 5H), 2.41 (s, 2H), 
1.86 (dd, J = 9.0, 3.9 Hz, 4H); 13C NMR (75 MHz, CDCl3): δ = 145.37, 139.57, 
127.40, 126.78, 124.37, 123.45, 75.99, 61.21, 52.62, 35.34, 23.23; HRMS (ESI) calcd 
for C13H19N2 (M + H+) 203.1548, found 203.1543. 
 







To a solution of compound h (0.36 g, 1.78 mmol) in 10 mL DCM was added 
1-isothiocyanato-3,5-bis(trifluoromethyl)benzene (0.51 g, 1.87 mmol) dropwise. The 
mixture was stirred at room temperature for 30 min, reaction completed. The solvent 
was removed by rotary evaporation and pure product 2-2b (0.84 g, 95% yield) was 
obtained by silica gel chromatography (eluting with 1:5 EtOAc-hexane then 1: 10 
methanol-DCM). 1H NMR (500 MHz, CDCl3): δ = 12.82 (s, 1H), 8.05 (s, 2H), 7.63 (s, 
1H), 7.34 (ddd, J = 37.5, 21.3, 6.6 Hz, 4H), 6.68 (s, 1H), 5.25-5.23 (m, 1H), 4.03 (q, J 
= 8.2 Hz, 1H), 3.11 (dd, J = 8.7, 3.6 Hz, 2H), 2.94-2.84 (m, 4H), 1.90 (s, 4H); 13C 
NMR (125 MHz, CDCl3): δ = 182.77, 141.97, 140.04, 137.91, 132.10, 131.83, 131.31, 
129.36, 127.95, 125.62, 124.29, 123.49, 123.42, 122.12, 117.94, 77.25, 77.00, 76.75, 
70.55, 63.20, 48.55, 26.86, 23.93; HRMS (ESI) calcd for C22H22F6N3S (M + H+) 
474.1439, found 474.1443. 
 
tert-Butyl (1S,2S)-2-(piperidin-1-yl)-2,3-dihydro-1H-inden-1-ylcarbamate f130 
 
Compound c (0.75 g, 3 mmol), 1,5-dibromopentane(0.83 g, 3.6 mmol), 
potassium carbonate (1.08 g, 7.8 mmol), potassium iodide (0.1 g, 0.6 mmol) and 10 
mL iso-propanol were added into a sealed tube. The mixture was heated at 80 °C for 
48hrs and then allowed to cool to room temperature. The mixture was filtered and 
washed with DCM, the filtrate was concentrated and the resulting residue was 




purified by silica gel chromatography (eluting with 1:10 EtOAc-hexane then 1:10 
methanol-DCM) to obtain the product f (0.71 g, 75% yield). 1H NMR (500 MHz, 
CDCl3): δ = 7.28-7.12(m, 4H), 5.24 (dd, J = 13.7, 5.2 Hz, 1H), 4.89-4.87 (m, 1H), 
3.05 (s, 2H), 2.87 (dd, J = 18.6, 11.7 Hz, 1H), 2.60 (dd, J = 23.2, 4.9 Hz, 4H), 
1.61-1.59 (m, 4H), 1.48 (s, 11H); 13C NMR (125 MHz, CDCl3): δ = 155.41, 142.52, 
139.97, 127.85, 126.88, 124.50, 124.14, 79.44, 74.64, 56.53, 51.60, 33.81, 28.41, 




To a solution of compound f (0.7 g, 2.2 mmol) in 3 mL methanol was added 3 
mL concentrated HCl solution. The mixture was stirred at room temperature for 5 hrs, 
then 40% NaOH solution was added until pH of mixture was 14. After extraction by 
DCM (5 x 10 mL), the organic layer was combined and dried by MgSO4, then 
concentrated. The pure product (0.43 g, 90% yield) was obtained by silica gel 
chromatography (very short column, eluting with 1:10 to 1:5 methanol-DCM). 1H 
NMR (500 MHz, CDCl3): δ = 7.22 (d, J = 7.3 Hz, 1H), 7.14-7.07 (m, 3H), 4.25 (d, J 
= 6.9 Hz, 1H), 2.92 (dd, J = 13.9, 6.6 Hz, 1H), 2.81 (ddd, J = 21.8, 14.7, 8.2 Hz, 2H), 
2.53 (s, 4H), 2.15 (s, 2H), 1.58-1.53 (m, 4H), 1.40 (dt, J = 11.3, 5.8 Hz, 2H); 13C 
NMR (125 MHz, CDCl3): δ = 145.16, 139.87, 127.20, 126.56, 124.42, 123.38, 77.71, 
58.33, 51.96, 31.95, 25.96, 24.40; HRMS (ESI) calcd for C14H21N2 (M + H+) 









To a solution of compound i (0.4 g, 1.85 mmol) in 10 mL DCM was added 
1-isothiocyanato-3,5-bis(trifluoromethyl)benzene (0.53 g, 1.95 mmol) dropwise. The 
mixture was stirred at room temperature for 30 min, reaction completed. The solvent 
was removed by rotary evaporation and pure product 2-2c (0.87 g, 97% yield) was 
obtained by silica gel chromatography (eluting with 1:10 EtOAc-hexane then 1: 10 
methanol-DCM). 1H NMR (500 MHz, CDCl3): δ = 12.20 (s, 1H), 8.06 (s, 2H), 7.70 (s, 
1H), 7.43-7.26 (m, 4H), 6.72 (s, 1H), 5.31 (m, 1H), 3.72 (q, J = 8.2 Hz, 1H), 3.21 (dd, 
J = 16.1, 8.5 Hz, 1H), 3.01 (dd, J = 16.1, 8.8 Hz, 1H), 2.77-2.67 (m, 4H), 1.56 (dd, J 
= 44.8, 22.4 Hz, 7H); 13C NMR (125 MHz, CDCl3): δ = 183.44, 141.53, 140.37, 
137.76, 132.13, 131.85, 131.58, 131.31, 129.41, 127.85, 125.78, 125.58, 124.25, 
123.61, 122.07, 118.82, 75.27, 62.04, 50.65, 26.33, 25.94, 23.84; HRMS (ESI) calcd 
for C23H24F6N3S (M + H+) 488.1595, found 488.1598. 
 
Preparation of indane catalysts 2-3 
(1S,2S)-1-(Piperidin-1-yl)-2,3-dihydro-1H-inden-2-ol k130 
 
Compound j (0.75 g, 5 mmol), 1,5-dibromopentane (1.38 g, 6.0 mmol), 
potassium carbonate (1.80 g, 13 mmol), potassium iodide (0.17 g, 1.0 mmol) and 10 
mL iso-propanol were added into a sealed tube. The mixture was heated at 80 °C for 
48 hrs and then allowed to cool to room temperature. The mixture was filtered and 
washed with DCM, the filtrate was concentrated and the resulting residue was 
purified by silica gel chromatography (eluting with 1:5 EtOAc-hexane then 1:10 




methanol-DCM) to obtain the product k (0.82 g, 75% yield). 1H NMR (300 MHz, 
CDCl3): δ = 7.36-7.33 (m, 1H), 7.12-7.16 (m, 3H), 4.66 (dd, J = 12.3, 5.3 Hz, 1H), 
4.08 (d, J = 4.8 Hz, 1H), 3.25 (dd, J = 16.2, 7.1 Hz, 1H), 2.80 (dd, J = 16.2, 5.5 Hz, 
1H), 2.62-2.61 (m, 4H), 1.58-1.54 (m, 4H), 1.46 (d, J = 5.3 Hz, 2H); 13C NMR (75 
MHz, CDCl3): δ = 140.62, 140.33, 127.66, 126.41, 125.82, 124.90, 78.49, 73.54, 





To a stirred solution of compound k (0.78 g, 3.6 mmol) and triethylamine (1.1 g, 
10.8 mmol) in dry DCM (10 mL) at 0°C under nitrogen was added dropwise 
methanesulfonyl chloride (0.62 g, 5.4 mmol). The mixture was stirred for another 20 
min at room temperature, and the solvent was evaporated under reduced pressure. The 
residue was extracted with DCM, washed successively with water, and brine, and 
dried over MgSO4. The organic layer was concentrated to afford crude mesylate 
intermediate. Then the crude mesylate intermediate was redissolve d in DMF (10 mL), 
followed by adding NaN3 (1.87 g, 28.8 mmol). The mixture was heated under 
nitrogen at 70°C for 6 hrs. After the mixture was cooled, the solvent was evaporated 
under reduced pressure and the residue was extracted with EtOAc (25 mL x 3) and 
dried over MgSO4. The organic layer was removed under reduced pressure, and the 
crude product was purified by silica gel chromatography (eluting with 1:10 
EtOAc-hexane) to afford product l (0.48 g, 55% yield, two step). 1H NMR (500 MHz, 
CDCl3): δ = 7.26-7.10 (m, 4H), 4.63 (d, J = 6.9 Hz, 1H), 3.17 (td, J = 8.0 Hz, 6.8, 1H), 
3.03 (dd, J = 15.8, 7.9 Hz, 1H), 2.81 (dd, J = 15.8, 7.9 Hz, 1H), 2.48 (ddt, J = 38.5, 
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10.7, 5.2 Hz, 4H), 1.53 (dt, J = 11.3, 5.7 Hz, 4H), 1.39 (dd, J = 11.7, 6.0 Hz, 2H); 13C 
NMR (125 MHz, CDCl3): δ = 140.43, 139.14, 128.56, 126.94, 124.71, 124.15, 72.82, 
66.85, 51.91, 33.83, 25.94, 24.30; HRMS (ESI) calcd for C14H19N4 (M + H+) 




To a solution of compound l (0.46 g, 1.9 mmol) in 10 mL THF was added 
triphenylphosphane (1.5 g, 5.7 mmol). The mixture was stirred at room temperature 
for 3 h, then added 3 mL water, heated at 60 oC for 4 hrs. The solvent was removed by 
reduced pressure, and the resulting residue was purified by a very short silica gel 
column (eluting with 1:10 to 1: 5 methanol-DCM) to afford compound m (0.39 g, 95% 
yield). 1H NMR (500 MHz, CDCl3): δ = 7.27 (t, J = 5.8 Hz, 1H), 7.19-7.11 (m, 3H), 
4.31 (d, J = 6.9 Hz, 1H), 2.99-2.83 (m, 3H), 2.60-2.58(m, 4H), 2.45 (s, 2H), 1.64-1.59 
(m, 4H), 1.45 (dt, J = 11.7, 5.8 Hz, 2H); 13C NMR (125 MHz, CDCl3): δ = 144.92, 
139.73, 127.18, 126.54, 124.36, 123.34, 77.45, 58.16, 51.84, 31.67, 25.82, 24.29; 





To a solution of compound m (0.39 g, 1.81 mmol) in 10 mL DCM was added 




1-isothiocyanato-3,5-bis(trifluoromethyl)benzene (0.52 g, 1.90 mmol) dropwise. The 
mixture was stirred at room temperature for 30min, reaction completed. The solvent 
was removed by rotary evaporation and pure product 2-3 (0.90 g, 97% yield) was 
obtained by silica gel chromatography (eluting with 1:10 EtOAc-hexane then 1: 10 
methanol-DCM). 1H NMR (300 MHz, CDCl3): δ = 12.14 (s, 1H), 7.98 (s, 2H), 7.61 (s, 
1H), 7.27 (ddd, J = 20.9, 12.6, 4.3 Hz, 4H), 6.68 (s, 1H), 5.22 (m, 1H), 3.63 (dd, J = 
6.2, 8.3 Hz, 1H), 3.13 (dd, J = 16.1, 8.6 Hz, 1H), 2.92 (dd, J = 16.2, 8.9 Hz, 1H), 
2.68-2.60 (m, 4H), 1.56-1.44 (m, 6H); 13C NMR (75 MHz, CDCl3): δ = 183.34, 
141.50, 140.33, 137.67, 132.31, 131.87, 131.42, 130.98, 129.36, 127.78, 125.76, 
125.53, 124.93, 123.58, 121.31, 118.75, 75.21, 62.01, 50.56, 26.29, 25.90, 23.78; 
HRMS (ESI) calcd for C23H24F6N3S (M + H+) 488.1595, found 488.1587. 
 
Preparation of indane catalysts 2-4 
tert-Butyl (1S,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-ylcarbamate n127 
 
It was prepared by using the same procedure for the synthesis of compound b. 
Quantitative yield. 1H NMR (300 MHz, CDCl3): δ = 7.18-7.11 (m, 4H), 5.00 (s, 1H), 
4.82 (t, J = 5.9 Hz, 1H), 4.35-4.28 (m, 1H), 3.19 (dd, J = 15.8, 7.7 Hz, 1H), 2.81 (dd, 
J = 15.8, 8.1 Hz, 1H), 1.41 (s, 9H); 13C NMR (75 MHz, CDCl3): δ = 157.35, 140.12, 
139.34, 128.40, 127.09, 125.09, 123.05, 81.82, 80.40, 63.98, 38.31, 28.31; HRMS 
(ESI) calcd for C14H19NO3 (M + H+) 249.1365, found 249.1366. 
 
tert-Butyl (1S,2R)-2-amino-2,3-dihydro-1H-inden-1-ylcarbamate o128 
 




It was prepared by using the same procedure for the synthesis of compound c. 
(67% yield, two steps) 1H NMR (500 MHz, CDCl3): δ = 7.29 (m, 1H), 7.21 (d, J = 2.2 
Hz, 3H), 5.23 (s, 1H), 5.03 (s, 1H), 3.82 (s, 1H), 3.12 (dd, J = 15.9, 6.1 Hz, 1H), 2.69 
(dd, J = 15.9, 3.3 Hz, 1H), 1.73 (s, 2H), 1.49 (s, 9H); 13C NMR (125 MHz, CDCl3): δ 
= 156.05, 141.43, 140.60, 128.00, 126.94, 125.20, 124.71, 79.53, 58.56, 54.70, 39.70, 
28.38; HRMS (ESI) calcd for C14H21N2O2 (M + H+) 249.1603, found 249.1606. 
 
tert-Butyl (1S,2R)-2-(piperidin-1-yl)-2,3-dihydro-1H-inden-1-ylcarbamate p130 
 
It was prepared by using the same procedure for the synthesis of compound f. 
(75% yield) 1H NMR (300 MHz, CDCl3): δ = 7.58 (s, 1H), 7.21-7.14 (m, 3H), 5.81 (d, 
J = 5.3 Hz, 1H), 4.90 (s, 1H), 3.02 (p, J = 7.4 Hz, 1H), 2.92-2.89 (m, 2H), 2.42 (dd, J 
= 11.7, 6.2 Hz, 4H), 1.58 (dt, J = 12.0, 6.1 Hz, 6H), 1.46 (s, 9H); 13C NMR (75 MHz, 
CDCl3): δ = 156.03, 143.35, 140.42, 127.83, 126.62, 125.95, 124.17, 78.75, 67.58, 
54.81, 52.40, 34.51, 28.34, 25.76, 24.26; HRMS (ESI) calcd for C19H29N2O2 (M + H+) 




It was prepared by using the same procedure for the synthesis of compound i. (90% 
yield) 1H NMR (500 MHz, CDCl3): δ = 7.30 (d, J = 6.3 Hz, 1H), 7.14-7.08 (m, 3H), 
4.15 (d, J = 5.4 Hz, 1H), 2.80 (qd, J = 14.8, 8.5 Hz, 2H), 2.72-2.68 (m, 1H), 2.48 (s, 
2H), 2.38 (d, J = 3.8 Hz, 2H), 2.30 (s, 2H), 1.56 (dt, J = 11.0, 5.7 Hz, 4H), 1.42-1.40 
(m, 2H); 13C NMR (125 MHz, CDCl3): δ = 144.85, 140.48, 127.51, 126.39, 124.44, 




124.35, 69.87, 55.40, 52.58, 33.51, 25.53, 24.04; HRMS (ESI) calcd for C14H21N2 (M 





It was prepared by using the same procedure for the synthesis of catalyst 2-2c. 
(97% yield) 1H NMR (500 MHz, CDCl3): δ = 8.38 (s, 1H), 7.78 (d, J = 51.1 Hz, 3H), 
7.60 (s, 1H), 7.15-7.05 (m, 3H), 5.53 (s, 1H), 3.06 (d, J = 6.6 Hz, 1H), 2.89 (dd, J = 
15.4, 6.9 Hz, 1H), 2.79-2.74 (m, 1H), 2.31 (s, 4H), 1.25 (s, 6H); 13C NMR (125 MHz, 
CDCl3): δ = 180.13, 141.42, 140.74, 139.08, 133.36, 133.08, 132.81, 132.55, 128.71, 
126.97, 126.83, 126.05, 124.47, 123.88, 123.71, 121.71, 119.54, 118.85, 68.02, 58.90, 
52.26, 34.34, 25.63, 23.88; HRMS (ESI) calcd for C23H24F6N3S (M + H+) 488.1595, 
found 488.1590. 
 
2.4.3 Representative Procedure for Michael–Oxa-Michael–Tautomerization 
Reaction 
 
To a solution of malononitrile 2-6 (10 mg, 0.15mmol) in 0.2mL toluene was 
added (E)-3-benzylidenechroman-4-one 2-5a (24 mg, 0.1 mmol) at room temperature, 
followed by adding catalyst 2-4 (4.9 mg, 0.01 mmol). The mixture was stirred at room 
temperature for 4 d. The crude product was purified by column chromatography on 




silica gel, eluted by hexane/EtOAc=8:1 then 4:1 to afford 28.7 mg (95% yield) of the 
desired product 2-8a as yellow solid. 
 








(Table 2.3 , entry 1 ). 95% yield, 92% ee; 1H NMR (500 MHz, CDCl3): δ = 7.39‒7.32 
(m, 3H), 7.27 (q, J = 6.0 Hz, 3H), 7.23–7.15 (m, 1H), 6.95 (t, J = 7.5 Hz, 1H), 6.79 (d, 
J = 8.1 Hz, 1H), 4.64 (s, 2H), 4.63 (d, J = 13.2 Hz, 1H), 4.43 (d, J = 13.8 Hz, 1H), 
4.03 (s, 1H); 13C NMR (125 MHz, CDCl3): δ = 158.77, 154.12, 140.87, 138.01, 
130.30, 129.02, 127.92, 127.88, 121.26, 121.04, 119.26, 116.66, 115.94, 105.05, 
66.48, 61.16, 39.71; HRMS (EI) calcd for C19H14O2N2 302.1055, found 302.1048; 
HPLC (Chiralpak IC, i-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 254 nm): 




e (2-8b) (Table 2.3 , entry 2 ). 93% yield, 88% ee; 1H NMR (500 MHz, CDCl3): δ = 
7.35 (d, J = 7.7Hz, 1H), 7.30–7.26 (m, 3H), 7.21 (t, J = 7.9Hz, 1H), 7.17 (d, J = 6.8Hz, 
1H), 6.97 (t, J = 7.6Hz, 1H), 6.81 (d, J = 8.2Hz, 1H), 4.66 (s, 2H), 4.64 (d, J = 14.5Hz, 
1H), 4.43 (d, J = 14.5Hz, 1H), 4.02 (s, 1H); 13C NMR (125 MHz, CDCl3): δ = 158.99, 




154.13, 143.10, 138.35, 135.03, 130.52, 130.28, 128.25, 127.94, 126.19, 121.35, 
121.14, 119.04, 116.45, 116.00, 104.28, 66.30, 60.42, 39.53; HRMS (EI) calcd for 
C19H13O2N2Cl 336.0666, found 336.0649; HPLC (Chiralpak IC, i-propanol/hexane = 
20/80, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 12.1 min, tR (minor) = 7.1 min, 
ee = 88%; [α]30D = -53.6 (c = 0.85 in CHCl3). 
 
(S)-2-Amino-4-(4-chlorophenyl)-4,5-dihydropyrano[3,2-c]chromene-3-carbonitril
e (2-8c) (Table 2.3 , entry 3 ). 92% yield, 90% ee; 1H NMR (500 MHz, CDCl3): δ = 
7.37–7.29 (m, 3H), 7.24–7.16 (m, 3H), 6.96 (t, J = 7.6Hz, 1H), 6.80(d, J = 7.6Hz, 1H), 
4.67 (s, 2H), 4.62 (d, J = 13.7Hz, 1H), 4.41 (d, J = 13.8Hz, 1H), 4.02 (s, 1H); 13C 
NMR (125 MHz, CDCl3): δ = 158.82, 154.15, 139.49, 138.34, 133.82, 130.51, 129.25, 
129.24, 121.36, 121.12, 119.03, 116.49, 116.03, 104.44, 66.31, 60.78, 39.21; HRMS 
(EI) calcd for C19H13O2N2Cl 336.0666, found 336.0653; HPLC (Chiralpak IC, 
i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 12.5 min, 
tR (minor) = 7.3 min, ee = 90%; [α]30D = -62.3 (c = 0.90 in CHCl3). 
 
(S)-2-Amino-4-(3,4-dichlorophenyl)-4,5-dihydropyrano[3,2-c]chromene-3-carbon
itrile (2-8d) (Table 2.3 , entry 4 ). 88% yield, 92% ee; 1H NMR (500 MHz,DMSO-d6): 
δ = 7.64 (d, J = 8.3Hz, 1H), 7.53 (d, J = 2.0Hz, 1H), 7.37 (dd, J = 7.6, 1.3Hz, 1H), 
7.29 (dd, J = 8.3, 2.0Hz, 1H), 7.27–7.21 (m, 1H), 7.08 (s, 2H), 7.01 (t, J = 7.2Hz, 1H), 




6.82 (d, J = 8.0Hz, 1H), 4.75 (d, J = 14.6Hz, 1H), 4.33 (d, J = 14.0Hz, 1H), 4.21 (s, 
1H); 13C NMR (75 MHz, DMSO-d6): δ = 159.80, 153.63, 143.54, 137.26, 131.31, 
131.13, 130.43, 130.04, 129.67, 128.16, 121.29, 121.02, 119.82, 116.49, 115.70, 
104.34, 65.58, 55.44, 38.03; HRMS (EI) calcd for C19H12O2N2Cl2 370.0276, found 
370.0179; HPLC (Chiralpak IC, i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 
254 nm): tR (major) = 12.4 min, tR (minor) = 6.4 min, ee = 92%; [α]30D = -67.7 (c = 
1.05 in CHCl3). 
 
(S)-2-Amino-4-(4-chloro-2-fluorophenyl)-4,5-dihydropyrano[3,2-c]chromene-3-c
arbonitrile (2-8e) (Table 2.3 , entry 5 ). 83% yield, 87% ee; 1H NMR (500 MHz, 
CDCl3): δ = 7.33 (dd, J = 7.7, 1.5Hz, 1H), 7.26 (t, J = 8.2Hz, 1H), 7.20 (td, J = 7.9, 
1.5Hz, 1H), 7.16 (dd, J = 8.3, 1.9Hz, 1H), 7.11 (dd, J = 9.8, 2.0Hz, 1H), 6.96 (dd, J = 
11.0, 4.1Hz, 1H), 6.80 (d, J = 8.0Hz, 1H), 4.73–4.68 (m, 3H), 4.45–4.43 (m, 2H); 13C 
NMR (125 MHz, CDCl3): δ = 161.45, 159.63, 159.45, 154.18, 138.70, 134.58, 134.50, 
130.69, 130.66, 130.57, 126.55, 126.45, 125.50, 125.47, 121.37, 121.10, 118.77, 
116.73, 116.53, 116.43, 116.04, 103.67, 66.10, 59.08, 32.21; HRMS (EI) calcd for 
C19H12O2N2ClF 354.0571, found 354.0558; HPLC (Chiralpak IC, i-propanol/hexane 
= 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 10.6 min, tR (minor) = 6.4 
min, ee = 87%; [α]30D = -38.0 (c = 1.03 in CHCl3). 
 





le (2-8f) (Table 2.3 , entry 6 ). 99% yield, 86% ee; 1H NMR (500 MHz, CDCl3): δ = 
7.56 (dd, J = 8.0, 1.1Hz, 1H), 7.39–7.30 (m, 3H), 7.20 (td, J = 7.9, 1.6Hz, 1H), 7.14 
(ddd, J = 8.0, 7.1, 1.9Hz, 1H), 6.96 (td, J = 7.6, 1.0Hz, 1H), 6.79 (dd, J = 8.1, 0.9Hz, 
1H), 4.73 (m, 4H), 4.40 (dd, J = 13.8, 0.9Hz, 1H); 13C NMR (125 MHz, CDCl3): δ = 
159.35, 154.18, 139.89, 138.16, 133.21, 130.56, 130.40, 129.43, 128.49, 123.78, 
121.29, 121.05, 118.90, 116.52, 115.97, 104.95, 66.07, 60.05, 38.36; HRMS (EI) 
calcd for C19H13O2N2Br 380.0160, found 380.0143; HPLC (Chiralpak IC, 
i-propanol/hexane = 15/85, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 14.7 min, 
tR (minor) = 10.8 min, ee = 86%; [α]30D = -18.1 (c = 0.58 in CHCl3). 
 
(S)-2-Amino-4-(4-nitrophenyl)-4,5-dihydropyrano[3,2-c]chromene-3-carbonitrile 
(2-8g) (Table 2.3 , entry 7 ). 72% yield, 93% ee; 1H NMR (500 MHz, CDCl3): δ = 
8.30–8.21 (m, 2H), 7.53–7.44 (m, 2H), 7.36 (dd, J = 7.7, 1.5Hz, 1H), 7.23 (td, J = 7.9, 
1.6Hz, 1H), 6.98 (td, J = 7.6, 0.8Hz, 1H), 6.82 (d, J = 8.1Hz, 1H), 4.78 (s, 2H), 4.66 
(dd, J = 13.7, 0.9Hz, 1H), 4.38 (d, J = 13.7Hz, 1H), 4.18 (s, 1H); 13C NMR (125 MHz, 
CDCl3): δ = 159.09, 154.20, 148.23, 147.72, 139.07, 130.87, 128.86, 124.41, 121.53, 
121.26, 118.65, 116.22, 116.15, 103.37, 66.11, 59.90, 39.63; HRMS (EI) calcd for 
C19H13O4N3 347.0906, found 347.0917; HPLC (Chiralpak IC, i-propanol/hexane = 
20/80, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 32.3 min, tR (minor) = 21.0 
min, ee = 93%; [α]30D = -106.5 (c = 0.23 in CHCl3). 






rile (2-8h) (Table 2.3 , entry 8 ). 90% yield, 99% ee; 1H NMR (500 MHz, CDCl3): δ = 
7.34 (dd, J = 7.7, 1.4Hz, 1H), 7.23–7.14 (m, 3H), 6.95 (td, J = 7.6, 0.8Hz, 1H), 6.90–
6.84 (m, 2H), 6.79 (d, J = 8.1Hz, 1H), 4.62 (d, J = 13.9Hz, 1H), 4.60 (s, 2H),  4.44 
(d, J = 13.9Hz, 1H), 4.00 (s, 1H), 3.80 (s, 3H); 13C NMR (125 MHz, CDCl3): δ = 
159.28, 158.58, 154.14, 137.86, 133.00, 130.26, 128.96, 121.26, 121.02, 119.30, 
116.74, 115.95, 114.43, 105.31, 66.53, 61.62, 55.30, 38.94; HRMS (EI) calcd for 
C20H16O3N2 332.1161, found 332.1158; HPLC (Chiralpak IA, i-propanol/hexane = 
20/80, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 10.4 min, tR (minor) = 8.2 min, 
ee = 99%; [α]30D = -45.5 (c = 0.97 in CHCl3). 
 
(S)-4-(4-(Allyloxy)phenyl)-2-amino-4,5-dihydropyrano[3,2-c]chromene-3-carboni
trile (2-8i) (Table 2.3 , entry 9 ). 85% yield, 90% ee; 1H NMR (500 MHz, CDCl3): δ = 
7.34 (dd, J = 7.6, 1.5Hz, 1H), 7.22–7.14 (m, 3H), 6.95 (td, J = 7.6, 0.9Hz, 1H), 6.91–
6.85 (m, 2H), 6.79 (dd, J = 8.1, 0.8Hz, 1H), 6.05 (ddt, J = 17.1, 10.5, 5.3Hz, 1H), 5.41 
(ddd, J = 17.2, 3.1, 1.5Hz, 1H), 5.32–5.26 (m, 1H), 4.65–4.56 (m, 3H), 4.52 (dt, J = 
5.3, 1.4Hz, 2H), 4.44 (dd, J = 13.7, 0.9Hz, 1H), 3.99 (s, 1H); 13C NMR (125 MHz, 
CDCl3): δ = 158.62, 158.29, 154.10, 137.81, 133.17, 133.15, 130.24, 128.93, 121.25, 
121.01, 119.35, 117.75, 116.72, 115.93, 115.19, 105.28, 68.85, 66.51, 61.45, 38.92; 
HRMS (EI) calcd for C22H18O3N2 358.1317, found 358.1317; HPLC (Chiralpak IC, 




i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 15.3 min, 
tR (minor) = 10.1 min, ee = 90%; [α]30D = -52.9 (c = 1.05 in CHCl3). 
 
(S)-4-(2-(Allyloxy)phenyl)-2-amino-4,5-dihydropyrano[3,2-c]chromene-3-carboni
trile (2-8j) (Table 2.3 , entry 10 ). 91% yield, 92% ee,; 1H NMR (500 MHz, CDCl3): δ 
= 7.31 (dd, J = 7.7, 1.5Hz, 1H), 7.26 (dd, J = 7.7, 1.4Hz, 1H), 7.24–7.19 (m, 1H), 7.17 
(td, J = 7.8, 1.6Hz, 1H), 6.94 (ddd, J = 10.9, 8.4, 4.2Hz, 2H), 6.87 (d, J = 8.2Hz, 1H), 
6.77 (dd, J = 8.1, 0.6Hz, 1H), 6.06 (ddt, J = 17.1, 10.5, 5.3Hz, 1H), 5.46–5.36 (m, 1H), 
5.33–5.21 (m, 1H), 4.72 (dd, J = 13.9, 1.1Hz, 1H), 4.65 (s, 1H), 4.62 (s, 2H), 4.56 (d, 
J = 5.3Hz, 2H), 4.48 (dd, J = 13.9, 0.7Hz, 1H); 13C NMR (125 MHz, CDCl3): δ = 
159.56, 156.18, 154.10, 137.81, 133.16, 129.98, 129.32, 129.20, 128.80, 121.50, 
121.14, 120.83, 119.50, 117.65, 116.92, 115.80, 112.17, 105.82, 69.23, 66.50, 60.32, 
32.16; HRMS (EI) calcd for C22H18O3N2 358.1317, found 358.1311; HPLC 
(Chiralpak IC, i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR 
(major) = 11.3 min, tR (minor) = 8.0 min, ee = 92%; [α]30D = -11.6 (c = 0.6 in CHCl3). 
 
(S)-2-Amino-4-(3-phenoxyphenyl)-4,5-dihydropyrano[3,2-c]chromene-3-carbonit
rile (2-8k) (Table 2.3 , entry 11 ). 90% yield, 87% ee; 1H NMR (500 MHz, CDCl3): δ 
= 7.37–7.27 (m, 4H), 7.22–7.16 (m, 1H), 7.09 (t, J = 7.4Hz, 1H), 7.05–6.99 (m, 3H), 
6.97 (t, J = 1.9Hz, 1H), 6.94 (t, J = 7.5Hz, 1H), 6.88 (dd, J = 8.1, 2.3Hz, 1H), 6.80 (d, 




J = 8.1Hz, 1H), 4.65(s, 2H), 4.63 (d, J = 13.5Hz, 1H), 4.47 (d, J = 13.7Hz, 1H), 4.00 
(s, 1H); 13C NMR (125 MHz, CDCl3): δ = 158.89, 157.82, 156.90, 154.17, 143.07, 
138.13, 130.38, 130.32, 129.78, 123.40, 122.69, 121.29, 121.09, 119.07, 118.91, 
118.47, 118.00, 116.60, 115.95, 104.72, 66.45, 60.93, 39.66; HRMS (EI) calcd for 
C25H18O3N2 394.1317, found 394.1307; HPLC (Chiralpak IC, i-propanol/hexane = 
20/80, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 11.9 min, tR (minor) = 7.5 min, 
ee = 87%; [α]30D = -25.6 (c = 1.12 in CHCl3). 
 
(S)-2-Amino-4-(4-isopropylphenyl)-4,5-dihydropyrano[3,2-c]chromene-3-carboni
trile (2-8l) (Table 2.3 , entry 12 ). 88% yield, 88% ee; 1H NMR (500 MHz, CDCl3): δ 
= 7.34 (dd, J = 7.7, 1.5Hz, 1H), 7.22–7.14 (m, 5H), 6.95 (td, J = 7.6, 1.0Hz, 1H), 
6.83–6.76 (m, 1H), 4.68–4.56 (m, 3H), 4.46 (dd, J = 3.8, 0.7Hz, 1H), 3.99 (s, 1H), 
2.88 (m, 1H), 1.23 (d, J = 6.9Hz, 6H); 13C NMR (125 MHz, CDCl3): δ = 158.75, 
154.10, 148.45, 138.17, 137.83, 130.20, 127.73, 127.04, 121.22, 120.99, 119.42, 
116.73, 115.90, 105.34, 66.55, 61.29, 39.25, 33.72, 23.91, 23.88; HRMS (EI) calcd 
for C22H20O2N2 344.1525, found 344.1526; HPLC (Chiralpak IC, i-propanol/hexane = 
20/80, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 12.4 min, tR (minor) = 7.1 min, 
ee = 88%; [α]30D = -36.0 (c = 1.25 in CHCl3). 
 
(S)-2-Amino-4-(thiophen-2-yl)-4,5-dihydropyrano[3,2-c]chromene-3-carbonitrile 




(2-8m) (Table 2.3 , entry 13 ). 86% yield, 81% ee; 1H NMR (500 MHz, CDCl3): δ = 
7.34 (dd, J = 7.7, 1.5Hz, 1H), 7.28–7.24 (m, 1H), 7.21 (td, J = 7.9, 1.6Hz, 1H), 7.00–
6.96 (m, 1H), 6.97–6.92 (m, 2H), 6.81 (d, J = 8.1Hz, 1H), 4.69 (m, 3H), 4.64–4.58 (m, 
1H), 4.40 (s, 1H); 13C NMR (125 MHz, CDCl3): δ = 158.76, 154.25, 145.68, 137.90, 
130.49, 126.97, 125.83, 125.65, 121.32, 121.23, 119.01, 116.60, 116.04, 104.61, 
66.45, 61.45, 34.86; HRMS (EI) calcd for C17H12O2N2S 308.0619, found 308.0612; 
HPLC (Chiralpak IC, i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): 




e (2-8n) (Table 2.3 , entry 14 ). 88% yield, 92% ee; 1H NMR (500 MHz, CDCl3): δ = 
7.36 (dd, J = 10.1, 4.6Hz, 2H), 7.33–7.23 (m, 4H), 7.14 (dd, J = 8.6, 2.6Hz, 1H), 6.72 
(d, J = 8.6Hz, 1H), 4.70–4.60 (m, 3H), 4.43 (dd, J = 14.0, 0.8Hz, 1H), 4.03 (s, 1H); 
13C NMR (125 MHz, CDCl3): δ = 158.54, 152.61, 140.54, 137.15, 129.93, 129.13, 
128.08, 127.88, 126.40, 121.05, 118.94, 117.92, 117.27, 106.29, 66.68, 61.26, 39.72; 
HRMS (EI) calcd for C19H13O2N2Cl 336.0666, found 336.0653; HPLC (Chiralpak IC, 
i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 9.2 min, 
tR (minor) = 8.0 min, ee = 92%; [α]30D = -12.2 (c = 0.88 in CHCl3). 
 





e (2-8o) (Table 2.3 , entry 15 ). 91% yield, 94% ee; 1H NMR (500 MHz, CDCl3): δ = 
7.36–7.33 (m, 2H), 7.29–7.26 (m, 3H), 7.16 (d, J = 1.9Hz, 1H), 7.00 (dd, J = 8.2, 
1.9Hz, 1H), 6.70 (d, J = 8.2Hz, 1H), 4.60(s, 2H),  4.59 (dd, J = 13.7, 1.0Hz, 1H), 
4.39 (dd, J = 13.7, 0.8Hz, 1H), 4.03 (s, 1H); 13C NMR (125 MHz, CDCl3): δ = 158.76, 
152.00, 140.96, 138.22, 130.76, 130.66, 129.02, 127.89, 121.42, 119.22, 116.44, 
115.71, 105.13, 66.47, 61.37, 39.78, 20.68; HRMS (EI) calcd for C20H16O2N2 
316.1212, found 316.1214; HPLC (Chiralpak IC, i-propanol/hexane = 20/80, flow 
rate 1.0 mL/min, λ = 254 nm): tR (major) = 11.3 min, tR (minor) = 8.0 min, ee = 94%; 
[α]30D = -68.7 (c = 0.64 in CHCl3). 
 
(S)-2-Amino-4-phenyl-5,6-dihydro-4H-benzo[h]chromene-3-carbonitrile (2-8p) 
(Table 2.3 ,entry 16 ). 60% yield, 80% ee; 1H NMR (500 MHz, CDCl3): δ = 7.46 (d, J 
= 7.3Hz, 1H), 7.35–7.19 (m, 7H), 7.11 (d, J = 7.1Hz, 1H), 4.55 (s, 2H), 4.08 (s, 1H), 
2.84–2.65 (m, 2H), 2.23–2.00 (m, 2H); 13C NMR (125 MHz, CDCl3): δ = 158.99, 
142.67, 140.86, 135.55, 128.76, 128.42, 128.19, 128.04, 127.47, 126.47, 120.76, 
119.77, 111.77, 61.18, 42.82, 27.47, 25.00; HRMS (EI) calcd for C20H16ON2 
300.1263, found 300.1249; HPLC (Chiralpak IC, i-propanol/hexane = 15/85, flow 
rate 1.0 mL/min, λ = 254 nm): tR (major) = 10.6 min, tR (minor) = 12.3 min, ee = 80%; 
[α]30D = -39.5 (c = 0.45 in CHCl3). 
 





(2-8q) (Table 2.3 , entry 17 ). 85% yield, 81% ee; 1H NMR (500 MHz, CDCl3): δ = 
7.54–7.52 (m, 1H), 7.37–7.31 (m, 4H), 7.31–7.26 (m, 1H), 7.23 (dd, J = 6.4, 2.7Hz, 
1H), 7.21–7.14 (m, 2H), 4.59 (s, 2H), 4.14 (s, 1H), 3.28 (d, J = 15.2Hz, 1H), 3.13 (d, 
J = 15.1Hz, 1H); 13C NMR (125 MHz, CDCl3): δ = 158.62, 142.03, 141.61, 132.75, 
128.98, 128.12, 127.90, 127.30, 127.09, 125.50, 123.20, 119.28, 108.04, 61.18, 43.08, 
27.06; HRMS (EI) calcd for C19H14ON2S 318.0827, found 316.0816; HPLC 
(Chiralpak IA, i-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 254 nm): tR 
(major) = 9.9 min, tR (minor) = 6.7 min, ee = 81%; [α]30D = -68.5 (c = 0.88 in CHCl3). 
 
(S)-2-Amino-4-cyclohexyl-5,6-dihydro-4H-benzo[h]chromene-3-carbonitrile 
(2-8r) (Table 2.3 , entry 18 ). 86% yield, 86% ee; 1H NMR (500 MHz, DMSO-d6): δ 
= 7.28 (dd, J = 7.6, 1.5Hz, 1H), 7.21 (td, J = 7.8, 1.5Hz, 1H), 6.97 (t, J = 7.4Hz, 1H), 
6.84 (d, J = 7.7, 1H), 6.83 (s, 2H), 4.85 (d, J = 13.9Hz, 1H), 4.75 (d, J = 14.0Hz, 1H), 
2.83 (d, J = 2.5Hz, 1H), 1.76–0.90 (m, 11H); 13C NMR (75 MHz, DMSO-d6): δ = 
162.05, 153.60, 138.38, 129.81, 121.52, 121.19, 120.56, 117.11, 115.57, 106.71, 
66.50, 52.08, 42.73, 29.76, 29.31, 27.78, 26.15, 25.96, 25.78; HRMS (EI) calcd for 
C19H20O2N2 308.1525, found 308.1520; HPLC (Chiralpak IC, i-propanol/hexane = 
15/85, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 20.8 min, tR (minor) = 7.8 min, 
ee = 86%; [α]30D = -60.1 (c = 0.70 in CHCl3). 
 





(Table 2.3 , entry 19 ). 75% yield, 87% ee; 1H NMR (500 MHz, CDCl3): δ = 7.27 (dd, 
J = 7.7, 1.5Hz, 1H), 7.19 (td, J = 8.1, 1.6Hz, 1H), 6.94 (td, J = 7.6, 0.9Hz, 1H), 6.84 
(d, J = 8.1Hz, 1H), 4.83 (d, J = 13.6Hz, 1H), 4.68 (d, J = 13.6Hz, 1H), 4.60 (s, 2H), 
2.93 (d, J = 2.7Hz, 1H), 1.89 (m, 1H), 1.07 (d, J = 7.0Hz, 3H), 0.90 (d, J = 6.9Hz, 3H); 
13C NMR (125 MHz, CDCl3): δ = 161.27, 154.09, 139.46, 130.01, 121.35, 120.89, 
120.66, 117.18, 115.89, 106.14, 67.22, 56.72, 40.17, 32.77, 19.43, 17.88; HRMS (EI) 
calcd for C16H16O2N2 268.1212, found 268.1205; HPLC (Chiralpak IC, 
i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 12.2 min, 
tR (minor) = 6.6 min, ee = 87%; [α]30D = -83.2 (c = 0.61 in CHCl3). 
 
2.4.5 X-ray Crystallographic Analysis 
Table 2.4 Crystal data and structure refinement for 2-8f. 
Empirical formula  C19 H13 Br N2 O2 
Formula weight  381.22 
Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 6.6093(4) Å a= 90°. 
 b = 10.9299(7) Å b= 90°. 
 c = 22.8035(15) Å g = 90°. 
Volume 1647.30(18) Å3 
Z 4 
Density (calculated) 1.537 Mg/m3 
Absorption coefficient 2.509 mm-1 
F(000) 768 
Crystal size 0.54 x 0.50 x 0.08 mm3 
Theta range for data collection 1.79 to 27.48° 




Index ranges -8<=h<=8, -14<=k<=9, -29<=l<=29 
Reflections collected 11623 
Independent reflections 3778 [R(int) = 0.0629] 
Completeness to theta = 27.48° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8245 and 0.3444 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3778 / 0 / 225 
Goodness-of-fit on F2 1.006 
Final R indices [I>2sigma(I)] R1 = 0.0517, wR2 = 0.1142 
R indices (all data) R1 = 0.0730, wR2 = 0.1234 
Absolute structure parameter 0.005(13) 











































































































































The scope of metal-free organocatalysts to promote asymmetric cascade 
reactions has expanded in the last few years.132 Recently, a number of useful cascade 
reactions have been reported.133 Undoubtedly, the utilization of cascade reactions 
provides a useful synthetic tool for organic synthesis. It offers a possibility to form 
multiple chemical bonds in a one-pot process without isolating intermediates, 
changing reaction conditions, or adding reagents. Finally, this strategy reduces the 
synthetic costs and simplifies synthetic steps and processes. Inspired by the 
advantages and significances of this cascade strategy, we have become interested in 




In contrast, the utilization of 1,2-diones is still rare. 134  However, their 
                                                              
132  For reviews of organocatalytic cascade reactions, see: a) Enders, D.; Grondal, C.; Hüttl, M. R. M. Angew. 
Chem. Int. Ed. 2007, 119, 1570; b) see Ref. 2f; c) see Ref. 2j.  
133  For recent selected examples of cascade reactions, see: a) see Ref. 3b; b) see Ref. 3c; c) see Ref. 3d; d) see Ref. 
3e; e) see Ref. 3f; f) see Ref. 3h; g) Rios, R.; Sunden, H.; Ibrahem, I.; Zhao, G. L.; Eriksson, L.; Córdova, A. 
Tetrahedron Lett. 2006, 47, 8547; h) see Ref. 3i; i) see Ref. 3j; j) see Ref. 3k; k) Vicario, J. L.; Reboredo, S.; BadNa, 
D.; Carrillo, L. Angew. Chem. Int. Ed. 2007, 119, 5260. 
134  For selected examples of the application of 1,2-diones in organic synthesis, see: a) Parsons, A. F.; Williams, D. 
Tetrahedron Lett. 2000, 56, 7217; b) Wolf, C.; Liu, S. J. Am. Chem. Soc. 2006, 128, 10996; c) Li, X.; Vince, R. 
Bioorg. Med. Chem. Lett. 2006, 14, 2942; d) Maruoka, H.; Kashige, N.; Miake, F.; Yamaguchi, T. Chem. Pharm. 
Bull. 2005, 53, 1359; e) Zhao, Z.; Wisnoski, D. D.; Wolkenberg, S. E.; Leister, W. H.; Wang, Y.; Lindsley, C. W. 
Tetrahedron Lett. 2004, 45, 4873; f) Curiel, D.; Cowley, A.; Beer, P. D. Chem. Commun. 2005, 2, 236; g) Ding, Y.; 




functionality offers a good starting point for additional transformations. Therefore, we 
wish to use them as a group of interesting synthetic blocks for further asymmetric 
transformations. Herein, we report a new enantioselective organocatalytic cascade 
reaction with a formation of functionalized 3,4-dihydro-2H-pyran complexes [Eq. (1)]. 
Notably, the features of the strategy include 1) a novel indane amine-thiourea catalyst; 
2) good to excellent yields (72–97%) and high to excellent enantioselectivities (92–97% 
ee); 3) a first trial of 1,2-diones to β,γ–unsaturated α–keto esters.  
Rueping et al. have reported a stereoselective Lewis base catalyzed domino 
Michael/aldol reaction for the formation of chiral 
bicycle[3.2.1]octane-6-carbaldehydes [Eq. (2)].135 Several α,β–unsaturated aldehydes 
have been applied to  this system to access the target compounds. Furthermore, 
nitroolefins have also been utilized as the replacement of α,β–unsaturated aldehydes 
to afford a similar bicycle[3.2.1]octane structure discovered by the Rueping and Zhao 
groups independently [Eq. (3)].136 As a significant complement, we document an 
interesting reaction which tolerated 1,2-diones as dual-nucleophiles to react with β,γ–
unsaturated α–keto esters which were firstly utilized as dual-electrophiles. A 
privileged 4-dihydro-2H-pyran structure (Eq. (1)) was finally constructed. 
 
3.2 Results and Discussion 
3.2.1 Catalyst Screening 
To probe the feasibility of the proposed cascade reaction, (E)-ethyl 
2-oxo-4-phenylbut-3-enoate (3-2a) was treated with 1,2-cyclohexadione 3-1 in the 
presence of catalyst 3-I, developed by the Soós137, Dixon138 and Connon139 groups 
                                                                                                                                                                                  
Girardet, J.; Smith, K. L.; Larson, G.; Prigaro, B.; Lai, V. C. H.; Zhong, W.; Wu, J. Z. Bioorg. Med. Chem. Lett. 
2005, 15, 675; h) Wu, S.; Fluxe, A.; Janusz, J. M.; Sheffer, J. B.; Browning, G.; Cobum, B. B. K.; Hedges, R.; 
Murawsky, M.; Fang, B.; Fadayel, G. M.; Hare, M.; Djandjighian, L. Bioorg. Med. Chem. Lett. 2006, 16, 5859; i) 
Held, I.; Xu, S.; Zipse, H. Synthesis 2007, 1185; j) Liu, S.; Wolf, C. Org. Lett. 2007, 9, 2965. 
135  Rueping, M.; Kuenkel, A.; Tato, F.; Bats, J. W. Angew. Chem. Int. Ed. 2009, 48, 3699. 
136  a) Rueping, M.; Kuenkel, A.; Fröhlich, R. Chem. –Eur. J. 2010, 16, 4173; b) Ding, D.; Zhao, C. G.; Guo, Q. S.; 
Arman, H. Tetrahedron 2010, 66, 4424. 
137 See Ref. 124. 
138 See Ref. 54. 
139 See Ref. 53. 




respectively, in CH2Cl2 at room temperature (Table 3.1). As shown in Table 3.1, 
unfortunately, catalyst 3-I exhibited a poor catalytic activity so that a very trace 
amount of desired product was generated after 96 h (Table 3.1, entry 1). Therefore, we 
wish to discover an active chiral catalyst which could promote the reaction and result 
in high efficiency and excellent stereo-control. In planning our catalyst investigation, 
we were evoked by our group reported indane bifuncationl amine-thiourea catalysts. 
This type of catalysts demonstrated some interesting aspects, such as high activity, 
good stereo-control, and flexible chiral structure.140 On the basis of these experiences 
we decided to examine the catalytic activity and stereoselectivity of our indane 
catalysts in this type of reaction. Unfortunately, catalyst 3-II showed a similar 
performance as well as catalyst 3-I (Table 3.1, entries 2–4). In view of catalyst 3-II’s 
structure (Figure 3.1), we found that two functional groups, amine and thiourea, are in 
the anti-position. We then suspected if the relative position of the two functional 
groups would affect the catalyst’s activity. However, the results showed that our 
inference was wrong (Table 3.1, entry 5, < 5%). A switch of these important 
functional groups would not enhance the catalytic performance. Then the next 
exploration was the change of the chiral center’s orientation. As demonstrated in 
Figure 3.1, catalyst 3-V was synthesized and investigated. It is noteworthy that 
catalyst 3-V was firstly discovered by our research group and already verified as an 
active catalyst in some catalytic transformations.140 Surprisingly, it still could not 
efficiently promote this reaction (Table 3.1, entry 7). It appeared that indane amine–
thiourea catalysts have no enough power to complete such a task. However, we did 
not cease our exploration before we reached our target. By chance, we finally 
disclosed a novel indane bifuncational catalyst 3-IV which demonstrated a superior 
performance in both activity and stereoselectivity (Table 3.1, entry 6, 53%, 96% ee). 
It was obvious that catalyst 3-IV was derived from catalyst 3-V via a switch of two 
functional groups. These results again emphasized the unique of our indane C-1 
                                                              
140  For some examples of our group developed bifunctional indane thiourea catalyzed reactions, see: a) Gao, Y. J.; 
Ren, Q.; Wu, H.; Li, M. G.; Wang, J. Chem. Commun. 2010, 46, 9232; b) Ren, Q.; Gao, Y. J.; Wang, J. Chem. –Eur. 
J. 2010, 16, 13594; c) Gao,Y. J.; Ren, Q.; Siau, W.-Y.; Wang, J. Chem. Commun. 2011, 47, 5819; d) Gao, Y. J.; Ren, 
Q.; Siau, W.-Y.; Wang, J. Org. Biomol. Chem. 2011, 9, 3691.  




symmetric catalytic system. Based on NMR data, we found compound 3-3a coexisted 
with its anomer 3-3a'. In this reaction,  the compound 3-3a was kinetically favored 
based on the ratio (> 10:1) between 3-3a and it’s anomer (See Supporting 
Information). 
 
Figure 3.1 Evaluated bifunctional amine-thiourea organocatalysts. 
 
 
Table 3.1 Evaluation of bifunctional chiral organocatalysts.a 
 
Entry Cat. t(h) Yield(%)b 
1 3-I 96 <5 
2 3-II-a 96 <5 
3 3-II-b 96 <5 
4 3-II-c 96 <5 
5 3-III 96 <5 
6 3-IV 48 53 
7 3-V 96 <5 
a Reaction was conducted on 0.1 mmol scale in CH2Cl2 (0.5 mL) at r.t. for 48–96 h, and the ratio 
of 3-1/3-2a is 1.5:1. b Yield of isolated productafter column chromatography. 




3.2.2 Reaction Optimization 
Table 3.2 Optimization of the reaction conditions.a 
 
Entry Solvent T(oC) t(h) Yield(%)b ee(%)c 
1 CH2Cl2 23 48 53 96 
2 CH2Cl2 40 16 66 92 
3 Et2O 40 16 88 94 
4 Cl(CH2)2Cl 50 14 73 96 
5 Anisole 50 12 75 94 
6 Toluene 50 8 94 95 
7 Xylenes 50 8 84 95 
8 PhCF3 50 8 78 93 
9 i-PrOH 50 12 44 85 
10 DMSO 50 14 50 37 
a Unless specified, see the Experimental section for reaction conditions. b Yield of isolated product 
after column chromatography. c Enantiomeric excess (ee) was determined by HPLC. 
For further optimization, solvent, as well as reaction temperature, was varied 
(Table 3.2). These experiments revealed that the best results with regard to reactivity 
and stereoselectivity were obtained with toluene at 50oC (Table 3.2, entry 6). The 
process was completed within 8 h and afforded 3,4-dihydro-2H-pyran complex 3-3a 
in 94% yield and with an excellent enantioselectivity (95% ee). In varying reaction 
temperature, the catalytic activity can be dramatically enhanced by a slight addition 
on temperature. Most importantly, no significant drop in the stereoselectivity was 
found in the process (Table 3.2, entries 1 and 2, 48 to 16 h, 53% to 66% yield, 96% to 
92% ee). Furthermore, less polar solvents were fundamental for obtaining high 
enantioselectivities (Table 3.2, entries 1–8, 92–95% ee). For high polar solvents, 
relatively lower enantioselectivities were aroused by a potential destruction of 




H-bonding interaction (Table 3.2, entries 9 and 10, 85% and 37% ee).  
 
3.2.3 Reaction Scope 
Under the optimized reaction conditions, the generality of our cascade process 
was examined by using various β,γ–unsaturated α–keto esters 3-2 (Table 3.3). 
Aromatic β,γ–unsaturated α–keto esters 3-2 having both electron-withdrawing (Table 
3.3, entries 2–7) and electron-donating substituents (Table 3.3, entries 8–13) can 
effectively be applied to this transformation; the substitution pattern of the arene had 
limited influence on the enantioselectivity of the reaction (Table 3.3, entries 2–13). In 
addition, it was possible to use both heteroaromatic (Table 3.3, entry 14) and aliphatic 
β,γ–unsaturated α–keto esters (Table 3.3, entry 16) in this reaction. Meanwhile, the 
ester modification also had no obvious effect on the enantioselectivity (Table 3.3, 
entry 17). The ability to control the formation of two new stereogenic centers 
permitted the assembly of a variety of functionalized 3,4-dihydro-2H-pyran 
complexes 3-3 in good to high yields (72–97%) and with high to excellent 
enantioselectivities (92–97% ee). The absolute configuration of the products was 
determined by single-crystal X-ray analysis of 3-3i (Figure 3.2).141  
 
Figure 3.2 X-ray crystal structure of 3-3i. 
                                                              
141  CCDC 800064 (3-3i) contains the supplementary crystallographic data for this paper. These data can be 
obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/ 
data_request/cif. 




Table 3.3 Substrate scope.a 
 
Entry R1 R2 t(h) Yield(%)b ee(%)c 
1 Ph(3-3a) Et 8 94 95 
2 2-ClC6H4(3-3b) Et 6 92 96 
3 3-ClC6H4(3-3c) Et 6 95 92 
4 4-ClC6H4(3-3d) Et 6 90 96 
5 4-FC6H4(3-3e) Et 6 91 95 
6 2-BrC6H4(3-3f) Et 6 95 97 
7 4-NO2C6H4(3-3g) Et 4 84 93 
8 4-MeOC6H4(3-3h) Et 24 82 95 
9 4-MeSC6H4(3-3i) Et 24 82 95 
10 4-allyloxyC6H4(3-3j) Et 24 87 94 
11 4-PhOC6H4(3-3k) Et 12 94 96 
12 4-BnOC6H4(3-3l) Et 24 86 93 
13 4-iPrC6H4(3-3m) Et 12 91 95 
14 2-thiophenyl(3-3n) Et 24 84 93 
15 1-naphthyl(3-3o) Et 24 91 95 
16 Et(3-3p) Et 24 72 96 
17 Ph(3-3q) Me 6 97 96 
a Unless specified, see the Experimental section for reaction conditions. b Yield of isolated product 
after column chromatography. c Enantiomeric excess (ee) was determined by HPLC. 
 
3.2.4 Reaction Mechanism 
With regard to the reaction mechanism, an enantioselective cascade Michael–
enolation–cyclization process was proposed for the formation of highly 




stereo-controlled products 3-3 (Scheme 3.1). Catalyst 3-IV activated 
1,2-cyclohexadione 3-1 and β,γ–unsaturated α–keto esters 3-2 via amine and thiourea 
functional groups (Scheme 3.1). After formation of Michael adducts 3-4, an enolation 
automatically occurred to generate a tautomeric structure, intermediate 3-5, an active 
enol which subsequently underwent an oxa-nucleophilic attack to trigger the 
completion of cyclization step. Finally, complex 3-3 involving two possible anomers 
were in equilibrium with the Michael product 3-4. 
 






In summary, this project has disclosed a novel and highly stereoselective 
Michael–enolation–cyclization cascade reaction catalyzed by an elegant chiral indane 
amine-thiourea catalyst. A broad substrate scope of chiral dihydro-2H-pyran 
complexes that contained two stereogenic centers were obtained in a one-pot manner 




in good to excellent yields (72–97%) and high to excellent stereoselectivities (92–97% 
ee). Our investigation, with a new reaction mode, expands the scope of asymmetric 
organocatalytic reactions. It’s anticipated to find further applications of this activation 
mode in other organic transformations together with detailed mechanistic aspects. 
 
3.4 Experimental Section 
3.4.1 General Information 
Chemicals and solvents were purchased from commercial suppliers and used as 
received. 1H and 13C NMR spectra were recorded on a AMX500 (500 MHz) 
spectrometer. Chemical shifts were reported in parts per million (ppm), and the 
residual solvent peak was used as an internal reference: proton (chloroform δ 7.26), 
carbon (chloroform δ 77.0) or tetramethylsilane (TMS δ 0.00) was used as a reference. 
Multiplicity was indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m 
(multiplet), dd (doublet of doublet), bs (broad singlet). Coupling constants were 
reported in Hertz (Hz). Low resolution mass spectra were obtained on a 
Finnigan/MAT LCQ spectrometer in ESI mode, and a Finnigan/MAT 95XL-T mass 
spectrometer in EI mode. All high resolution mass spectra were obtained on a 
Finnigan/MAT 95XL-T spectrometer. For thin layer chromatography (TLC), Merck 
pre-coated TLC plates (Merck 60 F254) were used, and compounds were visualized 
with a UV light at 254 nm. Further visualization was achieved by staining with iodine, 
or ninhydrin followed by heating using a heat gun. Flash chromatography separations 
were performed on Merck 60 (0.040-0.063 mm) mesh silica gel. The enantiomeric 
excesses of products were determined by chiral phase HPLC analysis. Optical 










3.4.2 Representative Procedure for Michael–Enolation–Cyclization Reaction 
 
To a solution of (E)-ethyl 2-oxo-4-phenylbut-3-enoate 3-2a (20.4 mg, 0.1 mmol) 
and cyclohexane-1,2-dione 3-1 (16.8 mg, 0.15 mmol) in 0.2 mL toluene, catalyst 3-IV 
(4.9 mg, 0.01 mmol) was added. The reaction mixture was stirred at 50oC for 8 h. The 
crude product was purified by column chromatography on silica gel, eluted by 
hexane/EtOAc=5:1 then 3:1 to afford 30.0 mg (94% yield) of the desired product 3-3a 
as colorless oil. 
 
3.4.3 Analytical Data of Michael–Enolation–Cyclization Products 
 
(2R,4S)-Ethyl 2-hydroxy-8-oxo-4-phenyl-3,4,5,6,7,8-hexahydro-2H-chromene-2- 
carboxylate (3-3a) (Table 3.3 , entry 1). 94% yield, 95% ee; 1H NMR (500 MHz, 
CDCl3): δ = 7.36 (t, J = 7.4 Hz, 2H), 7.29 (t, J = 7.3 Hz, 1H), 7.24 (d, J = 7.2 Hz, 2H), 
4.50 (br, 1H), 4.38–4.23 (m, 2H), 3.81 (dd, J = 12.5, 6.5 Hz, 1H), 2.55–2.41 (m, 2H), 
2.34 (t, J = 13.1 Hz, 1H), 2.23 (dd, J = 13.6, 6.5 Hz, 1H), 2.09–2.01 (m, 2H), 1.96–
1.84 (m, 2H), 1.32 (t, J = 7.2 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ = 192.83, 
169.13, 142.88, 140.83, 134.12, 128.94, 128.53, 127.31, 93.67, 63.01, 40.09, 38.29, 
36.86, 27.81, 22.11, 13.93; HRMS (EI) calcd for C18H20O5 316.1311, found 316.1307; 
HPLC (Chiralpak IA, i-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 254 nm): 
tR (major) = 9.6 min, tR (minor) = 11.9 min, ee = 95%; [α]25D = +113.0 (c = 1.11 in 
CHCl3). 






chromene-2-carboxylate (3-3b) (Table 3.3, entry 2). 92% yield, 96% ee; 1H NMR 
(500 MHz, CDCl3): δ = 7.39 (dd, J = 11.8, 4.7 Hz, 1H), 7.32–7.17 (m, 3H), 4.54 (br, 
1H), 4.38–4.23 (m, 2H), 2.59–2.43 (m, 2H), 2.35–2.03 (m, 4H), 2.00–1.93 (m, 2H), 
1.32 (td, J = 7.1, 3.1 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ = 192.77, 168.96, 
144.26, 138.11, 134.14, 133.59, 131.86, 129.83, 129.72, 128.50, 128.35, 127.49, 
126.86, 94.51, 93.66, 63.04, 62.79, 38.41, 38.26, 35.55, 34.09, 34.04, 28.06, 27.59, 
22.25, 22.10, 13.96, 13.92;  HRMS (EI) calcd for C18H19O5Cl 350.0921, found 
350.0916; HPLC (Chiralpak IA, i-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 
254 nm): tR (major) = 9.8 min, tR (minor) = 11.9 min, ee = 96%; [α]25D = +75.3 (c = 
0.98 in CHCl3). 
 
(2R,4S)-Ethyl 4-(3-chlorophenyl)-2-hydroxy-8-oxo-3,4,5,6,7,8-hexahydro-2H- 
chromene-2- carboxylate (3-3c) (Table 3.3, entry 3). 95% yield, 92% ee; 1H NMR 
(500 MHz, CDCl3): δ = 7.32–7.22 (m, 3H), 7.13 (dt, J = 7.0, 1.5 Hz, 1H), 4.71 (br, 
1H), 4.38–4.24 (m, 2H), 3.81 (dd, J = 12.3, 6.7 Hz, 1H), 2.57–2.41 (m, 2H), 2.34–
2.26 (m, 1H), 2.23 (dd, J = 13.6, 6.7 Hz, 1H), 2.14–1.99 (m, 2H), 1.94–1.89 (m, 2H), 
1.33 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ = 192.80, 168.93, 142.95, 
142.90, 134.75, 132.98, 130.21, 128.59, 127.57, 126.72, 93.57, 63.04, 39.86, 38.18, 
36.66, 27.69, 22.05, 13.90;  HRMS (EI) calcd for C18H19O5Cl 350.0921, found 




350.0918; HPLC (Chiralpak IA, i-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 
254 nm): tR (major) = 9.0 min, tR (minor) = 11.4 min, ee = 92%; [α]25D = +104.2 (c = 
0.96 in CHCl3). 
 
(2R,4S)-Ethyl 4-(4-chlorophenyl)-2-hydroxy-8-oxo-3,4,5,6,7,8-hexahydro-2H- 
chromene-2- carboxylate (3-3d) (Table 3.3, entry 4). 90% yield, 96% ee; 1H NMR 
(500 MHz, CDCl3): δ = 7.34 (d, J = 8.3 Hz, 2H), 7.18 (d, J = 8.2 Hz, 2H), 4.54 (br, 
1H), 4.38–4.21 (m, 2H), 3.80 (dd, J = 12.4, 6.6 Hz, 1H), 2.56–2.41 (m, 2H), 2.29 (t, J 
= 13.0 Hz, 1H), 2.21 (dd, J = 13.6, 6.6 Hz, 1H), 2.09–1.98 (m, 2H), 1.96–1.85 (m, 
2H), 1.32 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ = 192.70, 168.96, 
153.86, 142.97, 139.32, 133.19, 129.85, 129.16, 93.58, 63.08, 39.53, 38.24, 36.77, 
27.75, 22.08, 13.92; HRMS (EI) calcd for C18H19O5Cl 350.0921, found 350.0910; 
HPLC (Chiralpak IA, i-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 254 nm): 




chromene-2- carboxylate (3-3e) (Table 3.3, entry 5). 91% yield, 95% ee; 1H NMR 
(500 MHz, CDCl3): δ = 7.20 (dd, J = 8.6, 5.3 Hz, 2H), 7.05 (t, J = 8.6 Hz, 2H), 4.50 (br, 




1H), 4.36–4.27 (m, 2H), 3.81 (dd, J = 12.5, 6.6 Hz, 1H), 2.54–2.46 (m, 2H), 2.30 (t, J = 
13.1 Hz, 1H), 2.21 (dd, J = 13.6, 6.6 Hz, 1H), 2.08–2.02 (m, 2H), 1.93–1.88 (m, 2H), 
1.33 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ = 192.83, 169.01, 162.96, 
161.00, 142.88, 136.45, 136.42, 133.68, 130.03, 129.96, 115.94, 115.78, 93.62, 63.10, 
39.34, 38.24, 36.88, 27.77, 22.08, 13.93; HRMS (EI) calcd for C18H19O5F 334.1217, 
found 334.1216; HPLC (Chiralpak IA, i-propanol/hexane = 10/90, flow rate 1.0 
mL/min, λ = 254 nm): tR (major) = 10.7 min, tR (minor) = 13.5 min, ee = 95%; [α]25D = 




chromene-2- carboxylate (3-3f) (Table 3.3, entry 6). 95% yield, 97% ee; 1H NMR 
(500 MHz, CDCl3): δ = 7.58 (dd, J = 12.7, 4.6 Hz, 1H), 7.34 (t, J = 7.4 Hz, 1H), 7.21–
7.13 (m, 2H), 4.63 (br, 1H), 4.51 (dd, J = 11.2, 6.3 Hz, 1H), 4.38–4.22 (m, 2H), 2.59–
2.43 (m, 2H), 2.32 (dd, J = 13.2, 6.5 Hz, 1H), 2.24–2.02 (m, 3H), 2.01–1.88 (m, 2H), 
1.32 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ = 192.75, 168.89, 143.36, 
140.17, 133.57, 133.07, 132.94, 129.12, 128.70, 128.61, 128.14, 127.50, 125.24, 
93.63, 62.98, 62.72, 38.98, 38.34, 38.24, 35.73, 34.40, 27.61, 22.21, 22.07, 13.95, 
13.88; HRMS (EI) calcd for C18H19O5Br 394.0416, found 394.0400; HPLC 
(Chiralpak IA, i-propanol/hexane = 5/95, flow rate 1.0 mL/min, λ = 254 nm): tR 
(major) = 17.8 min, tR (minor) = 21.6 min, ee = 97%; [α]25D = +63.3 (c = 0.98 in 
CHCl3). 






chromene-2- carboxylate (3-3g) (Table 3.3, entry 7). 84% yield, 93% ee; 1H NMR 
(500 MHz, CDCl3): δ = 8.24 (d, J = 8.7 Hz, 2H), 7.44 (d, J = 8.7 Hz, 2H), 4.50 (br, 1H), 
4.37–4.28 (m, 2H), 3.97 (dd, J = 12.4, 6.6 Hz, 1H), 2.61–2.43 (m, 2H), 2.31 (dd, J = 
20.1, 7.7 Hz, 1H), 2.24 (dd, J = 13.5, 6.6 Hz, 1H), 2.07–1.87 (m, 4H), 1.33 (t, J = 7.1 Hz, 
3H); 13C NMR (125 MHz, CDCl3): δ = 192.48, 168.68, 148.57, 147.38, 143.28, 131.47, 
129.46, 124.29, 93.40, 63.29, 40.09, 38.25, 36.63, 27.80, 22.11, 13.94; HRMS (EI) 
calcd for C18H19O7N 361.1162, found 361.1160; HPLC (Chiralcel OD-H, 
i-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 17.8 min, tR 
(minor) = 29.3 min, ee = 93%; [α]25D = +127.2 (c = 1.00 in CHCl3). 
 
(2R,4S)-Ethyl 2-hydroxy-4-(4-methoxyphenyl)-8-oxo-3,4,5,6,7,8-hexahydro-2H- 
chromene-2- carboxylate (3-3h) (Table 3.3, entry 8). 82% yield, 95% ee; 1H NMR 
(500 MHz, CDCl3): δ = 7.15 (d, J = 8.6 Hz, 2H), 6.89 (d, J = 8.6 Hz, 2H), 4.52 (br, 1H), 
4.39–4.22 (m, 2H), 3.81 (s, 3H), 3.77 (dd, J = 13.6, 7.6 Hz, 1H), 2.55–2.41 (m, 2H), 
2.31 (t, J = 13.1 Hz, 1H), 2.20 (dd, J = 13.6, 6.5 Hz, 1H), 2.12–2.01 (m, 2H), 1.95–1.83 
(m, 2H), 1.32 (t, J = 7.3 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ = 192.76, 169.16, 




158.88, 142.77, 134.53, 132.69, 129.48, 114.39, 93.74, 62.94, 55.28, 39.22, 38.28, 
36.90, 27.80, 22.11, 13.91; HRMS (EI) calcd for C19H22O6 346.1416, found 346.1413; 
HPLC (Chiralpak IA, i-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 254 nm): tR 




2H-chromene-2-carboxylate (3-3i) (Table 3.3, entry 9). 82% yield, 95% ee; 1H NMR 
(500 MHz, CDCl3): δ = 7.25 (d, J = 8.2 Hz, 2H), 7.16 (d, J = 8.2 Hz, 2H), 4.50 (br, 
1H), 4.39–4.22 (m, 2H), 3.77 (dd, J = 12.5, 6.5 Hz, 1H), 2.56–2.41 (m, 5H), 2.31 (t, J 
= 13.0 Hz, 1H), 2.20 (dd, J = 13.6, 6.5 Hz, 1H), 2.13–2.01 (m, 2H), 1.97–1.83 (m, 
2H), 1.32 (t, J =7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ = 192.85, 169.07, 
142.86, 137.57, 137.51, 133.98, 128.98, 127.07, 93.62, 63.05, 39.53, 38.26, 36.74, 
27.79, 22.08, 15.80, 13.92; HRMS (EI) calcd for C19H22O5S 362.1188, found 
362.1180; HPLC (Chiralpak IA, i-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 
254 nm): tR (major) = 12.6 min, tR (minor) = 17.2 min, ee = 95%; [α]25D = +140.8 (c = 
0.97 in CHCl3). 
 
(2R,4S)-Ethyl 4-(4-(allyloxy)phenyl)-2-hydroxy-8-oxo-3,4,5,6,7,8-hexahydro 




-2H-chromene-2- carboxylate (3-3j) (Table 3.3, entry 10). 87% yield, 94% ee; 1H 
NMR (500 MHz, CDCl3): δ = 7.16– 7.11(m, 2H), 6.93–6.88 (m, 2H), 6.12–5.98 (m, 
1H), 5.42 (ddd, J = 17.3, 3.1, 1.6 Hz, 1H), 5.30 (ddd, J = 10.5, 2.7, 1.3 Hz, 1H), 4.55–
4.53 (m, 3H), 4.39–4.22 (m, 2H), 3.76 (dd, J = 12.5, 6.6 Hz, 1H), 2.56–2.41 (m, 2H), 
2.36–2.27 (m, 1H), 2.20 (dd, J = 13.6, 6.6 Hz, 1H), 2.13–1.98 (m, 2H), 1.97–1.83 (m, 
2H), 1.32 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ = 193.02, 169.19, 
157.85, 142.71, 134.73, 133.18, 132.77, 129.48, 117.71, 115.14, 93.71, 68.87, 63.01, 
39.20, 38.25, 36.84, 27.80, 22.08, 13.93; HRMS (EI) calcd for C21H24O6 372.1573, 
found 372.1561; HPLC (Chiralpak IA, i-propanol/hexane = 10/90, flow rate 1.0 
mL/min, λ = 254 nm): tR (major) = 11.7 min, tR (minor) = 15.0 min, ee = 94%; [α]25D 
= +144.6 (c = 0.83 in CHCl3). 
 
(2R,4S)-ethyl 2-hydroxy-8-oxo-4-(3-phenoxyphenyl)-3,4,5,6,7,8-hexahydro-2H- 
chromene-2- carboxylate (3-3k) (Table 3.3, entry 11). 94% yield, 96% ee; 1H NMR 
(500 MHz, CDCl3): δ = 7.37-7.29 (m, 3H), 7.13 (t, J = 7.4 Hz, 1H), 7.05–6.99 (m, 
2H), 6.97 (d, J = 7.7 Hz, 1H), 6.94–6.88 (m, 2H), 4.52 (br, 1H), 4.38–4.23 (m, 2H), 
3.78 (dd, J = 12.4, 6.6 Hz, 1H), 2.56–2.40 (m, 2H), 2.31 (t, J = 13.0 Hz, 1H), 2.23 (dd, 
J = 13.6, 6.6 Hz, 1H), 2.18–2.02 (m, 2H), 1.98–1.85 (m, 2H), 1.32 (t, J = 7.2 Hz, 3H); 
13C NMR (125 MHz, CDCl3): δ = 192.82, 169.02, 157.82, 156.82, 142.85, 142.83, 
133.60, 130.19, 129.80, 123.56, 123.21, 118.95, 118.85, 117.44, 93.58, 63.04, 39.94, 
38.24, 36.64, 27.71, 22.08, 13.92; HRMS (EI) calcd for C24H24O6 408.1573, found 
408.1559; HPLC (Chiralpak IA, i-propanol/hexane = 5/95, flow rate 1.0 mL/min, λ = 
254 nm): tR (major) = 17.5 min, tR (minor) = 21.9 min, ee = 96%; [α]25D = +95.0 (c = 
1.05 in CHCl3). 











2H-chromene-2-carboxylate (3-3l) (Table 3.3, entry 12). 86% yield, 93% ee; 1H 
NMR (500 MHz, CDCl3): δ = 7.46–7.30 (m, 5H), 7.17–7.12 (m, 2H), 6.99–6.94 (m, 
2H), 5.06 (s, 2H), 4.51 (br, 1H), 4.37–4.23 (m, 2H), 3.76 (dd, J = 12.5, 6.5 Hz, 1H), 
2.56–2.40 (m, 2H), 2.35–2.27 (m, 1H), 2.20 (dd, J = 13.6, 6.5 Hz, 1H), 2.12–1.97 (m, 
2H), 1.96–1.83 (m, 2H), 1.32 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ = 
192.91, 169.17, 158.08, 142.75, 136.89, 134.60, 132.94, 129.53, 128.59, 128.00, 
127.43, 115.28, 93.71, 70.12, 63.00, 39.22, 38.26, 36.87, 27.82, 22.09, 13.92; HRMS 
(EI) calcd for C25H26O6 422.1729, found 422.1709; HPLC (Chiralpak IA, 
i-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 17.5 min, tR 
(minor) = 22.4 min, ee = 93%; [α]25D = +104.5 (c = 1.11 in CHCl3). 
 
(2R,4S)-Ethyl 2-hydroxy-4-(4-isopropylphenyl)-8-oxo-3,4,5,6,7,8-hexahydro-2H- 
chromene-2- carboxylate (3-3m) (Table 3.3, entry 13). 91% yield, 95% ee; 1H NMR 
(500 MHz, CDCl3): δ = 7.21 (d, J = 8.1 Hz, 2H), 7.16–7.12 (m, 2H), 4.53 (br, 1H), 
4.38–4.22 (m, 2H), 3.78 (dd, J = 12.5, 6.5 Hz, 1H), 2.91 (dt, J = 13.9, 6.9 Hz, 1H), 
2.56–2.41 (m, 2H), 2.33 (t, J = 13.1 Hz, 1H), 2.21 (dd, J = 13.6, 6.6 Hz, 1H), 2.15–1.99 




(m, 2H), 1.96–1.83 (m, 2H), 1.31 (t, J = 7.3 Hz, 3H), 1.26 (d, J = 6.9 Hz, 6H); 13C NMR 
(125 MHz, CDCl3): δ = 193.01, 169.21, 147.95, 142.76, 137.97, 134.69, 128.41, 126.93, 
93.69, 62.99, 39.65, 38.27, 36.89, 33.70, 27.85, 23.92, 22.07, 13.92; HRMS (EI) calcd 
for C21H26O5 358.1780, found 358.1764; HPLC (Chiralpak IA, i-propanol/hexane = 
10/90, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 7.0 min, tR (minor) = 9.8 min, ee 
= 95%; [α]25D = +121.1 (c = 0.95 in CHCl3). 
 
(2R,4R)-Ethyl 2-hydroxy-8-oxo-4-(thiophen-2-yl)-3,4,5,6,7,8-hexahydro-2H- 
chromene-2-carboxylate (3-3n) (Table 3.3, entry 14). 84% yield, 93% ee; 1H NMR 
(500 MHz, CDCl3): δ = 7.25 (dd, J = 5.0, 0.6 Hz, 1H), 7.00–6.94 (m, 2H), 4.60 (br, 1H), 
4.41–4.24 (m, 2H), 4.19 (dd, J = 12.5, 6.3 Hz, 1H), 2.51–2.40 (m, 3H), 2.33 (dd, J = 
13.5, 6.4 Hz, 1H), 2.21–2.11 (m, 2H), 1.91 (dd, J = 10.2, 4.2 Hz, 2H), 1.34 (t, J = 7.1 Hz, 
3H); 13C NMR (125MHz, CDCl3): δ = 193.04, 168.90, 143.29, 142.01, 133.44, 126.84, 
126.43, 124.65, 93.60, 63.10, 38.12, 37.04, 35.00, 27.24, 21.98, 13.91; HRMS (EI) 
calcd for C16H18O5S 322.0875, found 322.0870; HPLC (Chiralpak IA, 
i-propanol/hexane = 5/95, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 17.4 min, tR 
(minor) = 20.8 min, ee = 93%; [α]25D = +82.9 (c = 1.02 in CHCl3). 
 
(2R,4S)-Ethyl 2-hydroxy-4-(naphthalen-1-yl)-8-oxo-3,4,5,6,7,8-hexahydro-2H- 
chromene-2-carboxylate (3-3o) (Table 3.3, entry 15). 91% yield, 95% ee; 1H NMR 




(500 MHz, CDCl3): δ = 8.24–7.98 (m, 1H), 7.94–7.87 (m, 1H), 7.86–7.75 (m, 1H), 
7.61–7.32 (m, 4H), 4.86–4.63 (m, 1H), 4.38–4.21 (m, 2H), 2.89 (t, J = 13.3 Hz, 0.4H), 
2.65–2.45 (m, 2H), 2.39 (d, J = 8.5, 1H), 2.29 (dd, J = 14.9, 7.9 Hz, 0.8H), 2.20 (dd, J 
= 13.8, 6.5 Hz, 1H), 2.05–1.79 (m, 4H), 1.29 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, 
CDCl3): δ = 192.93, 169.13, 143.80, 141.98, 137.31, 136.05, 135.50, 134.95, 134.50, 
133.95, 132.03, 131.04, 129.45, 129.33, 129.13, 128.70, 127.61, 126.60, 126.42, 
125.91, 125.75, 125.66, 125.60, 125.48, 125.42, 123.57, 122.32, 93.93, 93.83, 63.02, 
41.71, 38.38, 38.21, 37.12, 34.30, 34.08, 29.65, 27.74, 27.25, 22.23, 22.05, 14.01, 
13.90; HRMS (EI) calcd for C22H22O5 366.1467, found 366.1481; HPLC (Chiralpak 
IA, i-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 9.2 




2-carboxylate (3-3p) (Table 3.3, entry 16). 72% yield, 96% ee; 1H NMR (500 MHz, 
CDCl3): δ = 4.40–4.19 (m, 2H), 2.63–2.22 (m, 4H), 2.11–1.78 (m, 4H), 1.45–1.16 (m, 
6H), 0.96 (t, J = 7.5, 3H); 13C NMR (125 MHz, CDCl3): δ = 192.96, 169.51, 142.24, 
135.43, 93.72, 62.97, 37.98, 33.10, 32.36, 29.69, 26.78, 23.74, 22.02, 13.96, 10.71; 
HRMS (EI) calcd for C14H20O5 268.1311, found 268.1310; HPLC (Chiralpak AD-H, 
i-propanol/hexane = 2/98, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 34.5 min, tR 
(minor) = 37.3 min, ee = 96%; [α]25D = +13.3 (c = 0.15 in CHCl3). 






-2-carboxylate (3-3q) (Table 3.3, entry 17). 97% yield, 96% ee; 1H NMR (500 MHz, 
CDCl3): δ = 7.35 (t, J = 7.4 Hz, 2H), 7.31–7.27 (m, 1H), 7.23 (dd, J = 5.2, 3.1 Hz, 
2H), 4.48 (br, 1H), 3.85 (s, 3H), 3.81 (dd, J = 12.6, 6.6 Hz, 1H), 2.56–2.41 (m, 2H), 
2.39–2.30 (m, 1H), 2.24 (dd, J = 13.6, 6.6 Hz, 1H), 2.13–2.00 (m, 2H), 1.96–1.84 (m, 
2H); 13C NMR (125 MHz, CDCl3) δ = 192.90, 169.56, 142.74, 140.67, 134.26, 
128.94, 128.49, 127.33, 93.74, 53.54, 39.97, 38.22, 36.82, 27.78, 22.06; HRMS (EI) 
calcd for C17H18O5 302.1154, found 302.1151; HPLC (Chiralpak IA, 
i-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 10.4 min, 
tR (minor) = 13.1 min, ee = 96%; [α]25D = +124.0 (c = 1.05 in CHCl3). 
 
3.4.4 X-ray Crystallographic Analysis 
Table 3.4 Crystal data and structure refinement for 3-3i. 
Empirical formula  C19 H22 O5 S 
Formula weight  362.43 
Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 7.8373(7) Å a= 90°. 
 b = 8.6462(8) Å b= 94.152(2)°. 
 c = 13.3583(12) Å g = 90°. 
Volume 902.82(14) Å3 
Z 2 




Density (calculated) 1.333 Mg/m3 
Absorption coefficient 0.205 mm-1 
F(000) 384 
Crystal size 0.60 x 0.44 x 0.12 mm3 
Theta range for data collection 1.53 to 27.49° 
Index ranges -10<=h<=10, -6<=k<=11, -17<=l<=17 
Reflections collected 6390 
Independent reflections 2899 [R(int) = 0.0246] 
Completeness to theta = 27.49° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9758 and 0.8867 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2899 / 31 / 256 
Goodness-of-fit on F2 1.076 
Final R indices [I>2sigma(I)] R1 = 0.0428, wR2 = 0.1088 
R indices (all data) R1 = 0.0447, wR2 = 0.1102 
Absolute structure parameter 0.06(9) 
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The concept of “privileged medicinal scaffold” has emerged as one of the 
guiding principles in the process of drug discovery.142  The privileged scaffold 
commonly consists of a rigid hetero-ring system that assigns a well-defined 
orientation of appended functionalities for target recognition.143 In the light of this, 
the accessibility of convenient methods for the diversification of privileged scaffold 
functionalities impacts on the success in seeking potential drugs. Undoubtedly, the 
discovery of novel synthetic methodologies to facilitate the preparation of compound 
libraries is a pivotal focal point in modern medicinal chemistry.144 
 
Figure 4.1 Examples of 2-amino-4H-chromene derivatives as pharmaceutical drugs. 
 
 
Chromene, as one of the privileged scaffolds, often appears as an important 
structural component in both biologically active and natural compounds. It appears in 
natural alkaloids, tocopherols, flavonoids, and anthocyanins.145 Moreover, in recent 
                                                              
142  a) Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; 
Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; Lotti, V. G.; Cerino, D. J.; Chen, T. B.; Kling, P. J.; Kunkel, K. A.; 
Springer, J. P.; Hirshfield, J. J. Med. Chem. 1988, 31, 2235; b) Patchett, A. A.; Nargund, R. P. Ann. Rep. Med. 
Chem. 2000, 35, 28; c) Triggle, D. J. Cell. Mol. Neurobiol. 2003, 23, 293; d) Poupaert, J.; Carato, P.; Colacino, E. 
Curr. Med. Chem. 2005, 12, 87. 
143  Bemis, G. W.; Murcko, M. A. J. Med. Chem. 1996, 39, 2887. 
144  For selected reviews, see: a) Nefzi, A.; Ostresh, J. M.; Houghten, R. A. Chem. Rev. 1997, 97, 44; b) Thompson, 
L. A. Curr. Opin. Chem. Biol. 2000, 4, 32. 
145  For selected examples of natural molecules containing the chromene scaffold, see: a) Iacobucci, G. A.; Sweeny, 
J. G. Tetrahedron 1983, 39, 3005; b) Harborne, J. B. (Ed.), The Flavanoids – Advances in Research, Chapman & 
Hall, London, 1988; c) Bohm, B. A.; Choy, J. B.; Lee, A. Y.-M. Phytochemistry 1989, 28, 501; d) Parmar, V. S.; 
Jain, S. C.; Bisht, K. S.; Jain, R.; Taneja, P.; Jha, A.; Tyagi, O. D.; Prasad, A. K.; Wengel, J.; Olsen, C. E.; Boll, P. 
M. Phytochemistry 1997, 46, 597.  




years functionalized chromenes have played an ever-increasing role in the field of 
synthetic and medicinal chemistry. 146  Among the diverse chromene systems, 
2-amino-4H-chromenes are particular privileged medicinal scaffolds serving for the 
generation of small-molecule based ligands with highly pronounced spasmolytic, 
diuretic, anticoagulant, and antianaphylactic activities.147 In particular, the current 
interest in 2-amino-4H-chromene derivatives bearing a nitrile functionality arises 
from their potential applications in the treatment of human inflammatory 
TNFa-mediated diseases, such as rheumatoid and psoriatic arthritis (Figure 4.1).148 
The corresponding cyano-functionalized benzopyranopyridine (Figure 4.1, 
inhibitor of MK-2) originating from the 2-amino-4H-chromene scaffold was found to 
inhibit mitogen-activated protein kinase (MAPK)-activated protein kinase 2 (MK-2) 
and suppress the expression of TNF-a in U937 cells.148 In the case of cancer therapy, 
the tumor antagonist HA14-1 (Figure 4.1) and a family of related alkyl 
(4H-chromen-4-yl)cyanoacetates are a new class of small molecules that exhibit a 
binding activity for the surface pocket of the cancer-implicated Bcl-2 protein and 
induce apoptosis or programmed cell death in follicular lymphoma B cells and 
leukemia HL-60 cells.148 The 2-amino-3-cyano-4H-chromene MX58151 (Figure 4.1) 
bearing a 3-bromo-4,5-dimethoxyphenyl substituent at the 4-position represents a 
                                                              
146  For recent selected examples, see: a) Garino, C.; Bihel, F.; Pietrancosta, N.; Laras, Y.; QuSlSver, G.; Woo, I.; 
Klein, P.; Bain, J.; Boucher, J.-L.; Kraus, J.-L. Bioorg. Med. Chem. Lett. 2005, 15, 135; b) Sun, W.; Cama, L. J.; 
Birzin, E. T.; Warrier, S.; Locco, L.; Mosley, R.; Hammond, M. L.; Rohrer, S. P. Bioorg. Med. Chem. Lett. 2006, 16, 
1468; c) Stachulski, A. V.; Berry, N. G.; Low, A. C. L.; Moores, S.; Row, E.; Warhurst, D. C.; Adagu, I. S.; 
Rossignol, J.-F. J. Med. Chem. 2006, 49, 1450.  
147  a) Andreani, L. L.; Lapi, E. Boll. Chim. Farm. 1960, 99, 583; b) Witte, E. C.; Neubert, P.; Roesch, A. German 
Patent DE 3,427,985, 1986; c) Foye, W. O. Prinicipi di Chemico Farmaceutica, Piccin, Padova, 1991, p 416; d) 
Bonsignore, L.; Loy, G.; Secci, D.; Calignano, A. Eur. J. Med. Chem. 1993, 28, 517; e) DeSimone, R. W.; Currie, 
K. S.; Mitchell, S. A.; Darrow, J. W.; Pippin, D. A. Comb. Chem. High Throughput Screening 2004, 7, 473.  
148  a) Wang, J. L.; Liu, D.; Zhang, Z.; Shan, S.; Han, X.; Srinvasula, S. M.; Croce, C. M.; Alnemeri, E. S.; Huang, 
Z. Proc. Natl. Acad. Sci. 2000, 97, 7124; b) Kasibhatla, S.; Gourdeau, H.; Meerovitch, K.; Drewe, J.; Reddy, S.; 
Qiu, L.; Zhang, H.; Bergeron, F.; Bouffard, D.; Yang, Q.; Herich, J.; Lamothe, S.; Cai, S. X.; Tseng, B. Mol. 
Cancer Ther. 2004, 3, 1365; c) Gourdeau, H.; Leblond, L.; Hamelin, B.; Desputeau, C.; Dong, K.; Kianicka, I.; 
Custeau, D.; Bourdeau, C.; Geerts, L.; Cai, S. X.; Drewe, J.; Labrecque, D.; Kasibhatla, S.; Tseng, B. Mol. Cancer 
Ther. 2004, 3, 1375; d) Kemnitzer, W.; Drewe, J.; Jiang, S.; Zhang, H.; Wang, Y.; Zhao, J.; Jia, S.; Herich, J.; 
Labreque, D.; Storer, R.; Meerovitch, K.; Bouffard, D.; Rej, R.; Denis, R.; Blais, C.; Lamothe, S.; Attardo, G.; 
Gourdeau, H.; Tseng, B.; Kasibhatla, S.; Cai, S. X. J. Med. Chem. 2004, 47, 6299; e) Anderson, D. R.; Hegde, S.; 
Reinhard, E.; Gomez, L.; Vernier, W. F.; Lee, L.; Liu, S.; Sambandam, A.; Snider, P. A.; Masih, L. Bioorg. Med. 
Chem. Lett. 2005, 15, 1587; f) Kemnitzer, W.; Kasibhatla, S.; Jiang, S.; Zhang, H.; Zhao, J.; Jia, S.; Xu, L.; 
Crogan-Grundy, C.; Denis, R.; Barriault, N.; Vaillancourt, L.; Charron, S.; Dodd, J.; Attardo, G.; Labrecque, D.; 
Lamothe, S.; Gourdeau, H.; Tseng, B.; Drewe, J.; Cai, S. X. Bioorg. Med. Chem. Lett. 2005, 15, 4745; g) Yeatman, 
H.; Frederick, F. A. O.; Chai, S. Y.; Albiston, A. L.; Ye, S. Y.; Watson, K. G.; Parker, M. W.; Ng, H. L. Aust. Pat. 
Appl. 2009, 55. 




promising class of proapoptotic small-molecule agents with multiple action modes 
against the breast cancer cell line T47D, the lung cancer cell line H1299, and the 
colorectal cancer cell line DLD-1.148 It induces caspase-mediated apoptosis in tumor 
cells, and is about as potent as or slightly more potent than the commonly prescribed 
anticancer alkaloids vinblastine and paclitaxel in the caspase activation assay.148 
Furthermore, compound MX58151 might have an advantage for the treatment of 
drug-resistant cancers as it retains activity in tumor cells resistant towards current 
antimitotic agents, taxanes (including Taxol and Taxotere), and Vinca alkaloids.148 
The inhibition of tubuline polymerization and disruption of preformed endothelial cell 
capillary tubules constitute other significant activities of 
2-amino-3-cyano-4-aryl-4H-chromenes of type 3 that can place them in the row of 
effective anticancer therapeutics with an analogous mode of action.148 Most recently, 
another 2-amino-4-aryl-4H-chromene compound (Figure 4.1, IRSP inhibitor) has 
been discovered as an insulin-refulated aminopeptidase inhibitor. In particular, this 
inhibitor is maybe useful in therapeutic application including enhancing memory and 
learning functions.148 
In view of the significance of this framework, efficient syntheses of 
2-amino-4H-chromenes are of great interest. Despite the fact that asymmetric 
organocatalysis has evolved as a powerful tool for the preparation of enantiomerically 
enriched compound, 149  organocatalytic method to generate optically pure 
2-amino-4H-chromenes is still absent. Recently, H-bonding mediated catalysis for C–
C bond formation has been discovered as a new powerful tool and powerful synthetic 
method for the efficient construction of molecular architectures.150 In particular, there 
was a remarkable development and application on chiral bifunctional thiourea 
catalysis.151 The utilization of inexpensive and readily synthesized chiral thiourea 
                                                              
149  For selected books of organocatalysis, see: a) see Ref. 1a; b) see Ref. 1b; c) see Ref. 1c; d) see Ref. 1d. 
150  For selected reviews on hydrogen bonding, see: a) Schreiner, P. R. Chem. Soc. Rev. 2003, 32, 289; b) see Ref. 
16a; c) see Ref. 29; d) Miyabe, H.; Takemoto, Y. Bull. Chem. Soc. Jpn. 2008, 81, 785; e) Connon, S. J. Chem. 
Commun. 2008, 2499. 
151  For selected examples of chiral bifunctional thiourea catalysis, see: a) Sigman, M. S.; Jacobsen, E. N. J. Am. 
Chem. Soc. 1998, 120, 5315; b) Sigman, M. S.; Vachal, P.; Jacobsen, E. N. Angew. Chem. Int. Ed. 2000, 39, 1279; 
c) see Ref. 30; d) see Ref. 39; e) see Ref. 41; f) see Ref. 150a; g) Pihko, P. M. Angew. Chem. Int. Ed. 2004, 43, 2062; 




catalysts attracted considerable interests and proved to be effective in several 
asymmetric transformations. Herein, we document a novel strategy for the preparation 
of chiral 2-amino-4H-chromenes through a H-bonding mediated enantioselective 
cascade process. To date, such a progress has not been described. Significantly, this 
strategy allows a quick construction of diversely functionalized 
2-amino-4H-chromenes under mild reaction conditions with good to high 
enantioselectivities (74–89% ee) and high to excellent yields (81–94%) could be 
achieved. In this context, we sought to extend the usage of the indane catalytic system 
for the construction of novel and useful complexes based on the several successful 
examples disclosed by our research group. 
 
4.2 Results and Discussion 
4.2.1 Catalyst Screening 
We began our investigation by examining the organic base catalyzed reaction of 
2-hydroxy imine with malononitrile. The initial experiment results showed that the 
use of a catalytic amount of quinine enabled a reaction between 2-hydroxy imine and 
malononitrile. Surprisingly, if a phenyl group was introduced to 2-hydroxy imine, a 
mixture of undesired compound 4-a and 4-b were generated in 10 mins (Scheme 4.1, 
4-a:4-b = 10:90). Then we tried a stronger electron-withdrawing group involved 
2-hydroxy N-Tos imine (Scheme 4.1, X = Tos). However, only compound 4-b was 
finally resembled (Scheme 4.1, 4-a:4-b = 0:100). Based on above experimental results, 
we deduced that both strong electron withdrawing groups and good leaving groups 
supported 2-hydroxyl imine might assist the Knoevenagel-type reaction to form 
intermediate 4-a. Then it triggered the sequential reactions to generate undesired 
compound 4-b. In order to avoid these side reactions, we were tentative to introduce a 
poor leaving group (X = Boc) with a less electron-withdrawing character to the imine 
                                                                                                                                                                                  
h) see Ref. 17; i) Connon, S. J. Chem. –Eur. J. 2006, 12, 5419; j) see Ref. 16a; k) see Ref. 36; l) Peschiulli, A.; 
Procuranti, B.; O'Connor, C. J.; Connon, S. J. Nat. Chem. 2010, 2, 380; m) see Ref. 53. 




structure. To our knowledge, N-Boc protected imine is an ideal choice. Unfortunately, 
we failed to seek a successful method to synthesize 2-hydroxyl N-Boc imine (Scheme 
4.1). Instead, an N-Boc α-amido sulfone,152 one of the precursors of N-Boc imine, 
was used to react with malononitrile. Gratifyingly, the investigation showed only 
desired compound 4-c was afforded (Scheme 4.1, 4-a:4-b:4-c = 0:0:100). 
 




Having this finding in hands, we then wish to probe the asymmetric catalytic 
feasibility of this reaction. tert-Butyl (2-hydroxyphenyl)(phenylsulfonyl) 
methylcarbamate 4-1a was treated with malononitrile 4-2 in the presence of catalyst 
4-VII (quinine-thiourea) which was developed by the Soós, Dixon and Connon 
groups respectively (Figure 4.2).153 As shown in Table 4.1, catalyst 4-VII gave a 43% 
yield in 10 min with a 16% ee value (Table 4.1, entry 7). Takemoto thiourea catalyst 
                                                              
152  For selected examples of the application of N-Boc α-amido sulfones, see: a) Fini, F.; Sgarzani, V.; Pettersen, D.; 
Herrera, R. P.; Bernardi, L.; Ricci, A. Angew. Chem. Int. Ed. 2005, 44, 7975; b) Marianacci, O.; Micheletti, G.; 
Bernardi, L.; Fini, F.; Fochi, M.; Pettersen, D.; Sgarzani, V.; Ricci, A. Chem. –Eur. J. 2007, 13, 8338; c) Mizuta, S.; 
Shibata, N.; Goto, Y.; Furukawa, T.; Nakamura, S.; Toru, T. J. Am. Chem. Soc. 2007, 129, 6394; d) Niess, B.; 
Jørgensen, K. A. Chem. Commun. 2007, 1620; e) Gianelli, C.; Sambri, L.; Carlone, A.; Bartoli, G.; Melchiorre, P. 
Angew. Chem. Int. Ed. 2008, 47, 8700; f) Jiang, X.; Zhang, Y. F.; Wu, L. P.; Zhang, G.; Liu, X.; Zhang, H. L.; Fu, 
D.; Wang, R. Adv. Synth. Catal. 2009, 351, 2096; g) Momo, R. D.; Fini, F.; Bernardi, L.; Riccia, A. Adv. Synth. 
Catal. 2009, 351, 2283; h) Cassani, C.; Bernardi, L.; Fini, F.; Ricci, A. Angew. Chem. Int. Ed. 2009, 48, 5694; i) 
Zhang, H. L.; Syed, S.; Barbas, C. F., III Org. Lett. 2010, 12, 708. 
153  a) see Ref. 124; b) see Ref. 54; c) see Ref. 53. 




4-VI also only offered a 46% yield and a 42% ee (Table 4.1, entry 6). Consequently, 
the discovery of a novel and active chiral catalyst which can promote this reaction 
with both high efficiency and excellent stereo-control became our main focus. In this 
context, we sought to extent the usage of the indane amine-thiourea catalytic system 
based on several successful examples disclosed by our research group. 154 
Undoubtedly, bifunctional indane amine-thiourea organocatalysts demonstrated some 
unique aspects, such as higher activity, excellent stereo-control, and flexible skeleton. 
Catalyst 4-I, 4-II and 4-IV (Figure 4.2) exhibited high stereoselectivity in several 
Michael addition reaction triggered cascade processes. Unfortunately, catalyst 4-I 
supported a poor result in this catalytic process (Table 4.1, 38% yield, 29% ee). 
Catalyst 4-III, the similar analogue of catalyst 4-I with a switch of amine and thiourea 
functional groups, showed a good enantioselectivity (Table 4.1, 50% yield, 77% ee). 
Further improvement went on, and we have noticed the critical factor played by the 
dihedral angle between the two functional groups on the catalyst in the 
stereochemistry control. Consequently, catalysts 4-II and 4-IV (Figure 4.2) were 
synthesized with the amine and thiourea group are anti to each other. In contrast to 
catalysts 4-I and 4-III’s structure, catalysts 4-II and 4-IV just have a chiral inversion 
on the amine part respectively while maintaining all the other features. Result showed 
that catalysts 4-II and 4-IV were not the best catalysts (Table 4.1, entries 2 and 4, 9% 
ee and 30% ee, respectively). Meanwhile, we examined catalyst 4-V, L-tert-leucine 
derivative. However, only a moderate result was generated (Table 4.1, entry 5, 61% 
yield, 44% ee). Having failed to find a catalyst more promising than 4-III, a base 









154  For some examples of our group developed bifunctional indane thiourea catalyzed reactions, see: a) see Ref. 
140a; b) see Ref. 140b; c) see Ref. 140c; d) see Ref. 140d. 




Figure 4.2 Bifunctional chiral organocatalysts. 
 
Table 4.1 Evaluation of different bifunctional chiral organocatalysts.a 
 
Entry Catalyst Yield [%]b ee [%]c 
1 4-I 38 -29 
2 4-II 43 9 
3 4-III 50 77 
4 4-IV 48 30 
5 4-V 61 44 
6 4-VI 46 42 
7 4-VII 43 16 
a Reaction conditions: DCM (0.2 mL), tert-butyl (2-hydroxyphenyl)(phenylsulfonyl) 
methylcarbamate 4-1a (0.1 mmol, 1.0 equiv.), malononitrile 4-2 (0.11 mmol, 1.1 equiv.), Na2CO3 
(0.1 M, 0.12 mmol, 1.2 equiv.) solution, 10 mol% catalyst at room temperature. b Yield of isolated 
product after column chromatography. c Enantiomeric excess (ee) was determined by HPLC. 
 
4.2.2 Reaction Optimization 
Optimization studies highlighted the ability of a range of bases, either a solid or 
an aqueous solution (Table 4.2), to generate the N-Boc imine in situ. Stronger aqueous 




bases K2CO3, Cs2CO3, LiOH or KOH, did increase the conversion to the desired 
product, but did not increase the ee value (Table 4.2, entries 4, 5, 7, and 8). Use of 
solid Na2CO3 (no water) decreased the reaction rate and ee value (entry 2, 720 min, 
52% ee). A slightly weaker base Li2CO3 improved the reaction conversion and 
remained the ee value (entry 3, 88% yield, 77% ee). Slow conversion was observed 
when NaHCO3 was used (Table 8, entry 9). These evidences promoted us to select 
aqueous Li2CO3 as the base media of choice and further optimization of the standard 
reaction parameters was carried out.  
 
Table 4.2 Base effect.a 
 
Entry Base t [min] Yield[%]b ee [%]c 
1 Na2CO3 10 50 77 
2d Na2CO3 720 74 52 
3 Li2CO3 10 88 77 
4 K2CO3 10 70 76 
5 Cs2CO3 10 77 74 
6 (NH4)2CO3 30 86 74 
7 LiOH 2 71 73 
8 NaOH 2 82 71 
9 NaHCO3 180 85 68 
a Reaction conditions: tert-butyl (2-hydroxyphenyl)(phenylsulfonyl) methylcarbamate 4-1a (0.1 
mmol, 1.0 equiv.), malononitrile 4-2 (0.11 mmol, 1.1 equiv.), base (0.1 M, 0.12 mmol, 1.2 equiv.), 
10 mol% catalyst 4-III, DCM (0.2 mL) and room temperature. b Yield of isolated product after 
column chromatography. c Enantiomeric excess (ee) was determined by HPLC. d 0.12 mmol of dry 
Na2CO3 was used. 
For further optimization, solvent, as well as reaction temperature, was examined 
(Table 4.3). The initial solvent screen was performed at room temperature. In general, 
less polar solvents were crucial for obtaining good enantioselectivities at room 




temperature (Table 4.3, entries 1–5, 71–78% ee). For high polar solvents, relatively 
lower enantioselectivities were obtained due to potential destruction of H-bonding 
interaction between substrates and the catalyst (Table 4.3, entries 6 and 7, 27% and 
3% ee, respectively). Finally, CH2Cl2 gave the best results with respect to reaction 
rate, yield and ee (Table 4.3, entry 1). In order to further optimize the reaction, we 
varied the reaction temperatures and the concentrations of Li2CO3. The results showed 
that the enantioselectivity can be enhanced by an appropriate temperature and base 
concentration (entry 10, 30 min, 94% yield, 88% ee). 
 
Table 4.3 Evaluation of other parameters.a 
 
Entry Solvent T [oC] [C]b t [min] Yield [%]c ee [%]d 
1 CH2Cl2 r.t. 0.5 10 88 77 
2 DCE r.t. 0.5 10 78 71 
3 Toluene r.t. 0.5 60 72 76 
4 PhCF3 r.t. 0.5 60 80 72 
5 Anisole r.t. 0.5 60 67 78 
6 i-PrOH r.t. 0.5 60 67 27 
7 DMSO r.t. 0.5 60 77 3 
8 CH2Cl2 0 0.5 10 89 79 
9 CH2Cl2 0 0.1 10 90 83 
10 CH2Cl2 0 0.05 30 94 88 
11 CH2Cl2 0 0.025 120 94 83 
12 CH2Cl2 -10 0.05 180 92 83 
a Reaction conditions: tert-butyl (2-hydroxyphenyl)(phenylsulfonyl) methylcarbamate 4-1a (0. 1 
mmol, 1.0 equiv.), malononitrile 4-2 (0.11 mmol, 1.1 equiv.), Li2CO3 (0.1 M, 0.12 mmol, 1.2 
equiv.), 10 mol% catalyst 4-III. b Concentration. c Yield of isolated product after column 
chromatography. d Enantiomeric excess (ee) was determined by HPLC. 
 




4.2.3 Reaction Scope 
Under the optimized reaction conditions, the generality of our cascade process 
was examined by using various in situ generated aromatic N-carbamoyl α-imino ethyl 
glyoxylates (Table 4.4). Aromatic N-carbamoyl α-imino ethyl glyoxylates 4-1 having 
both electron-withdrawing (Table 4.4, entries 2–4, 82–87% yield, 83–85% ee) and 
electron-donating substituents (Table 4.4, entries 5–8, 81–89% yield, 74–89% ee) 
could be applied to this transformation; the substitution pattern of the arene had 
limited influence on the enantioselectivity of the reaction. In addition, it was possible 
to use Cbz as protecting group in this reaction (Table 4.4, entry 9, 82% yield, 84% ee). 
The absolute configuration of the products was determined by single-crystal X-ray 
analysis of 4-3d (Figure 4.3).155 
 







155  CCDC 818689  (compound 4-3d) contains the supplementary crystallographic data for this paper. These data 
can be ontained free of charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 




Figure 4.3 X-ray crystal structure of 4-3d. 
 
4.2.4 Proposed Mechanism 
Our postulated reaction pathways were summarized in Scheme 4.2. In the initial 
step, elimination of compound 4-1a caused the formation of the intermediate imine 
4-4a in the presence of Li2CO3. The subsequent Mannich reaction of intermediate 
4-4a with malononitrile 4-2 formed the intermediate 4-5a catalyzed by indane 
amine-thiourea 4-III. Then, the intramolecular oxa-nucleophilic addition to nitrile 
group led to the intermediate 4-6a. Finally, intermediate 4-6a underwent 
tautomerization to offer the desired compound 4-3a. 
Scheme 4.2 Proposed catalytic cycle. 
 





In summary, we have developed an efficient and convenient cascade process for 
the synthesis of 2-amino-4H-chromenes in high to excellent yields (81–94%) and with 
good to high enantioselectivities (74–89% ee). This protocol proceeded through a 
Mannich-cyclization-tautomerization cascade sequence of malononitrile with 
2-hydroxyl N-protected α-amido sulfone. This finding is significant because it 
provides a novel and powerful route to the synthesis of privileged scaffold 
2-amino-4H-chromene bearing a nitrile functionality, which reveals potential 
application in the treatment of human inflammatory TNFa-mediated diseases. 
However, it is still highly desirable to apply this catalytic system and strategy to other 
asymmetric transformations to efficiently assemble chiral materials with complex 
structures. Further elaboration of the products to other types of biologically active 
compounds and potential applications of the catalytic system will draw much 
attention in the further. 
 
4.4 Experimental Section 
4.4.1 General Information 
Chemicals and solvents were purchased from commercial suppliers and used as 
received. 1H and 13C NMR spectra were recorded on a Bruker ACF300 (300 MHz) or 
AMX500 (500 MHz) spectrometer. Chemical shifts were reported in parts per million 
(ppm), and the residual solvent peak was used as an internal reference: proton 
(chloroform δ 7.26), carbon (chloroform δ 77.0) or tetramethylsilane (TMS δ 0.00) 
was used as a reference. Multiplicity was indicated as follows: s (singlet), d (doublet), 
t (triplet), q (quartet), m (multiplet), dd (doublet of doublet), bs (broad singlet). 
Coupling constants were reported in Hertz (Hz). Low resolution mass spectra were 
obtained on a Finnigan/MAT LCQ spectrometer in ESI mode, and a Finnigan/MAT 
95XL-T mass spectrometer in EI mode. All high resolution mass spectra were 




obtained on a Finnigan/MAT 95XL-T spectrometer. For thin layer chromatography 
(TLC), Merck pre-coated TLC plates (Merck 60 F254) were used, and compounds 
were visualized with a UV light at 254 nm. Further visualization was achieved by 
staining with iodine, or ninhydrin followed by heating using a heat gun. Flash 
chromatography separations were performed on Merck 60 (0.040-0.063 mm) mesh 
silica gel. The enantiomeric excesses of products were determined by chiral phase 
HPLC analysis. Optical rotations were recorded on Jasco DIP-1000 polarimeter. 
 




To a solution of tert-butyl (2-hydroxyphenyl)(phenylsulfonyl)methylcarbamate 
4-1a (36 mg, 0.1 mmol,), malononitrile 4-2 (7.3 mg, 0.11 mmol) and catalyst 4-III 
(4.9 mg, 0.01 mmol) in DCM (2.0 mL) at 0 °C, was added chilled lithium carbonate 
aqueous solution (0.10 M, 1.2 mL) in one portion. The resulting biphasic reaction 
mixture was kept stirring at 0°C for 0.5 h. Then the reaction mixture was diluted with 
water (2 mL) and extracted with ethyl acetate (5 mL, three times). Organic layers 
were combined, washed with brine (6 mL), dried over anhydrous sodium sulfate and 
concentrated under reduced pressure. Crude product was purified by silica gel flash 
chromatography, eluted by hexane/EtOAc=3:1 to afford the desired product 4-3a as 
white solid (27.0 mg, 94% yield). 
 
 




4.4.3 Analytical Data of Mannich–Intramolecular Ring Cyclization–
Tautomerization products 
 
(R)-tert-butyl 2-amino-3-cyano-4H-chromen-4-ylcarbamate (4-3a). 94% yield, 88% 
ee; 1H NMR (500 MHz, CDCl3): δ = 7.49 (s, 1H), 7.33 – 7.22 (m, 1H), 7.16 (t, J = 7.5 
Hz, 1H), 6.97 (d, J = 8.2 Hz, 1H), 5.64 (d, J = 7.9 Hz, 1H), 4.94 (d, J = 7.9 Hz, 1H), 
4.87 (m, 2H), 1.46 (s, 9H); 13C NMR (125 MHz, CDCl3): δ = 160.57, 155.07, 148.38, 
129.18, 129.11, 125.35, 121.35, 118.96, 116.13, 80.00, 58.56, 43.90, 28.30; HRMS 
(ESI) calcd for C15H17N3O3Na (M + Na+) 310.1162, found 310.1169; HPLC 
(Chiralpak IA, i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR 
(major) = 7.7 min, tR (minor) = 14.7 min, ee = 88%; [α]25D = -63.2 (c = 0.79 in 
Acetone). 
 
(R)-tert-butyl 2-amino-3-cyano-6-fluoro-4H-chromen-4-ylcarbamate (4-3b). 82% 
yield, 83% ee；1H NMR (500 MHz, DMSO-d6): δ = 7.60 (d, J = 8.6 Hz, 1H), 7.17 (td, 
J = 8.5, 3.0 Hz, 1H), 7.07 (dt, J = 7.4, 3.5 Hz, 2H), 7.02 (m, 2H), 5.33 (d, J = 8.6 Hz, 
1H), 1.39 (s, 9H); 13C NMR (125 MHz, DMSO-d6): δ = 161.16, 159.13, 157.21, 
155.06, 144.82, 119.93, 118.05, 117.69, 117.63, 115.97, 115.77, 113.97, 113.78, 78.14, 
53.83, 43.98, 28.12; HRMS (ESI) calcd for C15H16FN3O3Na (M + Na+) 328.1068, 
found 328.1073; HPLC (Chiralpak IA, i-propanol/hexane = 20/80, flow rate 1.0 
mL/min, λ = 254 nm): tR (major) = 7.2 min, tR (minor) = 15.8 min, ee = 83%; [α]25D = 
-78.1 (c = 1.00 in Acetone). 





(R)-tert-butyl 2-amino-6-chloro-3-cyano-4H-chromen-4-ylcarbamate (4-3c). 87% 
yield, 85% ee; 1H NMR (500 MHz, CDCl3): δ = 7.50 (s, 1H), 7.23 (dd, J = 8.8, 2.4 Hz, 
1H), 6.93 (d, J = 8.8 Hz, 1H), 5.59 (d, J = 8.3 Hz, 1H), 4.94 (s, 1H), 4.83 (m, 2H), 
1.47 (s, 9H); 13C NMR (125 MHz, CDCl3): δ = 160.28, 155.00, 146.93, 130.39, 
129.39, 128.80, 122.90, 118.49, 117.61, 80.40, 58.47, 43.79, 28.29; HRMS (ESI) 
calcd for C15H16ClN3O3Na (M + Na+) 344.0772, found 344.0776; HPLC (Chiralpak 
IA, i-propanol/hexane = 40/60, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 4.7 
min, tR (minor) = 8.6 min, ee = 85%; [α]25D = -21.9 (c = 0.88 in Acetone). 
 
(R)-tert-butyl 2-amino-6-bromo-3-cyano-4H-chromen-4-ylcarbamate (4-3d). 82% 
yield, 84% ee; 1H NMR (500 MHz, CDCl3): δ = 7.64 (s, 1H), 7.38 (dd, J = 8.7, 2.1 Hz, 
1H), 6.87 (d, J = 8.7 Hz, 1H), 5.59 (d, J = 7.4 Hz, 1H), 4.94 (s, 1H), 4.83 (m, 2H), 
1.47 (s, 9H); 13C NMR (75 MHz, CDCl3): δ = 160.22, 155.00, 147.47, 132.29, 131.79, 
123.28, 118.48, 117.96, 117.77, 80.41, 58.56, 43.69, 28.29; HRMS (ESI) calcd for 
C15H16BrN3O3Na (M + Na+) 388.0267, found 388.0274; HPLC (Chiralpak IA, 
i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 8.1 min, 
tR (minor) = 22.6 min, ee = 84%; [α]25D = -1.9 (c = 0.97 in Acetone). 
 




(R)-tert-butyl 2-amino-3-cyano-6-methyl-4H-chromen-4-ylcarbamate (4-3e). 89% 
yield, 87% ee; 1H NMR (500 MHz, DMSO-d6): δ = 7.48 (d, J = 8.8 Hz, 1H), 7.10 (d, 
J = 5.8 Hz, 1H), 6.95 – 6.86 (m, 3H), 5.32 (d, J = 8.9 Hz, 1H), 2.26 (s, 3H), 1.39 (s, 
9H); 13C NMR (125 MHz, DMSO-d6): δ = 161.13, 155.03, 146.44, 133.48, 129.27, 
128.25, 121.64, 120.08, 115.46, 77.85, 54.79, 43.79, 28.12, 20.20; HRMS (ESI) calcd 
for C16H19N3O3Na (M + Na+) 324.1319, found 324.1323; HPLC (Chiralpak IA, 
i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 7.4 min, 
tR (minor) = 17.6 min, ee = 87%; [α]25D = -3.9 (c = 0.79 in Acetone). 
 
(R)-tert-butyl 2-amino-6-tert-butyl-3-cyano-4H-chromen-4-ylcarbamate (4-3f). 82% 
yield, 88% ee; 1H NMR (500 MHz, DMSO-d6): δ = 7.50 (d, J = 9.0 Hz, 1H), 7.41 (s, 
1H), 7.33 (dd, J = 8.6, 2.0 Hz, 1H), 6.93 (d, J = 9.1 Hz, 3H), 5.36 (d, J = 9.0 Hz, 1H), 
1.40 (s, 9H), 1.24 (s, 9H); 13C NMR (125 MHz, DMSO-d6): δ = 161.22, 155.25, 
146.88, 146.12, 125.80, 124.45, 121.66, 120.20, 115.19, 77.89, 54.13, 44.01, 33.95, 
31.00, 28.09; HRMS (ESI) calcd for C19H25N3O3Na (M + Na+) 366.1788, found 
366.1795; HPLC (Chiralpak IA, i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 
254 nm): tR (major) = 5.9 min, tR (minor) = 10.7 min, ee = 88%; [α]25D = -18.9 (c = 
1.02 in Acetone). 
 
(R)-tert-butyl 2-amino-3-cyano-6-methoxy-4H-chromen-4-ylcarbamate (4-3g). 81% 
yield, 89% ee; 1H NMR (500 MHz, CDCl3): δ = 7.02 (s, 1H), 6.90 (d, J = 9.0 Hz, 1H), 
6.81 (dd, J = 8.9, 2.9 Hz, 1H), 5.62 (d, J = 8.7 Hz, 1H), 4.93 (d, J = 7.8 Hz, 1H), 4.78 




(m, 2H), 3.77 (s, 3H), 1.47 (s, 9H); 13C NMR (125 MHz, CDCl3): δ = 160.72, 156.83, 
155.20, 142.37, 122.08, 119.05, 117.14, 116.30, 111.88, 80.03, 58.06, 55.71, 44.35, 
28.31; HRMS (ESI) calcd for C16H19N3O4Na (M + Na+) 340.1268, found 340.1274; 
HPLC (Chiralpak IA, i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): 
tR (major) = 8.7 min, tR (minor) = 19.1 min, ee = 89%; [α]25D = -31.6 (c = 0.84 in 
Acetone). 
 
(R)-tert-butyl 2-amino-3-cyano-8-methoxy-4H-chromen-4-ylcarbamate (4-3h). 81% 
yield, 74% ee; 1H NMR (500 MHz, DMSO-d6) δ = 7.49 (d, J = 8.9 Hz, 1H), 7.09 (t, J 
= 7.9 Hz, 1H), 6.99 (dd, J = 14.8, 7.2 Hz, 3H), 6.87 (d, J = 7.7 Hz, 1H), 5.34 (d, J = 
8.9 Hz, 1H), 3.81 (s, 3H), 1.38 (s, 9H); 13C NMR (125 MHz, DMSO-d6) δ = 161.05, 
154.98, 146.74, 138.08, 124.22, 122.85, 120.06, 119.31, 111.22, 77.85, 59.67, 55.71, 
43.92, 28.15; HRMS (ESI) calcd for C16H19N3O4Na (M + Na+) 340.1268, found 
340.1273; HPLC (Chiralpak IA, i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 
254 nm): tR (major) = 12.9 min, tR (minor) = 11.5 min, ee = 74%; [α]25D = -18.3 (c = 
1.17 in Acetone). 
 
(R)-benzyl 2-amino-3-cyano-4H-chromen-4-ylcarbamate (4-3i). 82% yield, 84% 
ee; 1H NMR (500 MHz, DMSO-d6): δ = 7.99 (d, J = 8.7 Hz, 1H), 7.39 – 7.25 (m, 7H), 
7.18 (d, J = 7.4 Hz, 1H), 7.02 (d, J = 7.1 Hz, 3H), 5.42 (d, J = 8.7 Hz, 1H), 5.06 (s, 
2H); 13C NMR (125 MHz, DMSO-d6) δ = 161.25, 155.54, 148.50, 137.01, 128.95, 
128.41, 128.26, 127.68, 127.53, 124.63, 121.72, 120.03, 115.77, 65.20, 54.29, 44.55; 




HRMS (ESI) calcd for C18H15N3O3Na (M + Na+) 344.1006, found 344.1010; HPLC 
(Chiralpak IB, i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR 
(major) = 15.8 min, tR (minor) = 35.7 min, ee = 84%; [α]25D = -51.4 (c = 1.17 in 
Acetone). 
 
4.4.4 X-ray Crystallographic Analysis 
Table 4.5 Crystal data and structure refinement for 4-3d.  
Empirical formula  C15 H16 Br N3 O3 
Formula weight  366.22 
Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 5.3714(4) Å a= 90°. 
 b = 16.8874(11) Å b= 90°. 
 c = 17.4864(12) Å g = 90°. 
Volume 1586.17(19) Å3 
Z 4 
Density (calculated) 1.534 Mg/m3 
Absorption coefficient 2.607 mm-1 
F(000) 744 
Crystal size 0.70 x 0.08 x 0.06 mm3 
Theta range for data collection 1.68 to 27.48° 
Index ranges -6<=h<=6, -20<=k<=21, -21<=l<=22 
Reflections collected 11171 
Independent reflections 3592 [R(int) = 0.0573] 
Completeness to theta = 27.48° 99.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8621 and 0.6334 
Refinement method Full-matrix least-squares on F2 




Data / restraints / parameters 3592 / 3 / 211 
Goodness-of-fit on F2 1.016 
Final R indices [I>2sigma(I)] R1 = 0.0467, wR2 = 0.0954 
R indices (all data) R1 = 0.0600, wR2 = 0.1003 
Absolute structure parameter 0.010(12) 
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5.1 Introduction  
Over the past few decades, natural products have proven to be useful small 
molecule probes in the medicinal community.156 Since they have coevolved with their 
putative biological targets, natural products intersect biological space effectively and 
perturb its function in a highly controlled manner. It is not surprising that natural 
products have endured as promising leads for drug discovery. A rapid access to small 
molecules that are guided by natural products appears to be quintessential for the 
success of chemical genetics/genomics-based program. The design and synthesis of 
novel scaffolds as chiral core structures for the library generation of natural 
product-like derivatives is an essential step in accessing a wide range of structural 
complexes in an efficient manner.157 
Herein, we wish to disclose a concise decarboxylative158 [1,2]-addition process 
of readily accessible α-functionalized carboxylic acids with isatins under mild 








































Figure 5.1 Representative bioactive natural products built on a 3-hydroxy-2-oxindole core 
scaffold. 
                                                              
156  a) see Ref. 110b; b) Dewick, P. M. Medicinal Natural Products, Wiley, West Sussex, 2009. 
157  a) Schreiber, S. L. Bioorg. Med. Chem. 1998, 6, 1127; b) Schreiber, S. L. Science 2000, 287, 1964; c) Crew, C. 
M. Curr. Opin. Chem. Biol. 2000, 4, 47; d) Weber, L. Curr. Opin. Chem. Biol. 2000, 4, 295; e)Wendeborn, S.; De 
Mesmaeker, A.; Brill, W. K.-D.; Berteina, S. Acc. Chem. Res. 2000, 33, 215. 
158  a) see Ref. 90; b) Liu, M.; Sibi, M. P. Tetrahedron 2002, 58, 7991; c) see Ref. 91; d) Jiang, Z.; Pan, Y.; Zhao, Y.; 
Ma, T.; Lee, R.; Yang, Y.; Huang, K.-W.; Wong, M. W.; Tan, C.-H. Angew. Chem. Int. Ed. 2009, 48, 3627. 
159  a) Galliford, C. V.; Scheidt, K. A. Angew. Chem. Int. Ed. 2007, 46, 8748; b) Marti, C.; Carreira, E. M. Eur. J. 
Org. Chem. 2003, 2209. 




Good to excellent yields have been obtained at a suitable condition. These 
features render this synthetic protocol particularly attractive for practical application 
in drug discovery. It is noteworthy that the synthetic value has been broadly 
demonstrated in the formal and total synthesis of bioactive natural products,159, 160 
such as (±)-flustraminol B, (±)-convolutamydine A, (±)-alline, donaxaridine, 
(±)-convolutamydine E, (±)-convolutamydine B, and (±)-CPC-1.  
 
Scheme 5.1 Routes for the preparation of 3-functionalized-3-hydroxy-2-oxindole framework. 
Some elegant works have been reported to directly construct the 
3-functionalized-3-hydroxy-2-oxindole framework (Scheme 5.1). One of the most 
straightforward strategies is the catalytic aldol reactions of ketones and aldehydes 
with isatins.161 In line with the nucleophilic addition to the 3-carbonyl of isatins as a 
strategy for the synthesis of 3-substituted-3-hydroxy oxindoles, metal-mediated 
additions of carbon nucleophiles/equivalents, such as boronic acids, have been 
                                                              
160  a) Goehring, R. R.; Sachdeva, Y. P.; Pisipati, J. S.; Sleevi, M. C.; Wolfe, J. F. J. Am. Chem. Soc. 1985, 107, 435; 
b) Rasmussen, H. B.; MacLeod, J. K. J. Nat. Prod. 1997, 60, 1152; c) Jiménez, J. I.; Huber, U.; Moore, R. E.; 
Patterson, G. M. L. J. Nat. Prod. 1999, 62, 569; d) Kohno, J.; Koguchi, Y.; Nishio, M.; Nakao, K.; Juroda, M.; 
Shimizu, R.; Ohnuki, T.; Komatsubara, S. J. Org. Chem. 2000, 65, 990; e) Suchy, M.; Kutschy, P.; Monde, K.; 
Goto, H.; Harada, N.; Takasugi, M.; Dzurilla, M.; Balentova, E. J. Org. Chem. 2001, 66, 3940; f) Komakine, N.; 
Takaishi, Y.; Honda, G.; Ito, M.; Takeda, Y.; Kodzhimatov, O. K.; Ahurmetov, O. Natural Medicines 2005, 59, 45; 
g) Kagata, T.; Saito, S.; Shigemori, H.; Ohsaki, A.; Ishiyama, H.; Kubota, T.; Kobayashi, J. J. Nat. Prod. 2006, 69, 
1517. 
161  a) Braude, F.; Lindwall, H. G. J. Am.Chem. Soc. 1933, 55, 325; b) Luppi, G.; Cozzi, P. G.; Monari, M.; Kaptein, 
B.; Broxterman, Q. B.; Tomasini, C. J. Org. Chem. 2005, 70, 7418; c) Guo, Q.; Bhanushali, M.; Zhao, C. G. Angew. 
Chem. Int. Ed. 2010, 49, 9460.  




explored.162 Recently, a catalytic Henry reaction of isatins with alkanes has also been 
reported to make this core structure.163 In addition, the oxidation of 3-substituted 
oxindoles is showing itself to be a useful method for the construction of this medicinal 
scaffold. 164  Notably, a dimeric quinidine-catalyzed enantioselective 
aminooxygenation of oxindoles has been reported to generate chiral 3-substituted 
oxindoles.165 However, all the above methods are limited to special substrates.166 To 
our knowledge, there has been no powerful method that can construct a 3-hydroxy 
oxindole scaffold and bear a wide spectrum of functional groups at the C3 position 
(Scheme 5.1). As part of a program geared toward the design and development of 
novel organocatalytic strategies for the efficient and mild synthesis of 
3-functionalized-3-hydroxy-2-oxindole framework, we proposed a decarboxylative 
[1,2]-addition of various α-functionalized acetic acids to isatins catalyzed by a weak 
base. 
 
5.2 Results and Discussion 
5.2.1 Catalyst Screening 
We began our investigation by examining base-promoted reaction of isatin 5-1a 
and cyanoacetic acid 5-2a (Table 5.1). The initial experiment results showed that the 
use of a stoichiometric amount of triethylamine 5-I (1.0 equiv.) enabled a reaction 
between isatin 5-1a and cyanoacetic acid 5-2a to afford a 82% yield at room 
temperature (Table 5.1, entry 1, 72 h). To seek more efficient catalysts, we then 
examined some other tertiary amines, second and primary amines, but the reaction 
                                                              
162 a) Marshall, J. A. Chem. Rev. 2000, 100, 3163; b) Denmark, S. E.; Fu, J. Chem. Rev. 2003, 103, 2763; c) 
Shintani, R.; Inoue, M.; Hayashi, T. Angew. Chem. Int. Ed. 2006, 45, 3353.  
163 Liu, L.; Zhang, S.; Xue, F.; Lou, G.; Zhang, H.; Ma, S.; Duan, W.; Wang, W. Chem. –Eur. J. 2011, 17, 7791. 
164 a) Miah, S.; Moody, C. J.; Richards, I. C.; Slawin, A. M. Z. J. Chem. Soc., Perkin Trans. 1, 1997, 2405; b) 
Ishimaru, T.; Shibata, N.; Nagai, J.; Nakamura, S.; Toru, T.; Kanemasa, S. J. Am. Chem. Soc., 2006, 128, 16488; c) 
Sano, D.; Nagata, K.; Itoh, T. Org. Lett. 2008, 10, 1593.  
165 Bui, T.; Candeias, N. R.; Barbas, C. F., III J. Am. Chem. Soc. 2010, 132, 5574. 
166 a) Qian, Z. Q.; Zhou, F.; Du, T. P.; Wang, B. L.; Ding, M.; Zhao, X. L.; Zhou, J. Chem. Commun. 2009, 6753; b) 
Hara, N.; Nakamura, S.; Shibata, N.; Toru, T. Chem.–Eur. J. 2009, 15, 6790; c) Zhou, F.; Liu, Y. L.; Zhou, J. Adv. 
Synth. Catal. 2010, 352, 1381; d) Liu, Y. L.; Wang, B. L.; Cao, J. J.; Chen, L.; Zhang, Y. X.; Wang, C.; Zhou, J. J. 
Am. Chem. Soc. 2010, 132, 15176; e) Liu, Y. L.; Zhou, J. Chem. Commun. 2012, 48, 1919.  




yields were lower (Table 5.1, entries 2-6, < 69%). Surprisingly, super organic bases, 
5-VII and 5-VIII did not show a higher activity as expected (entries 7 and 8). In 
addition, several inorganic bases were also investigated, but the results demonstrated 
these inorganic bases were not efficient promoters in this reaction. 
Table 5.1 Base effecta 
 
 
Entry Base Yield (%)b Entry Base Yield (%)b 
1 5-I 82 7 5-VII 80 
2 5-II 69 8 5-VIII 43 
3 5-III 18 9 Li2CO3 <5 
4 5-IV 48 10 Cs2CO3 <5 
5 5-V 42 11 NaOAc 27d 
6 5-VI c 12 NaOH 48 
a Reaction conditions: THF (1.0 mL), 5-1a (0.2 mmol, 1.0 equiv), 5-2a (0.4 mmol, 2.0 equiv), 
base (1.0 equiv), 72 h, room temperature. b Yield of isolated product after column chromatography. 
c No reaction. d NaOAc was dissolved in H2O (0.1 mL), 72 h. 
 
5.2.2 Reaction Optimization 
Having this finding in hands, we started to probe other parameters. A high yield 
was obtained if the reaction was carried out in polar solvent DMF (Table 5.2, entry 10, 
90%, 72 h, room temperature). Other polar solvents, such as water and isopropanol 
however were proved to be poor media in this reaction (Table 5.2, entries 8 and 9, no 
reaction and 49%, respectively). To reduce the reaction time, we tried to increase the 




reaction temperature. The results showed that a higher reaction temperature can 
largely improve the reaction rate (entry 12, 70 oC, 95%, 1 h). As shown in Table 5.2, a 
20 mol% catalyst 5-I also efficiently promoted the reaction (entry 13, 95%, 3 h). 
However, a high reaction concentration (1.0 mol/L) caused a loss of reaction yield 
because of some unknown side reactions (entry 14, 75%). In addition, the low catalyst 
loading also supported a good reaction yield in a suitable time (entry 16, 5 mol% 5-I, 
81%, 8 h). 
Table 5.2 Optimization of other parametersa 
 
Entry Solvent t(h) 5-I (mol%) T(oC) Yield (%)b 
1 CH2Cl2 72 100 r.t. 38 
2 toluene 72 100 r.t. f 
3 THF 72 100 r.t. 82 
4 Et2O 72 100 r.t. f 
5 MeCN 72 100 r.t. 72 
6 acetone 72 100 r.t. 65 
7 EtOAc 72 100 r.t. 33 
8 H2O 72 100 r.t. f 
9 IPAe 72 100 r.t. 49 
10 DMF 72 100 r.t. 90 
11 DMF 18 100 50 98 
12 DMF 1 100 70 95 
13c DMF 3 20 70 95 
14d DMF 3 20 70 75 
15 DMF 6 10 70 88 
16 DMF 8 5 70 81 




a Reaction conditions: 5-1a (0.2 mmol, 1.0 equiv), 5-2a (0.4 mmol, 2.0 equiv), concentration (0.2 
mol/L). b Yield of isolated product after column chromatography. c 5-2a (0.22 mmol, 1.1 equiv). d 
Concentration (1.0 mol/L). e Isopropyl alcohol. f No reaction. 
 
5.2.3 Reaction Scope 
Having established a standard reaction protocol, we then probed a diverse set of 
isatins 5-1 and α-functionalized acetic acids 5-2. As revealed in Table 5.3, the process 
proved to be a general strategy to construct 3-functionalized 3-hydroxyoxindoles 5-3. 
Impressively, all reactions proceeded quickly (3–24 h), in good to excellent yields (up 
to 96%). The substitution pattern of R1 was observed to possess limited effect on 
reaction rate, regardless of the neutral, electron-donating, or electron-withdrawing 
properties of substituents (Table 5.3, entries 1–16). We also found that the 
introduction of R2 did not obviously affect this reaction (entries 17–20, 80–95%, 3 h). 
More importantly, a variety of α-functionalized groups, such as nitriles, esters, 
thioesters, amides, ketones, and aryls were successfully introduced to the core 
scaffold and desired products 5-3u – 5-3z were achieved in moderate to high yields 
(entries 21–26, 61–95%, 3–24 h). 
 
Table 5.3 Substrate scopea 
 
Entry R1 R2 R3 T(h) Yield (%)b 
1 H H CN(5-3a) 3 95 
2 5-F H CN(5-3b) 3 95 
3 5-Cl H CN(5-3c) 3 96 
4 5-Br H CN(5-3d) 3 92 




5 5-NO2 H CN(5-3e) 3 85 
6 5-MeO H CN(5-3f) 3 91 
7 5-Me H CN(5-3g) 3 92 
8 5-i-Pr H CN(5-3h) 3 88 
9 5-n-C7H15 H CN(5-3i) 3 73 
10 4-Cl H CN(5-3j) 3 96 
11 4-Br H CN(5-3k) 3 90 
12 6-Cl H CN(5-3l) 3 93 
13 6-Br H CN(5-3m) 3 91 
14c 4,6-Me2 H CN(5-3n) 24 90 
15 4,6-Br2 H CN(5-3o) 3 87 
16 5,7-Br2 H CN(5-3p) 3 85 
17 H Bz CN(5-3q) 3 81 
18 H Ac CN(5-3r) 3 80 
19 H Bn CN(5-3s) 3 95 
20 H Me CN(5-3t) 3 91 
21 H H CO2Me(5-3u) 3 90 
22d H H CO2Ph(5-3v) 24 92 
23d H H COSPh(5-3w) 24 61 
24 H H CONHPh(5-3x) 18 81 
25 H H COPh(5-3y) 3 86 
26 H H 4-NO2Ph(5-3z) 3 95 
a Reaction Conditions: DMF (1.0 mL), 5-1 (0.2 mmol, 1.0 equiv), 5-2 (0.22 mmol, 1.1 equiv), 5-I 
(20 mol%), 70 oC. b Yield of isolated product after column chromatography. c 5-I (1.0 equiv). d 
Room temperature. 
 
5.2.4. Methodology Application: Synthesis of Natural Products 
To illustrate the broad synthetic utility of this methodology, we undertook the 




formal synthesis of several natural products, such as (±)-flustraminol B (eq 1)167, 
(±)-convolutamydine A (eq 2), (±)-alline (eq 3)168, (±)-convolutamydine E (eq 4), 
(±)-convolutamydine B (eq 4)169 and donaxaridine (eq 5)170. As shown in eqs 1-5, we 
efficiently synthesized a series of important intermediates 5-3a, 5-3m, 5-3w and 5-7 
which could be efficiently converted to targeted natural products (±)-alline 5-6, 
(±)-flustraminol B 5-4, donaxaridine 5-11, (±)-convolutamydine E 5-8 and 
(±)-convolutamydine B 5-9 via known methods respectively. Moreover, 
(±)-convolutamydine A 5-5 was directly synthesized by our one-pot decarboxylative 
[1,2]-addition strategy in 88% yield. 
In addition, this method was applied to efficiently synthesize (±)-CPC-1. The 
synthesis commenced with an initial step, the bis-methylation of 5-3a, to afford the 
N,O-dimethylated intermediate which was then converted to the Boc-protected amine 
in the presence of NiCl2 and reducing agent NaBH4. Followed that, the Boc protecting 
group was transferred into a methyl group using Red-Al. This intermediate then 
cyclized with the oxindole functionality to afford the desired alkaloid (±)-CPC-1 
(Scheme 5.2). Meanwhile, the large scale synthesis by using 1.47 g of 5-1a to react 




167  Singh, A.; Poth, G. P. Tetrahedron Lett. 2012, 53, 4889.  
168  Singh, A.; Poth, G. P. Org. Lett. 2011, 13, 2118.  
169  Hara, N.; Nakamura, S.; Shibata, N.; Toru, T. Chem. –Eur. J. 2009, 15, 6790.  
170  See Ref. 160b. 

































a Reagents: a) Cs2CO3, Me2SO4, CH3CN/DMF, 71%; b) NiCl2/NaBH4, (Boc)2O, MeOH, r.t., 77%; 
c) Red-Al, toluene, 0 to 80 oC. 





In conclusion, inspired by the “medicinal” scaffold of 3-functionalized 
3-hydroxyoxindoles, we have documented a concise decarboxylative [1,2]-addition 
strategy based on readily available isatins and α-functionalized acetic acids, using a 
catalytic amount of weak base. We have demonstrated the broad synthetic utility of 
our catalytic protocol in the efficient and quick assembly of pharmaceutical important 
3-hydroxyoxindole natural products. This protocol extends previous work on the 
highly efficient assembly of 3-hydroxy oxindole scaffold via a catalytic 
decarboxylative strategy. The formal and total synthesis of bioactive natural products 
demonstrates the synthetic value of this protocol for practical application in drug 
discovery. However, the synthesis of chiral pharmaceutical 3-hydroxyoxindole natural 
products was not taken into account due to lack of suitable powerful organocatalysts. 
Therefore, further research is necessary to apply this catalytic strategy to various 
crucial applications and to develop an enantioselective methodology to construct 
“medicinal” 3-hydroxyoxindole scaffolds. 
 
5.4 Experimental Section 
5.4.1 General Information 
Chemicals and solvents were purchased from commercial suppliers and used as 
received. 1H and 13C NMR spectra were recorded on a Bruker ACF300 (300 MHz) or 
AMX500 (500 MHz) spectrometer. Chemical shifts were reported in parts per million 
(ppm), and the residual solvent peak was used as an internal reference: proton 
(chloroform δ 7.26, DMSO δ 2.50), carbon (chloroform δ 77.0, DMSO δ 39.5) or 
tetramethylsilane (TMS δ 0.00) was used as a reference. Multiplicity was indicated as 
follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet of 
doublet), bs (broad singlet). Coupling constants were reported in Hertz (Hz). Low 
resolution mass spectra were obtained on a Finnigan/MAT LCQ spectrometer in ESI 




mode, and a Finnigan/MAT 95XL-T mass spectrometer in EI mode. All high 
resolution mass spectra were obtained on a Finnigan/MAT 95XL-T spectrometer. 
Melting points were checked on Gallenkamp melting point apparatus. For thin layer 
chromatography (TLC), Merck pre-coated TLC plates (Merck 60 F254) were used, 
and compounds were visualized with a UV light at 254 nm. Flash chromatography 
separations were performed on Merck 60 (0.040-0.063 mm) mesh silica gel.  
 
5.4.2 Representative Procedure for Organocatalytic Decarboxylative Addition 
 
To a solution of isatin 5-1a (29.4 mg, 0.20 mmol) in 1.0 mL DMF was added 
cyanoacetic acid 5-2a (18.7 mg, 0.22 mmol) at room temperature, followed by adding 
catalyst 5-I TEA (5.6 µL, 0.04 mmol). The mixture was stirred at 70 oC for 3 hours. 
The crude product was purified by column chromatography on silica gel, eluted by 
hexane/EtOAc = 2:1 to afford 35.8 mg (95% yield) of the desired product 5-3a as 
white solid. 
 
5.4.3 Analytical Data of Organocatalytic Decarboxylative Addition Products 
 
2-(3-hydroxy-2-oxoindolin-3-yl)acetonitrile (5-3a). White solid, 3h, 95% yield; mp 
164 – 166 oC; 1H NMR (500 MHz, DMSO-d6): δ = 10.52 (s, 1H), 7.46 (d, J = 7.2 Hz, 
1H), 7.29 (td, J = 7.7, 1.2 Hz, 1H), 7.04 (td, J = 7.6, 0.8 Hz, 1H), 6.87 (d, J = 7.8 Hz, 




1H), 6.59 (s, 1H), 3.04 (d, J = 16.4 Hz, 1H), 2.95 (d, J = 16.4 Hz, 1H); 13C NMR (125 
MHz, DMSO-d6): δ = 176.7, 141.6, 123.0, 129.8, 124.18, 122.0, 117.02, 110.0, 72.0, 
26.1; MS (ESI) m/z: 211 ([M + Na]+); HRMS (ESI): Exact mass calculated for 
C10H8N2O2 [M + Na]+ 211.0483, found 211.0481.  
 
 
2-(5-fluoro-3-hydroxy-2-oxoindolin-3-yl)acetonitrile (5-3b). White solid, 3h, 95% 
yield; mp 186 – 188 oC; 1H NMR (500 MHz, DMSO-d6): δ = 10.56 (s, 1H), 7.30 (dd, 
J = 8.1, 2.7 Hz, 1H), 7.17 – 7.10 (m, 1H), 6.87 (dd, J = 8.5, 4.3 Hz, 1H), 6.73 (s, 1H), 
3.09 (d, J = 16.4 Hz, 1H), 3.01 (d, J = 16.4 Hz, 1H); 13C NMR (125 MHz, DMSO-d6): 
δ = 176.57, 158.95, 157.07, 137.76, 137.74, 131.39, 131.33, 116.80, 116.36, 116.17, 
111.99, 111.80, 111.00, 110.94, 72.29, 25.83; MS (ESI) m/z: 229 ([M + Na]+); HRMS 
(ESI): Exact mass calculated for C10H7FN2O2 [M + Na]+ 229.0389, found 229.0383. 
 
 
2-(5-chloro-3-hydroxy-2-oxoindolin-3-yl)acetonitrile (5-3c). White solid, 3h, 96% 
yield; mp 217 – 219 oC; 1H NMR (500 MHz, DMSO-d6): δ = 10.67 (s, 1H), 7.48 (d, J 
= 2.2 Hz, 1H), 7.35 (dd, J = 8.3, 2.2 Hz, 1H), 6.89 (d, J = 8.3 Hz, 1H), 6.74 (s, 1H), 
3.11 (d, J = 16.4 Hz, 1H), 3.02 (d, J = 17.1 Hz, 1H); 13C NMR (125 MHz, DMSO-d6): 
δ = 176.29, 140.52, 131.70, 129.80, 125.93, 124.31, 116.83, 111.57, 72.07, 25.74;  
MS (ESI) m/z: 245 ([M + Na]+); HRMS (ESI): Exact mass calculated for 
C10H7ClN2O2 [M + Na]+ 245.0094, found 245.0097. 





2-(5-bromo-3-hydroxy-2-oxoindolin-3-yl)acetonitrile (5-3d). White solid, 3h, 92% 
yield; mp 238 – 240 oC; 1H NMR (500 MHz, DMSO-d6): δ = 10.68 (s, 1H), 7.60 (d, J 
= 2.0 Hz, 1H), 7.48 (dd, J = 8.3, 2.1 Hz, 1H), 6.84 (d, J = 8.3 Hz, 1H), 6.74 (s, 1H), 
3.11 (d, J = 16.4 Hz, 1H), 3.02 (d, J = 16.4 Hz, 1H); 13C NMR (125 MHz, DMSO-d6): 
δ = 176.17, 140.94, 132.65, 132.09, 127.05, 116.85, 113.57, 112.10, 72.03, 25.75; MS 
(ESI) m/z: 289 ([M + Na]+); HRMS (ESI): Exact mass calculated for C10H7BrN2O2 
[M + Na]+ 288.9589, found 288.9589. 
 
 
2-(3-hydroxy-5-nitro-2-oxoindolin-3-yl)acetonitrile (5-3e). White solid, 3h, 85% 
yield; mp 221 – 223 oC; 1H NMR (500 MHz, DMSO-d6): δ = 11.26 (s, 1H), 8.34 (d, J 
= 2.3 Hz, 1H), 8.27 (dd, J = 8.6, 2.4 Hz, 1H), 7.09 (d, J = 8.6 Hz, 1H), 6.93 (s, 1H), 
3.22 (d, J = 16.4 Hz, 1H), 3.14 (d, J = 17.0 Hz, 1H); 13C NMR (125 MHz, DMSO-d6): 
δ = 176.91, 148.13, 142.34, 130.64, 127.20, 119.90, 116.71, 110.39, 71.64, 25.45; MS 
(ESI) m/z: 232 ([M – H]-); HRMS (ESI): Exact mass calculated for C10H7N3O4 [M – 
H]- 232,0358, found 232.0354. 
 
 




2-(3-hydroxy-5-methoxy-2-oxoindolin-3-yl)acetonitrile (5-3f). White solid, 3h, 91% 
yield; mp 177 – 179 oC; 1H NMR (500 MHz, DMSO-d6): δ = 10.35 (s, 1H), 7.10 (d, J 
= 2.5 Hz, 1H), 6.86 (dd, J = 8.4, 2.6 Hz, 1H), 6.78 (d, J = 8.4 Hz, 1H), 6.60 (s, 1H), 
3.73 (s, 3H), 3.05 (d, J = 17.0 Hz, 1H), 2.95 (d, J = 17.0 Hz, 1H); 13C NMR (125 
MHz, DMSO-d6): δ = 176.52, 155.03, 134.63, 130.88, 116.96, 114.50, 111.15, 110.45, 
72.37, 55.50, 26.06; MS (ESI) m/z: 241 ([M + Na]+); HRMS (ESI): Exact mass 
calculated for C11H10N2O3 [M + Na]+ 241.0589, found 241.0590. 
 
 
2-(3-hydroxy-5-methyl-2-oxoindolin-3-yl)acetonitrile (5-3g). White solid, 3h, 92% 
yield; mp 196 – 198 oC; 1H NMR (500 MHz, DMSO-d6): δ = 10.42 (s, 1H), 7.27 (s, 
1H), 7.09 (dd, J = 7.9, 0.7 Hz, 1H), 6.76 (d, J = 7.9 Hz, 1H), 6.53 (s, 1H), 3.02 (d, J = 
17.1 Hz, 1H), 2.92 (d, J = 16.4 Hz, 1H), 2.28 (s, 3H); 13C NMR (125 MHz, 
DMSO-d6): δ = 176.61, 139.05, 130.79, 130.09, 129.78, 124.67, 116.99, 109.74, 
72.05, 26.08, 20.63; MS (ESI) m/z: 225 ([M + Na]+); HRMS (ESI): Exact mass 
calculated for C11H10N2O2 [M + Na]+ 225.0640, found 225.0645. 
 
 
2-(3-hydroxy-5-isopropyl-2-oxoindolin-3-yl)acetonitrile (5-3h). White solid, 3h, 88% 
yield; mp 170 – 172 oC; 1H NMR (500 MHz, DMSO-d6): δ = 10.42 (s, 1H), 7.37 (d, J 
= 1.3 Hz, 1H), 7.16 (dd, J = 8.0, 1.6 Hz, 1H), 6.79 (d, J = 7.9 Hz, 1H), 6.54 (s, 1H), 
3.02 (d, J = 16.4 Hz, 1H), 2.94 (d, J = 16.4 Hz, 1H), 2.87 (dt, J = 13.8, 6.9 Hz, 1H), 




1.20 (s, 3H), 1.19 (s, 3H); 13C NMR (125 MHz, DMSO-d6): δ = 176.72, 142.14, 
139.36, 129.76, 127.60, 122.10, 117.07, 109.71, 72.06, 33.10, 26.14, 24.07, 24.06; 
MS (ESI) m/z: 253 ([M + Na]+); HRMS (ESI): Exact mass calculated for C13H14N2O2 
[M + Na]+ 253.0953, found 253.0950. 
 
 
2-(5-heptyl-3-hydroxy-2-oxoindolin-3-yl)acetonitrile (5-3i). White solid, 6h, 73% 
yield; mp 188 – 190 oC; 1H NMR (500 MHz, DMSO-d6): δ = 10.44 (s, 1H), 7.29 (d, J 
= 1.2 Hz, 1H), 7.09 (dd, J = 7.9, 1.6 Hz, 1H), 6.76 (d, J = 7.9 Hz, 1H), 6.55 (s, 1H), 
3.02 (d, J = 16.4 Hz, 1H), 2.93 (d, J = 17.1 Hz, 1H), 2.53 (t, J = 7.6 Hz, 2H), 1.53 (br, 
2H), 1.34 – 1.21 (m, 8H), 0.85 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, DMSO-d6): δ 
= 176.70, 139.26, 136.01, 129.76, 129.56, 124.04, 117.08, 109.74, 72.06, 34.82, 31.29, 
31.25, 28.54, 26.13, 22.08, 13.95; MS (ESI) m/z: 309 ([M + Na]+); HRMS (ESI): 
Exact mass calculated for C17H22N2O2 [M + Na]+ 309.1579, found 309.1574. 
 
 
2-(4-chloro-3-hydroxy-2-oxoindolin-3-yl)acetonitrile (5-3j). White solid, 3h, 96% 
yield; mp 201 – 203 oC; 1H NMR (500 MHz, DMSO-d6): δ = 10.81 (s, 1H), 7.31 (t, J 
= 8.0 Hz, 1H), 7.03 (dd, J = 8.2, 0.5 Hz, 1H), 6.85 (dd, J = 7.8, 0.6 Hz, 1H), 6.75 (s, 
1H), 3.30 (d, J = 16.4 Hz, 1H), 3.15 (d, J = 16.4 Hz, 1H); 13C NMR (125 MHz, 
DMSO-d6): δ = 175.75, 143.92, 131.86, 130.48, 125.38, 122.82, 115.97, 109.11, 
73.43, 23.53; MS (ESI) m/z: 245 ([M + Na]+); HRMS (ESI): Exact mass calculated 




for C10H7ClN2O2 [M + Na]+ 245.0094, found 245.0090. 
 
 
2-(4-bromo-3-hydroxy-2-oxoindolin-3-yl)acetonitrile (5-3k). White solid, 3h, 90% 
yield; mp 227 – 229 oC; 1H NMR (500 MHz, DMSO-d6): δ = 10.80 (s, 1H), 7.26 – 
7.21 (m, 1H), 7.18 (dd, J = 8.1, 0.8 Hz, 1H), 6.89 (dd, J = 7.6, 0.8 Hz, 1H), 6.72 (s, 
1H), 3.34 (d, J = 17.1 Hz, 1H), 3.13 (d, J = 17.0 Hz, 1H); 13C NMR (125 MHz, 
DMSO-d6): δ = 175.80, 144.14, 132.04, 126.96, 125.88, 118.80, 115.88, 109.58, 
74.03, 23.39; MS (ESI) m/z: 289 ([M + Na]+); HRMS (ESI): Exact mass calculated 
for C10H7BrN2O2 [M + Na]+ 288.9589, found 288.9582. 
 
 
2-(6-chloro-3-hydroxy-2-oxoindolin-3-yl)acetonitrile (5-3l). White solid, 3h, 93% 
yield; mp 203 – 205 oC; 1H NMR (500 MHz, DMSO-d6): δ = 10.71 (s, 1H), 7.45 (d, J 
= 8.0 Hz, 1H), 7.11 (dd, J = 8.0, 1.9 Hz, 1H), 6.89 (d, J = 1.8 Hz, 1H), 6.69 (s, 1H), 
3.07 (d, J = 16.4 Hz, 1H), 2.99 (d, J = 17.0 Hz, 1H); 13C NMR (125 MHz, DMSO-d6): 
δ = 176.59, 143.16, 134.25, 128.66, 125.67, 121.75, 116.94, 110.13, 71.66, 25.84; MS 
(ESI) m/z: 245 ([M + Na]+); HRMS (ESI): Exact mass calculated for C10H7ClN2O2 
[M + Na]+ 245.0094, found 245.0095. 
 





2-(6-bromo-3-hydroxy-2-oxoindolin-3-yl)acetonitrile (5-3m). White solid, 3h, 91% 
yield; mp 229 – 231 oC; 1H NMR (500 MHz, DMSO-d6): δ = 10.68 (s, 1H), 7.40 (d, J 
= 7.9 Hz, 1H), 7.25 (dd, J = 7.9, 1.7 Hz, 1H), 7.02 (d, J = 1.7 Hz, 1H), 6.68 (s, 1H), 
3.06 (d, J = 16.4 Hz, 1H), 2.98 (d, J = 17.0 Hz, 1H); 13C NMR (125 MHz, DMSO-d6): 
δ = 176.44, 143.26, 129.04, 125.96, 124.62, 122.61, 116.83, 112.86, 71.71, 25.77; MS 
(ESI) m/z: 289 ([M + Na]+); HRMS (ESI): Exact mass calculated for C10H7BrN2O2 
[M + Na]+ 288.9589, found 288.9586. 
 
 
2-(3-hydroxy-4,6-dimethyl-2-oxoindolin-3-yl)acetonitrile (5-3n). White solid, 24h, 
90% yield; mp 261 – 263 oC; 1H NMR (500 MHz, DMSO-d6): δ = 10.46 (s, 1H), 6.60 
(s, 1H), 6.50 (s, 1H), 6.45 (s, 1H), 3.16 (d, J = 17.1 Hz, 1H), 3.03 (d, J = 16.4 Hz, 1H) 
2.32 (s, 3H), 2.24 (s, 3H); 13C NMR (125 MHz, DMSO-d6): δ = 177.02, 141.99, 
139.45, 135.41, 124.78, 123.76, 116.62, 108.35, 73.49, 24.83, 21.17, 16.90; MS (ESI) 
m/z: 239 ([M + Na]+); HRMS (ESI): Exact mass calculated for C12H12N2O2 [M + Na]+ 














2-(4,6-dibromo-3-hydroxy-2-oxoindolin-3-yl)acetonitrile (5-3o). White solid, 3h, 
87% yield; mp 239 – 241 oC; 1H NMR (300 MHz, DMSO-d6): δ = 10.97 (s, 1H), 7.45 
(d, J = 1.5 Hz, 1H), 7.05 (d, J = 1.5 Hz, 1H), 6.81 (s, 1H), 3.33 (d, J = 16.7 Hz, 1H), 
3.14 (d, J = 16.7 Hz, 1H); 13C NMR (75 MHz, DMSO-d6): δ = 175.77, 145.31, 127.65, 
126.52, 123.69, 119.70, 115.81, 112.52, 73.81, 23.31; MS (ESI) m/z: 343 ([M – H]-); 




2-(5,7-dibromo-3-hydroxy-2-oxoindolin-3-yl)acetonitrile (5-3p). White solid, 3h, 
85% yield; mp 246 – 248 oC; 1H NMR (500 MHz, DMSO-d6): δ = 11.04 (s, 1H), 7.76 
(d, J = 1.8 Hz, 1H), 7.62 (d, J = 1.8 Hz, 1H), 6.87 (s, 1H), 3.18 – 3.04 (m, 2H); 13C 
NMR (125 MHz, DMSO-d6) δ = 176.07, 140.66, 134.49, 133.29, 126.20, 116.66, 
114.06, 103.29, 72.76, 25.60; MS (ESI) m/z: 343 ([M – H]-); HRMS (ESI): Exact 
mass calculated for C10H6Br2N2O2 [M – H]- 342.8718, found 342.8713. 
 
 
2-(1-benzoyl-3-hydroxy-2-oxoindolin-3-yl)acetonitrile (5-3q). White solid, 3h, 81% 
yield; mp 140 – 142 oC; 1H NMR (500 MHz, DMSO-d6): δ = 7.79 (dd, J = 11.7, 4.5 
Hz, 3H), 7.68 (ddd, J = 9.5, 5.4, 1.0 Hz, 2H), 7.56 – 7.48 (m, 3H), 7.36 (t, J = 7.5 Hz, 




1H), 7.02 (s, 1H), 3.33 (d, J = 16.4 Hz, 1H), 3.23 (d, J = 16.4 Hz, 1H); 13C NMR (125 
MHz, DMSO-d6): δ = 175.03, 168.59, 139.29, 133.77, 133.09, 130.31, 129.35, 129.23, 
128.31, 125.27, 124.28, 116.82, 114.57, 71.89, 26.10; MS (ESI) m/z: 315 ([M + Na]+); 




2-(1-acetyl-3-hydroxy-2-oxoindolin-3-yl)acetonitrile (5-3r). White solid, 3h, 80% 
yield; mp 131 – 133 oC; 1H NMR (500 MHz, CDCl3): δ = 8.23 (d, J = 8.2 Hz, 1H), 
7.68 (dd, J = 7.6, 1.0 Hz, 1H), 7.48 (td, J = 8.1, 1.4 Hz, 1H), 7.33 (td, J = 7.6, 0.9 Hz, 
1H), 3.49 (s, 1H), 3.06 (d, J = 16.4 Hz, 1H), 2.84 (d, J = 17.1 Hz, 1H), 2.63 (s, 3H); 
13C NMR (125 MHz, CDCl3): δ = 175.72, 170.38, 139.42, 131.63, 126.44, 126.35, 
123.87, 117.20, 114.61, 72.46, 27.82, 26.42; MS (ESI) m/z: 253 ([M + Na]+); HRMS 
(ESI): Exact mass calculated for C12H10N2O3 [M + Na]+ 253.0589, found 253.0580. 
 
 
2-(1-benzyl-3-hydroxy-2-oxoindolin-3-yl)acetonitrile (5-3s). White solid, 3h, 95% 
yield; mp 152 – 154 oC; 1H NMR (500 MHz, CDCl3): δ = 7.65 (dd, J = 7.4, 0.7 Hz, 
1H), 7.35 – 7.27 (m, 6H), 7.14 (td, J = 7.6, 0.8 Hz, 1H), 6.78 (d, J = 7.9 Hz, 1H), 4.96 
(d, J = 15.1 Hz, 1H), 4.82 (d, J = 15.8 Hz, 1H), 4.00 (s, 1H), 3.12 (d, J = 17.1 Hz, 1H), 




2.79 (d, J = 16.4 Hz, 1H); 13C NMR (125 MHz, CDCl3): δ = 175.54, 142.00, 134.61, 
130.92, 128.96, 127.99, 127.44, 127.21, 124.33, 123.99, 115.27, 110.20, 72.67, 44.17, 
27.48;  MS (ESI) m/z: 301 ([M + Na]+); HRMS (ESI): Exact mass calculated for 
C17H14N2O2 [M + Na]+ 301.0953, found 301.0955. 
 
 
2-(3-hydroxy-1-methyl-2-oxoindolin-3-yl)acetonitrile (5-3t). White solid, 3h, 91% 
yield; mp 130 – 132 oC; 1H NMR (500 MHz, CDCl3): δ = 7.65 (d, J = 7.4 Hz, 1H), 
7.42 (td, J = 7.8, 1.1 Hz, 1H), 7.21 – 7.15 (m, 1H), 6.91 (d, J = 7.8 Hz, 1H), 4.32 (s, 
1H), 3.21 (s, 3H), 3.03 (d, J = 16.4 Hz, 1H), 2.70 (d, J = 17.0 Hz, 1H); 13C NMR (125 
MHz, CDCl3): δ = 175.52, 142.76, 130.93, 127.57, 124.25, 123.97, 115.37, 109.14, 
72.60, 27.35, 26.55; MS (ESI) m/z: 225 ([M + Na]+); HRMS (ESI): Exact mass 
calculated for C11H10N2O2 [M + Na]+ 225.0640, found 225.0639. 
 
Methyl 2-(3-hydroxy-2-oxoindolin-3-yl)acetate (5-3u). White solid, 3h, 90% yield; 
mp 127 – 129 oC; 1H NMR (500 MHz, DMSO-d6) δ = 10.26 (s, 1H), 7.31 (d, J = 7.3 
Hz, 1H), 7.22 – 7.16 (m, 1H), 6.93 (t, J = 7.5 Hz, 1H), 6.79 (d, J = 7.7 Hz, 1H), 6.10 
(s, 1H), 3.39 (s, 3H), 3.01 (d, J = 15.8 Hz, 1H), 2.94 (d, J = 15.2 Hz, 1H); 13C NMR 
(125 MHz, DMSO-d6): δ = 177.79, 169.10, 142.49, 130.84, 129.20, 124.00, 121.32, 
109.46, 72.58, 51.12, 41.32; MS (ESI) m/z: 244 ([M + Na]+); HRMS (ESI): Exact 
mass calculated for C11H11NO4 [M + Na]+ 244.0586, found 244.0586. 












Phenyl 2-(3-hydroxy-2-oxoindolin-3-yl)acetate (5-3v). White solid, 24h, 92% yield; 
mp 133 – 135 oC; 1H NMR (300 MHz, CDCl3): δ = 8.61 (s, 1H), 7.38 (d, J = 7.3 Hz, 
1H), 7.27 – 7.06 (m, 4H), 6.99 (td, J = 7.6, 0.9 Hz, 1H), 6.84 – 6.72 (m, 3H), 4.48 (s, 
1H), 3.23 – 3.09 (m, 2H); 13C NMR (75 MHz, CDCl3) δ = 178.58, 168.54, 150.02, 
140.81, 130.33, 129.40, 129.23, 126.12, 124.37, 123.24, 121.34, 110.80, 74.02, 41.61; 
MS (ESI) m/z: 306 ([M + Na]+); HRMS (ESI): Exact mass calculated for C16H13NO4 
[M + Na]+ 306.0742, found 306.0747. 
 
 
S-phenyl 2-(3-hydroxy-2-oxoindolin-3-yl)ethanethioate (5-3w). White solid, 24h, 
61% yield; mp 136 – 138 oC; 1H NMR (500 MHz, CDCl3): δ = 8.62 (s, 1H), 7.41 – 
7.33 (m, 4H), 7.23 (td, J = 7.7, 1.2 Hz, 1H), 7.06 (td, J = 7.6, 0.8 Hz, 1H), 6.80 (d, J = 
7.8 Hz, 1H), 4.47 (s, 1H), 3.35 (d, J = 15.8 Hz, 1H), 3.27 (d, J = 15.8 Hz, 1H); 13C 
NMR (125 MHz, CDCl3): δ = 195.05, 178.18, 140.63, 134.38, 130.21, 129.74, 129.27, 
128.99, 126.71, 124.49, 123.09, 110.78, 74.77, 49.32; MS (ESI) m/z: 322 ([M + Na]+); 
HRMS (ESI): Exact mass calculated for C16H13NO3S [M + Na]+ 322.0514, found 
322.0509. 






2-(3-hydroxy-2-oxoindolin-3-yl)-N-phenylacetamide (5-3x). White solid, 18h, 81% 
yield; mp 169 – 171 oC; 1H NMR (500 MHz, CDCl3): δ = 8.92 (s, 1H), 8.68 (s, 1H), 
7.32 (d, J = 7.9 Hz, 2H), 7.24 (d, J = 7.3 Hz, 1H), 7.15 (t, J = 7.8 Hz, 2H), 7.04 – 6.98 
(m, 2H), 6.86 (t, J = 7.5 Hz, 1H), 5.83 (br, 1H), 2.84 (d, J = 15.2 Hz, 1H), 2.68 (d, J = 
15.2 Hz, 1H); 13C NMR (125 MHz, CDCl3): δ = 179.09, 168.43, 140.23, 137.29, 
129.98, 129.94, 128.86, 124.62, 124.19, 123.21, 120.50, 110.99, 74.81, 43.26; MS 
(ESI) m/z: 305 ([M + Na]+); HRMS (ESI): Exact mass calculated for C16H14N2O3 [M 
+ Na]+ 305.0902, found 305.0903. 
 
3-hydroxy-3-(2-oxo-2-phenylethyl)indolin-2-one (5-3y). White solid, 3h, 86% yield; 
mp 174 – 176 oC; 1H NMR (500 MHz, DMSO-d6): δ = 10.28 (s, 1H), 7.92 – 7.86 (m, 
2H), 7.61 (d, J = 7.3 Hz, 1H), 7.49 (t, J = 7.7 Hz, 2H), 7.28 (d, J = 7.3 Hz, 1H), 7.16 
(t, J = 7.6 Hz, 1H), 6.91 – 6.76 (m, 2H), 6.08 (s, 1H), 4.07 (d, J = 17.6 Hz, 1H), 3.59 
(d, J = 17.6 Hz, 1H); 13C NMR (125 MHz, DMSO-d6): δ = 196.51, 178.38, 142.98, 
136.15, 133.45, 131.78, 128.95, 128.75, 127.92, 123.61, 121.16, 109.44, 73.02, 45.77; 
MS (ESI) m/z: 290 ([M + Na]+); HRMS (ESI): Exact mass calculated for C16H13NO3 
[M + Na]+ 290.0793, found 290.0797. 





3-hydroxy-3-(4-nitrobenzyl)indolin-2-one (3z). White solid, 3h, 95% yield; mp 226 
– 228 oC; 1H NMR (500 MHz, DMSO-d6): δ = 10.15 (s, 1H), 8.00 (d, J = 8.5 Hz, 2H), 
7.22 (d, J = 8.5 Hz, 2H), 7.13 (t, J = 7.6 Hz, 1H), 7.05 (d, J = 7.3 Hz, 1H), 6.91 (t, J = 
7.5 Hz, 1H), 6.65 (d, J = 7.7 Hz, 1H), 6.27 (s, 1H), 3.30 (d, J = 12.6 Hz, 1H), 3.11 (d, 
J = 12.7 Hz, 1H); 13C NMR (125 MHz, DMSO-d6): δ = 178.35, 146.23, 143.56, 
141.42, 131.46, 130.42, 129.10, 124.55, 122.47, 121.37, 109.47, 76.13, 42.98; MS 
(ESI) m/z: 283 ([M – H]-); HRMS (ESI): Exact mass calculated for C15H12N2O4 [M – 
H]- 283.0719, found 283.0719. 
 
5.4.4 Methodology Application: Synthesis of Natural Products 
Synthesis of (±) Convolutamydine A 
 
To a solution of 4,6-dibromoisatin 5-1o (30.5 mg, 0.10 mmol) in 0.5 mL DMF 
was added acetoacetic acid (11.2 mg, 0.11 mmol) at room temperature, followed by 
adding catalyst 5-I TEA (2.8 µl, 0.02 mmol). The mixture was stirred at 70 oC for 3 
hours. The crude product was purified by column chromatography on silica gel, eluted 
by hexane/EtOAc = 2:1 to afford 32.1 mg (88% yield) of the desired product (±) 
Convolutamydine A 5-5 as white solid. mp 212 – 214 oC; 1H NMR (500 MHz, 
DMSO-d6): δ = 10.60 (s, 1H), 7.27 (d, J = 1.6 Hz, 1H), 6.95 (d, J = 1.6 Hz, 1H), 6.20 




(s, 1H), 3.73 (d, J = 17.6 Hz, 1H), 3.16 (d, J = 17.6 Hz, 1H), 2.03 (s, 3H); 13C NMR 
(125 MHz, DMSO-d6): δ = 205.16, 177.23, 146.35, 128.70, 126.69, 122.32, 118.93, 
111.77, 73.68, 48.27, 29.93; MS (ESI) m/z: 384 ([M + Na]+); HRMS (ESI): Exact 
mass calculated for C11H9Br2NO3 [M + Na]+ 383.8847, found 383.8838. 
 
Synthesis of (±) Convolutamydine E 
 
To a solution of 4,6-dibromoisatin 5-1o (100.6 mg, 0.33 mmol) in 1.65 mL DMF 
was added malonic acid half thioester 5-2w (71.2 mg, 0.36 mmol) at room 
temperature, followed by adding catalyst 5-I TEA (9.2 µl, 0.066 mmol). The mixture 
was stirred at 70 °C for 3 hours. The crude product was purified by column 
chromatography on silica gel, eluted by hexane/EtOAc = 2:1 to afford 130.7 mg (85% 
yield) of the desired product 5-7 as white solid. mp 226 – 228 oC; 1H NMR (300 MHz, 
Acetone-d6): δ = 9.69 (s, 1H), 7.42 – 7.36 (m, 3H), 7.34 (d, J = 1.6 Hz, 1H), 7.29 – 
7.23 (m, 2H), 7.07 (d, J = 1.6 Hz, 1H), 5.54 (s, 1H), 4.06 (d, J = 15.8 Hz, 1H), 3.49 (d, 
J = 15.8 Hz, 1H); 13C NMR (75 MHz, Acetone-d6): δ = 194.00, 177.73, 147.54, 
135.89, 131.06, 130.73, 129.18, 128.92, 128.71, 124.82, 121.49, 113.92, 76.17, 49.62; 
MS (ESI) m/z: 454 ([M – H]-); HRMS (ESI): Exact mass calculated for 
C16H11Br2NO3S [M – H]- 453.8748, found 453.8749. 
 
To a solution of 5-7 (45.7 mg, 0.1 mmol) in THF (0.5 ml) was added NaBH4 




(18.9 mg, 0.5 mmol) at 0 ℃. The reaction mixture was stirred for additional 30 min 
at RT, before it was quenched with aqueous HCl solution. The mixture was extracted 
with ethyl acetate. The combined organic phase was dried over Na2SO4 and 
concentrated under reduced pressure. The crude product was purified by column 
chromatography (50% ethyl acetate in hexane) on silica gel to afford 28.3 mg (81% 
yield) (±) Convolutamydine E 5-8 as white solid. mp 211 – 213 oC; 1H NMR (500 
MHz, Acetone-d6) δ = 9.54 (s, 1H), 7.32 (d, J = 1.6 Hz, 1H), 7.06 (d, J = 1.6 Hz, 1H), 
5.22 (s, 1H), 3.67 (s, 1H), 3.51 – 3.49 (m, 2H), 2.45 (t, J = 6.7 Hz, 2H); 13C NMR (75 
MHz, Acetone-d6) δ = 179.53, 146.96, 130.31, 129.24, 124.18, 121.51, 113.77, 77.98, 
58.80, 39.10; MS (ESI) m/z: 348 ([M – H]-); HRMS (ESI): Exact mass calculated for 
C10H9Br2NO3 [M – H]- 347.8871, found 347.8868. 
 








( ) Convolutamydine E, 5-8
TsCl (10 equiv)







( ) Convolutamydine B, 5-9
Chem. Eur. J. 2009, 15, 6790  
 
Synthesis of Donaxaridine170 
 
To a solution of 5-3w (59.5 mg, 0.2 mmol) in THF (1.0 mL) was added NaBH4 
(37.8 mg, 1.0 mmol) at 0 ℃. The reaction mixture was stirred for additional 30 min 
at RT, before it was quenched with aqueous HCl solution. The mixture was extracted 




with ethyl acetate. The combined organic phase was dried over Na2SO4 and 
concentrated under reduced pressure. The crude product was purified by column 
chromatography (60% ethyl acetate in hexane) on silica gel to afford 25.2 mg of 5-10 
(65% yield) as white solid. mp 146 – 148 oC; 1H NMR (500 MHz, Acetone-d6): δ = 
9.16 (s, 1H), 7.24 (d, J = 7.4 Hz, 1H), 7.11 (td, J = 7.7, 1.2 Hz, 1H), 6.90 (td, J = 7.5, 
0.9 Hz, 1H), 6.77 (d, J = 7.7 Hz, 1H), 5.00 (s, 1H), 3.68 (s, 1H), 3.58 (s, 2H), 2.00 – 
1.89 (m, 2H); 13C NMR (125 MHz, Acetone-d6): δ = 180.73, 143.07, 133.67, 130.60, 
125.61, 123.46, 111.22, 76.76, 58.94, 41.79; MS (ESI) m/z: 192 ([M – H]-); HRMS 








A solution of 5-3a (0.752 g, 4.0 mmol) in CH3CN/DMF (2:1, 30.0 mL) was 




cooled to 0 °C and Cs2CO3 (4.56 g, 14.0 mmol) was added followed by Me2SO4 (1.33 
ml, 14.0 mmol). The reaction was stirred for 1.5 h at 0 °C (monitored by TLC) before 
filtering over celite (washings by EtOAc). The crude product was purified by column 
chromatography  (40% ethyl acetate in hexane) to provide 5-12 as a yellow oil (617 
mg, 71%). 1H NMR (500 MHz, CDCl3): δ = 7.59 (d, J = 7.5 Hz, 1H), 7.44 (td, J = 7.8, 
1.2 Hz, 1H), 7.23 – 7.18 (m, 1H), 6.92 (d, J = 7.9 Hz, 1H), 3.25 (s, 3H), 3.10 – 3.04 
(m, 4H), 2.67 (d, J = 16.5 Hz, 1H); 13C NMR (125 MHz, CDCl3): δ = 173.14, 143.75, 
131.20, 124.81, 124.11, 123.78, 115.30, 108.96, 78.17, 53.39, 26.64, 26.42; MS (ESI) 
m/z: 239 ([M + Na]+); HRMS (ESI): Exact mass calculated for C12H12N2O2 [M + Na]+ 
239.0796, found 239.0796. 
A solution of 5-12 (0.216 g, 1.0 mmol), (Boc)2O (0.436 g, 2.0 mmol), and NiCl2 
(25 mg, 0.2 mmol) in MeOH (25 mL) was cooled to 0 °C and NaBH4 (257 mg, 7.0 
mmol) was added in portions. The reaction was stirred for 4 hours at room 
temperature and then quenched with water and filtered over celite (washings with 
EtOAc). The crude product was purified by column chromatography (40% ethyl 
acetate in hexanes) to provide 5-13 as a white solid (245 mg, 77%). mp 100 – 102 oC; 
1H NMR (500 MHz, CDCl3): δ = 7.35 (t, J = 7.7 Hz, 1H), 7.31 (d, J = 7.3 Hz, 1H), 
7.12 (t, J = 7.5 Hz, 1H), 6.85 (d, J = 7.8 Hz, 1H), 4.91 (s, 1H), 3.25 (m, 2H), 3.21 (s, 
3H), 3.00 (s, 3H), 2.07 (t, J = 6.8 Hz, 2H), 1.41 (s, 9H); 13C NMR (125 MHz, CDCl3) 
δ = 175.80, 155.76, 143.69, 130.00, 126.80, 124.37, 123.17, 108.50, 81.87, 79.00, 
52.92, 37.33, 35.45, 28.40, 26.13;  MS (ESI) m/z: 343 ([M + Na]+); HRMS (ESI): 
Exact mass calculated for C17H24N2O4 [M + Na]+ 343.1634, found 343.1615. 
A solution of 5-13 (32.0 mg, 0.1 mmol) was cooled to 0 °C and Red-Al® (289 uL, 
70 w% in toluene, 1.0 mmol) was added. The reaction was stirred at room 
temperature for 30 minutes and then heated at 80 °C overnight. Reaction was then 
cooled, quenched with water, and the suspension obtained was filtered through celite 
(washings with EtOAc). The crude product obtained was purified by column 
chromatography to provide 5-14 as a colorless oil (11.2 mg, 51%). 1H NMR (500 




MHz, CDCl3): δ = 7.20 (t, J = 7.7 Hz, 1H), 7.15 (d, J = 7.3 Hz, 1H), 6.75 (t, J = 7.3 
Hz, 1H), 6.51 (d, J = 8.0 Hz, 1H), 4.36 (s, 1H), 3.04 (s, 3H), 2.97 (s, 3H), 2.82 – 2.78 
(m, 1H), 2.64 – 2.59 (m, 1H), 2.58 (s, 3H), 2.38 – 2.32 (m, 1H), 2.16 – 2.11 (m, 1H); 
13C NMR (125 MHz, CDCl3): δ = 153.15, 129.74, 128.04, 124.08, 117.92, 107.80, 
94.06, 91.73, 52.49, 52.43, 39.37, 38.67, 36.27; MS (ESI) m/z: 219 ([M + H]+); 



































































































































The assembly of O-heterocycles is an important field of research due to their 
prevalence in natural products and drugs.171 Of the O-heterocycles, δ-lactones are 
well-known six-membered oxygen-containing heterocycles that form the structural 
scaffolds of many biologically active molecules,172 hence, they are broadly used in 
medicinal chemistry as important structural elements. Notably, a large number of 
δ-lactones involved biologically active important molecules exist as a single 
enantiomer.172,173 As exemplified in Figure 6.1, Lovastatin174 6-a marketed by Merck 
under the trade name Mevacor, is a member of the drug class of statins, used in the 
treatment of dyslipidemia and the prevention of cardiovascular disease. 
Artemisitene175 6-b, isolated from Artemisia annua L., has been shown to possess 
antimalarial activity. Crassin acetate176 6-c, a lactonic cembrane diterpene, has been 
shown to be the principal antineoplastic agent present in the marine invertebrates. 
Leiodermatolide 177  6-d is a structurally unique macrolide isolated from the 
deep-water marine sponge Leiodermatium sp. which exhibits potent antiproliferative 
activity against a range of human cancer cell lines and drastic effects on spindle 
formation in mitotic cells. 
                                                              
171  For selected books, see: a) Collett, L. A.; Davis-Coleman, M. T.; Rivett, D. E. A. In Progress in the Chemistry 
of Organic Natural Products, Springer-Verlag, New York, 1998; b) Francke, W.; Schultz, S. Comprehensive 
Natural Products Chemistry, Elsevier, Amsterdam, 1999; c) see Ref. 110b; d) Dewick, P. M. Medicinal Natural 
Products, Wiley-VCH, Weinheim, 2009.  
172 For reviews, see: a) Collins, I. J. Chem. Soc. Perkin Trans. 1 1999, 1377; b) Mondon, M.; Gesson, J. P. Curr. 
Org. Synth. 2006, 3, 41; c) Boucard, V.; Broustal, G.; Campagne, J. M. Eur. J. Org. Chem. 2007, 225; d) Florence, 
G. J.; Gardner, N. M.; Paterson, I. Nat. Prod. Rep. 2008, 25, 342; e) Chiu, P.; Leung, L. T.; Ko, C. B. B. Nat. Prod. 
Rep. 2010, 27, 1066.  
173 For selected recent reports, see: a) Connolly, J. D.; Hill, R. A. Dictionary of Terpenoids, Vol. 1, Chapman and 
Hall, London, 1991; b) Istvan, E. S.; Deisenhofer, J. Science, 2001, 292, 1160; c) Shaw, S. J.; Sundermann, K. F.; 
Burlingame, M. A.; Myles, D. C.; Freeze, B. S.; Xian, M.; Brouard, I.; Smith, A. B., III J. Am. Chem. Soc. 2005, 
127, 6532; d) You, Z. W.; Jiang, Z. X.; Wang, B. L.; Qing, F. L. J. Org. Chem. 2006, 71, 7261; e) Bonazzi, S.; 
Güttinger, S.; Zemp, I.; Kutay, U.; Gardemann, K. Angew. Chem. Int. Ed. 2007, 46, 8707; f) Giaralli, L.; Bassetti, 
M.; Pasquini, C. J. Org. Chem. 2007, 72, 6067; g) Esteban, J.; Costa, A. M.; Gómez, A.; Vilarrasa, J. Org. Lett. 
2008, 10, 65; h) Fukui, H.; Shiina, I. Org. Lett. 2008, 10, 3153; i) Prasad, K. R.; Gholap, S. L. J. Org. Chem. 2008, 
73, 2; j) Maauer, T.; Martin, H. J.; Mulzer, J. Angew. Chem. Int. Ed. 2009, 48, 6032; k) Exner, C. J.; Laclef, S.; Poli, 
F.; Turks, M.; Vogel, P. J. Org. Chem. 2011, 76, 8707.  
174 Gunde-Cimerman, N.; Cimerman, A. Exp Mycol. 1995, 19, 1. 
175  a) Ekthawathchai, S.; Kamchonwongpaisan, S.; Kongsaeree, P.; Tarnchompoo, B.; Thebtaranonth, Y.; 
Yuthavong, Y. J. Med. Chem. 2001, 44, 4688; b) Avery, M. A.; Alvim-Gaston, M.; Vroman, J. A.; Wu, B.; Ager, A.; 
Peters, W.; Robinson, B. L.; Charman, W. J. Med. Chem. 2002, 45, 4321. 
176  a) Weinheimer, A. J.; Chang, C. W. J.; Matson, J. A. Fortschr. Chem. Org. Naturst. 1979, 36, 285; b) McMurry, 
J. E.; Dushin, R. G. J. Am. Chem. Soc. 1990, 112, 6942. 
177 Paterson, I.; Dalby, S. M.; Roberts, J. C.; Naylor, G. J.; Guzmán, E. A.; Isbrucker, R.; Pitts, T. P.; Linley, P.; 
Divlianska, D.; Reed, J. K.; Wright, A. E. Angew. Chem. Int. Ed. 2011, 50, 3219. 







Figure 6.1 Examples of natural products or drugs containing δ-lactone moiety. 
Especially, pharmaceuticals are figuring large in human health due to their 
chirality. Most beneficial drugs are sold as a single enantiomeric form because of the 
higher efficiency than its mirror image enantiomer and displaying better fit to its 
receptor. In addition, the other enantiomer may even cause harmful results.178 Given 
the fact that within a chiral surrounding two enantiomers often show distinct 
biological activity, the development of effective protocols to access optical pure 
δ-lactones would be extremely desirable for further studies of the correlation between 
the chirality of these compounds and their propensities for biological activities to seek 
more potent and/or appropriate pharmaceutical candidates. Building enantiopure 
complex molecules simply, in a minimum number of operations, and in 
environmentally benign approach is one of the greatest challenges for synthetic 
chemistry, and particularly, for the industrial application of an laboratory-scale 
                                                              
178  a) O'Reilly, R. A. N. Engl. J. Med. 1976, 295, 354; b) Wingard, L. B.; O'Reilly, R. A.; Levy, G. Clic. 
Pharmacol. Ther. 1978, 23, 212; c) Rang, H. P.; Dale, M. M.; Ritter, J. M.; Gardner, P. Pharmacology, 4th ed. 
Churchill Livingston. Philadephia. 2001. 




reaction (functional group/H2O tolerance, simple procedures, no extreme 
temperatures),179 cascade organocatalysis has recently appeared as a method of choice 
to fulfil this ideal goal of reaction efficiency.179 In our continuing efforts toward the 
development of new approaches for the stereoselective construction of enantiopure 
synthetically useful building blocks,180 we thought about expanding the scope of 
organocatalytic decarboxylative reactions 181 , 182  to α,β-unsaturated aldehydes 183 . 
Although many methods have been reported on chiral δ-lactone synthesis, most of 
them were prepared for the assembly of α,β- or γ,δ-unsaturated δ-lactones.184,185 
Herein, we disclose a direct and efficient enantioselective strategy for functionalized 
and saturated δ-lactone synthesis (Scheme 6.1). 
 
                                                              
179  For recent reviews and selected examples on organocatalysis, see: a) List, B.; Yang, J.-W. Science 2006, 313, 
1584; b) see Ref. 2e; c) see Ref. 2d (special issue on organocatalysis); d) MacMillan, D. W. C. Nature 2008, 455, 
304; e) Melchiorre, P.; Marigo, M.; Carlone, A.; Bartoli, G. Angew. Chem. Int. Ed. 2008, 47, 6138; f) see Ref. 2h; g) 
see Ref. 2j; h) Moyano, A.; Rios, R. Chem. Rev. 2011, 111, 4703; i) Vaxelaire, C.; Winter, P.; Christmann, M. 
Angew. Chem. Int. Ed. 2011, 50, 3605; j) see Ref. 2k; k) Jensen, K. L.; Dickmeiss, G.; Jiang, H.; Albrecht, Ł.; 
Jørgensen, K. A. Acc. Chem. Res. 2012, 45, 248; For an interesting recent highlight on the necessary factors for the 
application of an academic reaction to industry, see: l) Cooper, T. W. J.; Campbell, I. B.; MacDonald, S. J. F. 
Angew. Chem. Int. Ed. 2010, 49, 8082.  
180  a) see Ref. 140a; b) see Ref. 140b; c) see Ref. 125; d) Ren, Q.; Siau, W.-Y.; Du, Z.; Zhang, K.; Wang, J. Chem. 
–Eur. J. 2011, 17, 7781; e) see Ref. 40; f) see Ref. 140c; g) Tan, H. R.; Ng, H. F.; Chang, J.; Wang, J. Chem. –Eur. J. 
2012, 18, 3865; h) Siau, W.-Y.; Li, W.-J.; Xue, F.; Ren, Q.; Wu, M.-H.; Sun, S.-F.; Guo, H.-B.; Jiang, X.-F.; Wang, 
J. Chem. –Eur. J. 2012, 18, 9491; i) Li, W.-J.; Liu, H.; Jiang, X. F.; Wang, J. ACS Catal. 2012, 2, 1535. 
181  For examples of decarboxylative reactions, see: a) see Ref. 87; b) see Ref. 88a; c) see Ref. 89; d) see Ref. 88b; e) 
see Ref. 88c. 
182  For selected examples of enantioselective decarboxylative reactions, see: a) see Ref. 90; b) see Ref. 96d; c) see 
Ref. 91; d) see Ref. 92; e) see Ref. 97a; f) see Ref. 98a; g) see Ref. 97b; h) Zheng, Y.; Xiong, H.; Nie, J.; Hua, M.; 
Ma, J. Chem. Commun. 2012, 48, 4308; i) Hara, N.; Nakamura, S.; Sano, M.; Tamura, R.; Funahashi, Y.; Shibata, 
N. Chem. –Eur. J. 2012, 18, 9276; j) see Ref. 98c;. k) Yuan, H. A.; Wang, S.; Nie, J.; Meng, W.; Yao, Q. W.; Ma, J. 
A. Angew. Chem. Int. Ed. 2013, 52, 3869.  
183  To the best of our knowledge, there is no enantioselective decarboxylative reaction of α,β-unsaturated 
carbonyls and half-thioesters catalyzed by second amine. 
184  For selected examples of α,β- or γ,δ-unsaturated δ-lactone synthesis, see: a) Du, H.; Zhao, D.; Ding, K. Chem. 
–Eur. J. 2004, 10, 5964; b) Oisaki, K.; Zhao, D.; Kanai, M.; Shibasaki, M. J. Am. Chem. Soc. 2007, 129, 7439; c) 
Tiseni, P. S.; Peters, R. Angew. Chem. Int. Ed. 2007, 46, 5325; d) Tozawa, T.; Nagao, H.; Yamane, Y.; Mukaiyama, 
T. Chem. Asian. J. 2007, 2, 123; e) Tiseni, P. S.; Peters, R. Org. Lett. 2008, 10, 2019; f) Lin, L.; Chen, Z.; Yang, X.; 
Liu, X.; Feng, X. Org. Lett. 2008, 10, 1311; g) Ryan, S. J.; Candish, L.; Lupton, D. W. J. Am. Chem. Soc. 2009, 
131, 14176; h) You, G. Q; Dai, L.-X.; You, S.-L. Org. Lett. 2009, 11, 1623; i) Tiseni, P. S.; Peters, R. Chem. –Eur. J. 
2010, 16, 2503; j) Belmessieri, D.; Morrill, L. C.; Simal, C.; Slawin, A. M. Z.; Smith, A. D. J. Am. Chem. Soc. 
2011, 133, 2714; k) Lin, L.; Kuang, Y. L.; Liu, X. H.; Feng, X. M. Org. Lett. 2011, 15, 3868; l) Mo, J. M.; Chen, X. 
K.; Chi, Y. G. J. Am. Chem. Soc. 2012, 134, 8810; m) Mahatthananchai, J.; Kaeobamrung, J.; Bode, J. W. ACS 
Catal. 2012, 2, 494. 
185  For examples of enantioselective synthesis of saturated δ-lactones, see: a) Brandau, S.; Landa, A.; Franzén, J.; 
Marigo, M.; Jøgensen, K. A. Angew. Chem. 2006, 118, 4411; Angew. Chem., Int. Ed. 2006, 45, 4305; b) Moran, J.; 
Smith, A. G.; Carris, R. M.; Johnson, J. S.; Krische, M. J. J. Am. Chem. Soc. 2011, 131, 18618; c) Peed, J.; 
Domínguez, I. P.; Davis, I. R.; Cheeseman, M.; Taylor, J. E.; Kociok-Köhn, G.; Bull, S. D. Org. Lett. 2011, 13, 
3592; d) Albrecht, A.; Morana, F.; Fraile, A.; Jøgensen, K. A. Chem. –Eur. J. 2012, 18, 10348; e) Murai, K.; 
Nakamura, A.; Matsushita, T.; Shimura, M.; Fujioka, H. Chem. –Eur. J. 2012, 18, 8448; f) Jiang, X. J.; Tan, C. K.; 
Zhou, L.; Yeung, Y. Y. Angew. Chem. Int. Ed. 2012, 51, 7771; g) Dobish, M. C.; Johnston, J. N. J. Am. Chem. Soc. 
2012, 134, 6068.  






Scheme 6.1 Efficient synthesis of chiral δ-lactones. 
 
6.2 Results and Discussion 
6.2.1 Reaction Optimization for Decarboxylation of MAHTs and Enals 
During our initial studies on the use of malonic acid mono-protected esters 
(6-2a–c, Scheme 6.2) in amino-catalyzed intermolecular reactions with 
cinnamaldehyde 6-1a we have observed no reaction for malonic monoesters (6-2a–b). 
However, in the context of exploring an efficient and enantioselective catalytic 
process we observed that when a malonic half-thioester (6-2c) and a TMS-protected 
prolinol catalyst 6-II (Table 6.1) were employed for the combination of 
cinnamaldehyde (6-1a) and malonic half-thioester (6-2c), the product δ-lactone (6-3ac) 
was obtained (72% ee, 59% yield). Further screening of catalysts revealed that 
increasing the bulk of the silyl ether moiety of catalysts (Cat. 6-I-VI) led to improved 
enantiocontrol of the reaction. As shown in Table 6.1, tert-butyldimethylsilane ether 









Scheme 6.2 Initial experiments.a 
 
a Reaction conditions: 6-1a (0.20 mmol), 6-2 (0.24 mmol), TEA (0.20 mmol), DCM (1.0 mL), 72 
h, room temperature. 
 
Table 6.1 Screened catalysts.a 
 
a Reaction condition: 6-1a (0.20 mmol), 6-2c (0.24 mmol), TEA (1.0 equiv.), Cat. 6-I-VI (20 
mol%), DCM (1.0 mL), 72 h, room temperature. 
 
 




Table 6.2 Optimization of other reaction parameters.a 
 
 
Entry Additive Solvent 6-3ac [%]b 6-3ac ee [%]c 
1 TEA DCM 51 89 
2 Na2CO3 DCM 22(6-4ac) 18 
3 TBDg DCM 37 78 
4 TEA Toluene 53 81 
5 TEA THF 47 84 
6 TEA IPAf 47 89 
7d TEA DCM 57 89 
8d,e TEA DCM 82 92 
a Reactions were performed with 6-1a (0.20 mmol), 6-2c (0.24 mmol), additive (0.20 mmol) in the 
solvent (1.0 mL). b Isolated yield. c Determined by chiral HPLC analysis. d 6-2c (0.50 mmol), TEA 
(0.50 mmol). e TEA dissolved in 0.50 mL of DCM was added dropwise in 10 min, 0 oC. f 
Isopropanol. g 1,5,7-Triazabicyclo[4.4.0]dec-5-ene. 
Subsequent solvent survey (Table 6.2, entries 1 and 4–6) indicated that the use of 
DCM resulted in pronounced increase in enantioselectivity (81–89% ee). Further 
screening other additives applied (e.g. bases) did not lead to an improvement of the 
results (Table 6.2, entries 2–3). It was noteworthy that Na2CO3 caused the major 
formation of acyclic 3-phenyl 1-aldehyde 5-thioester 6-4ac. Occasionally, we 
disclosed that dropwise addition of additive TEA in a limited amount of solvent can 
further improve the enantiocontrol and chemical yield (92% ee, 82% yield). 
Controlled experiment indicated that one-pot addition of TEA caused a rapid 
decomposition of malonic half-thioester 6-2c. 
 
 




6.2.2 Reaction Scope for Decarboxylation of MAHTs and Enals 
After having optimized the conditions for the cascade reaction, the scope of the 
methodology was evaluated. Initially, various α,β-unsaturated aldehydes 6-1 with 
different substitution patterns and electronic properties were examined (Table 6.3). 
The substitution patterns of malonic half-thioesters had limited impact on the yields or 
enantioselectivities, thereby providing the only regioisomer with ee values ranging 
from 91 to 94% (Table 6.3, 6-3ac–ah, all dr > 20:1). Pleasingly, α,β-unsaturated 
aldehydes 6-1a–h bearing different electron-withdrawing and electron-donating 
substituents on the aromic ring were easily reacted under the established reaction 
conditions (6-3ac–hc). In most of the cases, good yields and high steroselectivities 
were obtained. Additionally, α,β-unsaturated aldehydes 6-1i–k bearing heterocyclic 
rings and alkyl groups could be utilized as well in good yields with rigorous 
stereoselectivities (6-3ic–kc). 186  Additionally, α,β,γ,δ-unsaturated aldehyde 6-1l 
could react with 6-2c to afford 3-alkenyl δ-lactone 3lc in 74% yield and with 80% ee 
(Eq. [3]). 
 





186  CCDC 856259 (6-3ac) contains the supplementary crystallographic data for this paper. These data can be 
obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/ 
data_request/cif. 







a Reaction conditions: 6-1a-k (0.20 mmol), 6-2c-h (0.50 mmol), TEA (0.50 mmol) and catalyst 
6-VI (0.04 mmol), DCM (1.0 mL), 0 oC for 24 h. b Isolated yield. c Determined by chiral HPLC 




6.2.3 Reaction Scope for Decarboxylation of MAHTs and Enones 
With the successful implementation of highly enantioselective annulations of 
α,β-unsaturated aldehydes and malonic half-thioesters, we moved our focus to the use 
of a different type of α,β-unsaturated carbonyls. α,β-unsaturated ketones are a class of 
α,β-unsaturated substrates prepared from simple condensation of aldehydes and 
ketones. Taking into account their similar properties relative to the parent 
α,β-unsaturated aldehydes, we envisaged that their use as electrophiles in the 
enantioselective annulation developed herein would provide a logical and 




distinguished way to give the corresponding products. Unfortunately, no reaction was 
found in the presence of previous standard condition, which was used in the 
annulations of α,β-unsaturated aldehydes and malonic half-thioesters. This result 
showed that secondary amine catalyst (6-VI) was not suitable for the reaction of 
α,β-unsaturated ketones. A further catalyst screening indicated that catalyst 6-VII (a 
cinchona alkaloid structure based primary amine) proved to be an efficient catalyst 
and gave 3-substituted 1,5-dicarbonyls instead. α,β-Unsaturated ketones bearing a 
variety of substituent patterns and electron-withdrawing and electron-donating groups 
were all tolerated, giving the corresponding acyclic 1,5-dicarbonyls in moderate to 
high yields (Table 6.4, 62–87%) and good to excellent stereocontrol (80–98% ee).187 
Notably, the 3-substituted 1,5-dicarbonyl is also a potential precursor of chiral 
δ-lactone.  
Table 6.4 Substrate scope of α,β-unsaturated ketones.a-c 
 
                                                              
187  CCDC 903996 (6-6lc) contains the supplementary crystallographic data for this paper. These data can be 
obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/ 
data_request/cif. 






a Reaction conditions: 6-5a-l (0.20 mmol), 6-2c-h (0.50 mmol), catalyst 6-VII (0.04 mmol), THF 
(1.0 mL), 24 h, room temperature. b Isolated yield. c Determined by chiral HPLC analysis. 
 
6.2.4 Mechanistic Investigations 
We speculate that the mechanism of this cascade reaction may involve the 
following sequence (Scheme 6.3). Initially, malonic half-thioester 6-2c reacts with 
triethyl amine to form the intermediate 6-8 followed by nucleophilic attack on the 
iminium intermediate 6-7. A subsequent decarboxylation triggers the formation of the 
Michael addition intermediate 6-9. Hydrolysis of intermediate 6-9 would lead to a 
recycle of cat.6-VI and generates the intermediate 6-10. The intermediate 6-10 
undergoes a sequence of tautomerization, cyclization and nucleophilic addition to 
afford the product 6-3ac. As proof of this mechanism, we set out to investigate the 
key intermediate. For example, the potential intermediate 6-4ac was synthesized and 
applied to synthesize the product 6-3ac in the absence of cat. 6-VI (Eq. [4]). The 
result exhibited that the lactone cyclization step could be promoted by a weak base or 
even in a base-free condition (spontaneous reaction) and did not loss any ee value. We 
suspect that the formation of 6-9 may be the rate-determining step. To deeply 
understand the proton transfer in this transformation, we conducted an isotopic 
experiment using deuterated half-thioester d-6-2c to react with cinnamaldehyde 6-1a 
under standard conditions. 1H NMR analysis of d-6-3ac demonstrated the isotope 
labelling of two protons located at α-position of carbonyl group is ab. 49:51 (Eq. 




[5]). 188  This suggests that the water (generated from the condensation of 
cinnamaldehyde 6-1a and cat. 6-VI), functionalized as a potential proton source, is 
not involved in the Michael addition step. 
 
Scheme 6.3 Postulated mechanism. 
 
 
6.2.5. Methodology Application 
The thiophenyl moiety in lactone 6-3ac is a synthetically versatile functional 
group that can be readily converted into several valuable functionalities. Oxidation of 
6-3ac with m-CPBA and a subsequent elimination gave 3,4-dihydro δ-lactone 6-13 
without racemization (Scheme 6.4, 56% yield). Removal of thiophenyl group 
                                                              
188  See the details of isotope experiments in Experimental Section. 




(replaced by H) was achieved using Raney Ni and NaBH4. Performing the reduction 
in MeOH and the subsequent cyclization in the presence of TFA at room temperature 
afforded 6-14 in 62% yield. 
Scheme 6.4 Synthetic modification of the thiophenyl group 
 
Further application study was embarked on examining the applicability of our 
method to the concise synthesis of (-)-Paroxetine, marketed as Paxil/Seroxat (Scheme 
6.5). The reaction of 6-1m with 6-2c catalyzed by 6-VI and TEA gave the 
corresponding 6-3mc in 72% yield and 91% ee (Scheme 6.5). Next, Lewis acid 
Ni-catalyzed ring opening reaction gave the corresponding 3-substituted 
1,5-dicarbonyl 6-15, and subsequent reduction of 6-15 afforded the key intermediate 
6-16. According to reported procedure,189 the intermediate 6-16 can be converted to 
target (-)-Paroxetine, an antidepressant drug. 
Scheme 6.5 Formal total synthesis of (-)-Paroxetine (Paxil/Seroxat). 
 
                                                              
189  Yu, M. S.; Lantos, I.; Peng, Z. Q.; Yu, J.; Cacchio, T. Tetrahedron Lett. 2000, 41, 5647. 





In summary, we have established a new method for the direct enantioselective 
synthesis of α,β-unsaturated carbonyls and malonic half-thioesters using chiral 
prolinol derivatives or cinchona alkaloid amines as organocatalysts. Our methodology 
provided a straightforward way to generate valuable chiral δ-lactone scaffold, which 
may have ubiquitous biological significance in the field of medicinal chemistry, in 
high yields and high to excellent enantioselectivities. The ready accessibility of the 
starting materials makes the current methodology particularly attractive in organic 
synthesis. The synthetic utility of this strategy was demonstrated by the versatile ready 
modifications of the thiophenyl group and the applicability of this method to the 
concise synthesis of (-)-Paroxetine, marketed as Paxil/Seroxat. Studies towards 
further expanding the synthetic utility of this strategy are currently underway. 
 
6.4 Experimental Section 
6.4.1 General Information 
Chemicals and solvents were purchased from commercial suppliers and used as 
received. 1H and 13C NMR spectra were recorded on a Bruker ACF300 (300 MHz) or 
AMX500 (500 MHz) spectrometer. Chemical shifts were reported in parts per million 
(ppm), and the residual solvent peak was used as an internal reference: proton 
(chloroform δ 7.26), carbon (chloroform δ 77.0) or tetramethylsilane (TMS δ 0.00) 
was used as a reference. Multiplicity was indicated as follows: s (singlet), d (doublet), 
t (triplet), q (quartet), m (multiplet), dd (doublet of doublet), bs (broad singlet). 
Coupling constants were reported in Hertz (Hz). Low resolution mass spectra were 
obtained on a Finnigan/MAT LCQ spectrometer in ESI mode, and a Finnigan/MAT 
95XL-T mass spectrometer in EI mode. All high resolution mass spectra were 
obtained on a Finnigan/MAT 95XL-T spectrometer. For thin layer chromatography 
(TLC), Merck pre-coated TLC plates (Merck 60 F254) were used, and compounds 




were visualized with a UV light at 254 nm. Flash chromatography separations were 
performed on Merck 60 (0.040-0.063 mm) mesh silica gel. The enantiomeric excesses 
of products were determined by chiral phase HPLC analysis. Optical rotations were 
recorded on Jasco DIP-1000 polarimeter. 
 
6.4.2 Pepresentative Procedure for Decarboxylation of MAHTs and Enals 
 
 
To a solution of cinnamaldehyde 6-1a (26.4 mg, 25.2 uL, 0.2 mmol,) in DCM 
(0.5 mL) was added catalyst 6-VI (25.6 mg, 0.04 mmol) at 0 °C. After 40 min, 
malonic acid half thioester 6-2c (98.1 mg, 0.5 mmol) was added in one portion. Then, 
TEA (50.5 mg, 69.6 uL, 0.5 mmol) in 0.5 mL DCM was added dropwise via syringe 
in 10 min at 0 °C. The resulting reaction mixture was kept stirring at 0°C for 24 h. 
The crude product was purified by silica gel flash chromatography, eluted by 
hexane/EtOAc = 10:1 to afford the desired product 6-3ac as white solid (46.7 mg, 82% 
yield). 
 
6.4.3 Analytical Data for Decarboxylation of MAHTs and Enals 
 
 
(4S,6S)-4-phenyl-6-(phenylthio)tetrahydro-2H-pyran-2-one (6-3ac) (46.7 mg, 82% 
yield); 1H NMR (500 MHz, CDCl3) δ (ppm): 7.61 – 7.59 (m, 2H), 7.36 (ddd, J = 7.7, 
4.0, 1.7 Hz, 5H), 7.30 – 7.26 (m, 1H), 7.17 – 7.16 (m, 2H), 5.74 (dd, J = 11.3, 4.1 Hz, 




1H), 3.19 (tt, J = 12.3, 4.4 Hz, 1H), 2.88 (ddd, J = 17.7, 5.1, 2.3 Hz, 1H), 2.58 – 2.51 
(m, 2H), 2.04 – 1.97 (m, 1H); 13C NMR (125 MHz, CDCl3) δ (ppm): 169.43, 141.54, 
133.27, 131.78, 129.16, 129.05, 128.59, 127.47, 126.38, 86.32, 37.44, 37.20, 36.30; 
HRMS (EI) calcd for C17H16O2S 284.0871, found 284.0876; HPLC (Chiralpak IC, 
i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 28.2 min, 




(52.9 mg, 83% yield); 1H NMR (500 MHz, CDCl3) δ (ppm): 7.60 – 7.58 (m, 2H), 
7.38 – 7.34 (m, 3H), 7.34 – 7.31 (m, 2H), 7.11 – 7.09 (m, 2H), 5.72 (dd, J = 11.3, 4.1 
Hz, 1H), 3.17 (tt, J = 12.2, 4.5 Hz, 1H), 2.86 (ddd, J = 17.6, 5.1, 2.2 Hz, 1H), 2.56 – 
2.46 (m, 2H), 2.00 – 1.93 (m, 1H); 13C NMR (125 MHz, CDCl3) δ (ppm): 169.10, 
139.97, 133.34, 133.30, 131.57, 129.21, 129.19, 128.70, 127.75, 86.19, 37.10, 36.88, 
36.14; HRMS (EI) calcd for C17H15O2ClS 318.0481, found 318.0486; HPLC 
(Chiralpak IC, i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR 








(4S,6S)-4-(4-nitrophenyl)-6-(phenylthio)tetrahydro-2H-pyran-2-one (6-3cc) (57.3 
mg, 87% yield); 1H NMR (500 MHz, CDCl3) δ (ppm): 8.21 (d, J = 8.7 Hz, 2H), 7.60 
– 7.58 (m, 2H), 7.37 – 7.34 (m, 5H), 5.74 (dd, J = 11.1, 4.1 Hz, 1H), 3.35 (tt, J =12.1, 
4.5 Hz, 1H), 2.90 (ddd, J = 17.5, 5.2, 2.2 Hz, 1H), 2.61 – 2.51 (m, 2H), 2.02 (dt, J = 
13.8, 11.7 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ (ppm): 168.45, 148.66, 147.26, 
133.41, 131.25, 129.24, 128.84, 127.46, 124.32, 85.97, 37.27, 36.61, 35.69; HRMS 
(EI) calcd for C17H15O4NS 329.0722, found 329.0723; HPLC (Chiralpak IA, 
i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 36.5 min, 
tR (minor) = 26.9 min, ee = 95%; [α]25D = -68.8 (c = 0.97 in DCM). 
 
 
(4S,6S)-4-(2-nitrophenyl)-6-(phenylthio)tetrahydro-2H-pyran-2-one (3dc) (52.0 
mg, 79% yield); 1H NMR (500 MHz, CDCl3) δ (ppm): 7.87 (d, J = 8.1 Hz, 1H), 7.64 
(t, J = 7.6 Hz, 1H), 7.59 (dd, J = 6.4, 2.8 Hz, 2H), 7.44 (t, J = 7.7 Hz, 1H), 7.37 – 7.35 
(m, 4H), 5.74 (dd, J = 11.3, 3.8 Hz, 1H), 3.79 (td, J = 11.6, 5.8 Hz, 1H), 2.99 (ddd, J = 
17.5, 5.3, 1.8 Hz, 1H), 2.64 – 2.54 (m, 2H), 2.03 (dd, J = 25.3, 11.7 Hz, 1H); 13C 
NMR (125 MHz, CDCl3) δ (ppm): 168.74, 149.33, 135.98, 133.65, 133.32, 131.40, 
129.20, 128.73, 128.31, 127.36, 124.90, 85.99, 36.49, 35.84, 32.18; HRMS (EI) calcd 
for C17H15O4NS 329.0722, found 329.0734; HPLC (Chiralpak IA, i-propanol/hexane 
= 10/90, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 30.4 min, tR (minor) = 34.1 
min, ee = 96%; [α]25D = -57.2 (c = 1.00 in DCM). 
 






(51.7 mg, 82% yield); 1H NMR (500 MHz, CDCl3) δ (ppm): 7.59 (dd, J = 6.4, 3.2 Hz, 
2H), 7.35 (dd, J = 4.9, 1.9 Hz, 3H), 7.10 – 7.04 (m, 2H), 6.90 – 6.87 (m, 2H), 5.72 (dd, 
J = 11.3, 4.1 Hz, 1H), 3.80 (s, 3H), 3.13 (tt, J = 12.6, 3.8 Hz, 1H), 2.86 (ddd, J = 17.7, 
5.1, 2.3 Hz, 1H), 2.55 – 2.46 (m, 2H), 2.00 – 1.92 (m, 1H); 13C NMR (125 MHz, 
CDCl3) δ (ppm): 169.61, 158.82, 133.62, 133.23, 131.80, 129.15, 128.57, 127.36, 
114.38, 86.36, 55.30, 37.45, 36.66, 36.53; HRMS (EI) calcd for C18H18O3S 314.0977, 
found 314.0987; HPLC (Chiralpak IC, i-propanol/hexane = 20/80, flow rate 1.0 
mL/min, λ = 254 nm): tR (major) = 42.9 min, tR (minor) = 38.0 min, ee = 88%; [α]25D 
= -74.7 (c = 0.91 in DCM). 
 
 
(4S,6S)-6-(phenylthio)-4-p-tolyltetrahydro-2H-pyran-2-one (6-3fc) (48.6 mg, 81% 
yield); 1H NMR (500 MHz, CDCl3) δ (ppm): 7.60 (dd, J = 6.4, 3.1 Hz, 2H), 7.38 – 
7.33 (m, 3H), 7.16 (d, J = 8.0 Hz, 2H), 7.05 (d, J = 8.0 Hz, 2H), 5.73 (dd, J = 11.3, 4.1 
Hz, 1H), 3.15 (tt, J = 12.0, 4.4 Hz, 1H), 2.86 (ddd, J = 17.7, 5.1, 2.3 Hz, 1H), 2.55 – 
2.48 (m, 2H), 2.34 (s, 3H), 2.02 – 1.94 (m, 1H); 13C NMR (125 MHz, CDCl3) δ (ppm): 
169.56, 138.57, 137.16, 133.24, 131.82, 129.67, 129.14, 128.56, 126.23, 86.35, 37.30, 
37.05, 36.42, 20.96; HRMS (EI) calcd for C18H18O2S 298.1028, found 298.1028; 
HPLC (Chiralpak IC, i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): 








(58.3 mg, 93% yield); 1H NMR (500 MHz, CDCl3) δ (ppm): 7.63 – 7.59 (m, 2H), 
7.36 – 7.33 (m, 3H), 7.26 (td, J = 8.0, 1.7 Hz, 1H), 7.06 (dd, J = 7.5, 1.6 Hz, 1H), 6.94 
(td, J = 7.5, 0.9 Hz, 1H), 6.88 (d, J = 8.2 Hz, 1H), 5.74 (dd, J = 11.4, 3.9 Hz, 1H), 
3.81 (s, 3H), 3.53 (tt, J = 12.0, 4.7, 1H), 2.87 (ddd, J = 17.6, 5.4, 2.1 Hz, 1H), 2.57 
(dd, J = 17.6, 11.7 Hz, 1H), 2.49 (dtd, J = 13.8, 3.9, 2.1 Hz, 1H), 2.11 – 2.03 (m, 1H); 
13C NMR (125 MHz, CDCl3) δ (ppm): 170.22, 156.83, 133.11, 132.06, 129.59, 
129.08, 128.41, 128.37, 126.52, 120.83, 110.69, 86.44, 55.15, 35.53, 34.51, 31.94; 
HRMS (EI) calcd for C18H18O3S 314.0977, found 314.0977; HPLC (Chiralpak IC, 
i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 20.6 min, 




acetate (6-3hc) (60.8 mg, 82% yield); 1H NMR (500 MHz, CDCl3) δ (ppm): 7.61 – 
7.58 (m, 2H), 7.37 – 7.34 (m, 3H), 7.02 – 6.99 (m, 1H), 6.73 (dd, J = 6.7, 1.9 Hz, 2H), 
5.72 (dd, J = 11.3, 4.1 Hz, 1H), 3.82 (s, 3H), 3.18 (tt, J = 12.2, 4.4 Hz, 1H), 2.88 (ddd, 




J = 17.6, 5.1, 2.2 Hz, 1H), 2.60 – 2.47 (m, 2H), 2.31 (s, 3H), 2.04 – 1.91 (m, 1H); 13C 
NMR (125 MHz, CDCl3) δ (ppm): 169.30, 169.02, 151.37, 140.42, 138.91, 133.30, 
131.63, 129.16, 128.65, 123.22, 118.33, 110.65, 86.22, 55.87, 37.32, 37.15, 36.30, 
20.60; HRMS (EI) calcd for C20H20O5S 372.1031, found 372.1024; HPLC (Chiralpak 
IA, i-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 36.7 







(4S,6S)-4-(furan-2-yl)-6-(phenylthio)tetrahydro-2H-pyran-2-one (6-3ic) (43.8 mg, 
80% yield); 1H NMR (500 MHz, CDCl3) δ (ppm): 7.59 – 7.58 (m, 2H), 7.35 – 7.33 
(m, 4H), 6.31 (dd, J = 3.2, 1.9 Hz, 1H), 6.06 (d, J = 3.2 Hz, 1H), 5.70 (dd, J = 11.3, 
4.0 Hz, 1H), 3.32 (tt, J = 11.8, 4.6 Hz, 1H), 2.94 (ddd, J = 17.7, 5.3, 2.1 Hz, 1H), 2.66 
(dtd, J = 14.1, 4.0, 2.2 Hz, 1H), 2.57 (dd, J = 17.7, 11.9 Hz, 1H), 1.95 (dt, J = 14.1, 
11.6 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ (ppm): 168.80, 154.38, 142.06, 133.35, 
131.58, 129.16, 128.66, 110.25, 104.95, 86.03, 34.22, 33.91, 31.21; HRMS (EI) calcd 
for C15H14O3S 274.0664, found 274.0667; HPLC (Chiralpak IC, i-propanol/hexane = 
20/80, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 23.3 min, tR (minor) = 19.0 
min, ee = 91%; [α]25D = -67.7 (c = 0.96 in DCM). 
 
 
(4S,6S)-4-ethyl-6-(phenylthio)tetrahydro-2H-pyran-2-one (6-3jc) (33.4 mg, 71% 
yield); 1H NMR (500 MHz, CDCl3) δ (ppm): 7.58 – 7.56 (m, 2H), 7.35 – 7.32 (m, 3H), 




5.59 (dd, J = 11.2, 4.0 Hz, 1H), 2.68 (ddd, J = 17.5, 5.2, 2.0 Hz, 1H), 2.36 (dtd, J = 
13.9, 4.0, 2.2 Hz, 1H), 2.05 (dd, J = 17.5, 11.6 Hz, 1H), 1.91 – 1.82 (m, 1H), 1.48 (dt, 
J = 13.9, 11.4 Hz, 1H), 1.37 (p, J = 7.3, 2H), 0.93 (t, J = 7.4 Hz, 3H); 13C NMR (125 
MHz, CDCl3) δ (ppm): 170.08, 133.03, 132.12, 129.09, 128.41, 86.39, 35.88, 34.82, 
33.30, 28.67, 10.73; HRMS (EI) calcd for C13H16O2S 236.0871, found 236.0870; 
HPLC (Chiralpak IC, i-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 254 nm): 




(4S,6S)-4-pentyl-6-(phenylthio)tetrahydro-2H-pyran-2-one (6-3kc) (38.2 mg, 69% 
yield); 1H NMR (500 MHz, CDCl3) δ (ppm): 7.57 – 7.55 (m, 2H), 7.34 – 7.32 (m, 3H), 
5.59 (dd, J = 11.3, 4.0 Hz, 1H), 2.67 (ddd, J = 17.4, 5.0, 2.0 Hz, 1H), 2.37 – 2.32 (m, 
2H), 2.05 (dd, J = 17.4, 11.6 Hz, 1H), 1.95 – 1.91 (m, 1H), 1.48 (dt, J = 13.8, 11.4 Hz, 
1H), 1.37 – 1.26 (m, 8H), 0.88 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 
(ppm): 170.11, 133.01, 132.11, 129.09, 128.41, 86.41, 36.21, 35.83, 35.18, 31.69, 
31.62, 25.88, 22.48, 13.96; HRMS (EI) calcd for C16H22O2S 278.1341, found 
278.1341; HPLC (Chiralpak IC, i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 
254 nm): tR (major) = 18.1 min, tR (minor) = 20.7 min, ee = 94%; [α]25D = -20.6 (c = 











(4S,6S)-6-(4-fluorophenylthio)-4-phenyltetrahydro-2H-pyran-2-one (6-3ad) (51.6 
mg, 85% yield); 1H NMR (500 MHz, CDCl3) δ (ppm): 7.62 – 7.59 (m, 2H), 7.36 (dd, 
J = 10.3, 4.7 Hz, 2H), 7.30 – 7.27 (m, 1H), 7.17 – 7.15 (m, 2H), 7.08 – 7.04 (m, 2H), 
5.65 (dd, J = 11.3, 4.1 Hz, 1H), 3.19 (tt, J = 12.0, 4.4 Hz, 1H), 2.88 (ddd, J = 17.7, 5.1, 
2.3 Hz, 1H), 2.56 – 2.50 (m, 2H), 1.96 (ddd, J = 13.9, 12.2, 11.4 Hz, 1H); 13C NMR 
(125 MHz, CDCl3) δ (ppm): 169.42, 164.32, 162.34, 141.42, 136.22, 136.15, 129.08, 
127.54, 126.50, 126.37, 116.42, 116.24, 86.44, 37.40, 37.18, 36.23; HRMS (EI) calcd 
for C17H15O2FS 302.0777, found 302.0777; HPLC (Chiralpak IC, i-propanol/hexane = 
20/80, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 22.7 min, tR (minor) = 16.6 







(4S,6S)-6-(4-chlorophenylthio)-4-phenyltetrahydro-2H-pyran-2-one (6-3ae) (50.6 
mg, 79% yield); 1H NMR (500 MHz, CDCl3) δ (ppm): 7.54 – 7.52 (m, 2H), 7.38 – 
7.31 (m, 4H), 7.29 (d, J = 7.5 Hz, 1H), 7.17 (d, J = 7.5 Hz, 2H), 5.69 (dd, J = 11.3, 4.1 
Hz, 1H), 3.19 (tt, J = 12.3, 4.4 Hz, 1H), 2.89 (ddd, J = 17.7, 5.1, 2.2 Hz, 1H), 2.58 – 
2.52 (m, 2H), 1.98 (dt, J = 13.8, 11.9 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ (ppm): 
169.25, 141.38, 135.09, 134.65, 130.18, 129.36, 129.10, 127.56, 126.37, 86.12, 37.43, 
37.18, 36.26; HRMS (EI) calcd for C17H15O2ClS 318.0481, found 318.0485; HPLC 
(Chiralpak IC, i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR 
(major) = 23.8 min, tR (minor) = 18.0 min, ee = 92%; [α]25D = -90.1 (c = 1.05 in 
DCM). 
 






(53.6 mg, 85% yield); 1H NMR (500 MHz, CDCl3) δ (ppm): 7.56 – 7.53 (m, 2H), 
7.35 (dd, J = 10.3, 4.7 Hz, 2H), 7.28 (dt, J = 3.9, 1.6 Hz, 1H), 7.15 (d, J = 7.2 Hz, 2H), 
6.90 – 6.88 (m, 2H), 5.59 (dd, J = 11.2, 4.1 Hz, 1H), 3.82 (s, 3H), 3.16 (tt, J = 12.0, 
4.5 Hz, 1H), 2.85 (ddd, J = 17.7, 5.1, 2.3 Hz, 1H), 2.53 – 2.45 (m, 2H), 1.94 (ddd, J = 
13.9, 12.3, 11.4 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ (ppm): 169.64, 160.55, 
141.65, 136.44, 129.02, 127.43, 126.39, 121.47, 114.70, 86.71, 55.35, 37.38, 37.20, 
36.26; HRMS (EI) calcd for C18H18O3S 314.0977, found 314.0978; HPLC (Chiralpak 
IC, i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 43.3 




(52.7 mg, 84% yield); 1H NMR (500 MHz, CDCl3) δ (ppm): 7.61 (dd, J = 7.6, 1.6 Hz, 
1H), 7.37 – 7.27 (m, 4H), 7.21 – 7.18 (m, 2H), 6.97 (td, J = 7.5, 1.1 Hz, 1H), 6.91 (d, 
J = 8.2 Hz, 1H), 5.87 (dd, J = 10.9, 4.3 Hz, 1H), 3.89 (s, 3H), 3.20 (tt, J = 12.6, 4.4 
Hz, 1H), 2.88 (ddd, J = 17.5, 5.0, 2.3 Hz, 1H), 2.63 – 2.56 (m, 2H), 2.05 (ddd, J = 
14.0, 12.2, 11.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ (ppm): 169.60, 158.41, 
141.70, 134.40, 129.99, 129.02, 127.40, 126.39, 121.38, 119.91, 111.06, 84.53, 55.89, 
37.39, 37.33, 36.00; HRMS (EI) calcd for C18H18O3S 314.0977, found 314.0979; 




HPLC (Chiralpak IA, i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): 





(54.8 mg, 80% yield); 1H NMR (500 MHz, CDCl3) δ (ppm): 7.35 (dd, J = 10.2, 4.7 
Hz, 2H), 7.30 – 7.25 (m, 2H), 7.19 (dd, J = 8.3, 2.1 Hz, 1H), 7.16 – 7.13 (m, 3H), 
6.85 (d, J = 8.3 Hz, 1H), 5.63 (dd, J = 11.2, 4.2 Hz, 1H), 3.89 (s, 6H), 3.20 – 3.13 (m, 
1H), 2.85 (ddd, J = 17.7, 5.1, 2.3 Hz, 1H), 2.55 – 2.43 (m, 2H), 1.94 (ddd, J = 13.9, 
12.3, 11.3 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ (ppm): 169.58, 150.14, 149.05, 
141.59, 129.03, 127.93, 127.44, 126.38, 121.66, 117.65, 111.44, 86.55, 56.08, 55.93, 
37.33, 37.21, 36.27; HRMS (EI) calcd for C19H20O4S 344.1082, found 344.1081; 
HPLC (Chiralpak IA, i-propanol/hexane = 5/95, flow rate 1.0 mL/min, λ = 254 nm): 




(4S,6S)-6-(phenylthio)-4-styryltetrahydro-2H-pyran-2-one (6-3lc) (46.2 mg, 74% 
yield); 1H NMR (500 MHz, CDCl3) δ (ppm): 7.55 (dd, J = 6.5, 2.9 Hz, 2H), 7.31 – 
7.21 (m, 8H), 6.39 (d, J = 15.9 Hz, 1H), 5.97 (dd, J = 15.9, 7.0 Hz, 1H), 5.63 (dd, J = 




11.2, 4.0 Hz, 1H), 2.82 – 2.72 (m, 2H), 2.42 (ddd, J = 13.9, 6.1, 3.8 Hz, 1H), 2.29 (dd, 
J = 17.2, 11.4 Hz, 1H), 1.72 (dt, J = 13.8, 11.5 Hz, 1H); 13C NMR (125 MHz, CDCl3) 
δ (ppm): 169.21, 136.28, 133.30, 131.71, 130.80, 129.86, 129.15, 128.65, 128.60, 
127.87, 126.23, 86.09, 35.71, 35.11, 35.08; HRMS (EI) calcd for C19H18O2S 310.1028, 
found 310.1035; HPLC (Chiralpak IC, i-propanol/hexane = 20/80, flow rate 1.0 
mL/min, λ = 254 nm): tR (major) = 36.6 min, tR (minor) = 29.6 min, ee = 80%; [α]25D 
= -48.2 (c = 0.78 in DCM). 
 
 
(R)-S-phenyl 5-oxo-3-phenylpentanethioate (6-4ac). 1H NMR (500 MHz, CDCl3) δ 
(ppm): 9.74 (s, 1H), 7.47 – 7.45 (m, 3H), 7.42 – 7.38 (m, 4H), 7.34 – 7.31 (m, 3H), 3.95 
– 3.86 (m, 1H), 3.09 (d, J = 7.2 Hz, 2H), 3.00 – 2.89 (m, 2H); 13C NMR (125 MHz, 
CDCl3) δ (ppm): 200.35, 195.64, 141.83, 134.36, 129.47, 129.16, 128.83, 127.35, 




6.4.4 Condition Optimization for Decarboxylation of MAHTs and Enals 
 
Table 6.5 Screening of additivesa 
 




Entry Additive Yield(%)b ee(%)c Entry Additive Yield(%)b ee(%)c
1 LiOH <20 - 8 PhCOOH - - 
2 NH4OAc <20 - 9 2,6-lutidine 55(6-4ac) 49 
3 NaOAc <20 - 10 Et3N 51(6-3ac) 89 
4 NaHCO3 <20 - 11 TBD 37(6-3ac) 78 
5 Li2CO3 <20 - 12 DABCO 54(6-3ac) 89 
6 Na2CO3 22(6-4ac) 18 13 Quinine 63(6-3ac) 88 
7 Cs2CO3 46(6-4ac+6-3ac) 81/82     
a Reactions were performed with cinnamaldehyde 6-1a (0.20 mmol), MAHT 6-2c (0.24 mmol), 
additive (0.20 mmol) and catalyst 6-VI (0.04 mmol) in the DCM (1.0 mL) at RT. b Isolated yield 
after column chromatography. c Determined by HPLC analysis. 
 
Table 6.6 Optimization of the reaction conditionsa 
 
Entry Solvent T/oC TEA(equiv.) 6-1a:6-2c Yield(%)b ee(%)c 
1 DCM RT 1.0 1.0:1.2 51 89 
2 DCE RT 1.0 1.0:1.2 53 78 
3 CHCl3 RT 1.0 1.0:1.2 55 52 
4 Toluene RT 1.0 1.0:1.2 53 81 
5 Xylenes RT 1.0 1.0:1.2 50 82 
6 Anisole RT 1.0 1.0:1.2 52 80 
7 THF RT 1.0 1.0:1.2 47 84 
8 IPA RT 1.0 1.0:1.2 47 89 
9 EA RT 1.0 1.0:1.2 52 81 
10 DMF RT 1.0 1.0:1.2 <10 - 
11 DEGEE RT 1.0 1.0:1.2 - - 
12 Acetone RT 1.0 1.0:1.2 54 83 
13 DCM 40 1.0 1.0:1.2 46(6-4ac) 84 




14 DCM RT 1.0 2.0:1.0 45 44 
15 DCM RT 1.0 1.0:2.5 - 55 
16 DCM RT 2.5 1.0:2.5 57 89 
17 DCM RT 4.0 1.0:2.5 - - 
18 DCM RT 0.2 1.0:2.5 - - 
19d DCM RT 2.5 1.0:2.5 82 71 
20e DCM RT 2.5 1.0:2.5 81 86 
21f DCM RT 2.5 1.0:2.5 76 86 
22e DCM 0 2.5 1.0:2.5 82 92 
23e DCM -20 2.5 1.0:2.5 <10 - 
24e,g DCM 0 2.5 1.0:2.5 <10 - 
a Reactions were performed with cinnamaldehyde 6-1a (0.20 mmol), MAHT 6-2c, TEA and 
catalyst 6-VI (0.04 mmol) in the solvent (1.0 mL). b Isolated yield after column chromatography. c 
Determined by HPLC analysis. d TEA (69.6 uL) in 0.50 mL DCM was added dropwise in 1 hour. e 
TEA (69.6 uL) in 0.50 mL DCM was added dropwise in 10 min. f TEA (69.6 uL) in 0.50 mL DCM 
was added dropwise in 5 min. g 60.0 mg MS was added into the reaction mixture. 
 
6.4.5 Representative Procedure for Decarboxylation of MAHTs and Enones 
 
To a solution of trans-4-Phenyl-3-buten-2-one 6-5a (29.2 mg, 0.2 mmol,) and 
catalyst 6-VII (12.9 mg, 0.04 mmol) in THF (1.0 mL) at room temperature, was 
added malonic acid half thioester 6-2c (98.1 mg, 0.5 mmol) in one portion. The 
reaction mixture was kept stirring at room temperature for 24 h. The crude product 
was purified by silica gel flash chromatography, eluted by hexane/EtOAc = 10:1 to 
afford the desired product 6-6ac as colorless oil (48.3 mg, 81% yield). 
 
 




6.4.6 Analytical Data for Decarboxylation of MAHTs and Enones 
 
(R)-S-phenyl 5-oxo-3-phenylhexanethioate (6-6ac) (48.3 mg, 81% yield); 1H NMR 
(500 MHz, CDCl3) δ (ppm): 7.40 – 7.36 (m, 3H), 7.33 – 7.29 (m, 4H), 7.24 – 7.21 (m, 
3H), 3.77 (p, J = 7.2 Hz, 1H), 3.04 – 2.81 (m, 4H), 2.06 (s, 3H); 13C NMR (125 MHz, 
CDCl3) δ (ppm): 206.53, 195.84, 142.40, 134.37, 129.37, 129.12, 128.65, 127.49, 
127.36, 126.96, 49.36, 48.90, 37.81, 30.34; HRMS (ESI) calcd for C18H18O2SNa+ [M 
+ Na+] 321.0920, found 321.0929; HPLC (Chiralpak IC, i-propanol/hexane = 20/80, 
flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 15.6 min, tR (minor) = 20.5 min, ee = 
97%; [α]25D = -74.2 (c = 1.01 in DCM). 
 
 
(R)-S-phenyl 3-(4-fluorophenyl)-5-oxohexanethioate (6-6bc) (48.1 mg, 76% yield); 
1H NMR (500 MHz, CDCl3) δ (ppm): 7.42 – 7.36 (m, 3H), 7.33 – 7.27 (m, 2H), 7.23 
– 7.17 (m, 2H), 6.99 (t, J = 8.6 Hz, 2H), 3.76 (p, J = 7.2 Hz, 1H), 3.02 – 2.78 (m, 4H), 
2.06 (s, 3H); 13C NMR (125 MHz, CDCl3) δ (ppm): 206.25, 195.70, 162.66, 160.72, 
138.12, 138.10, 134.34, 129.45, 129.17, 128.96, 128.90, 127.36, 115.54, 115.38, 
49.34, 48.96, 37.04, 30.35; HRMS (ESI) calcd for C18H17O2FSNa+ [M + Na+] 
339.0825, found 339.0831; HPLC (Chiralpak IC, i-propanol/hexane = 20/80, flow 
rate 1.0 mL/min, λ = 254 nm): tR (major) = 9.9 min, tR (minor) = 14.5 min, ee = 97%; 
[α]25D = -77.1 (c = 0.90 in DCM). 





(R)-S-phenyl 3-(4-isopropylphenyl)-5-oxohexanethioate (6-6cc) (59.2 mg, 87% 
yield); 1H NMR (500 MHz, CDCl3) δ (ppm): 7.38 – 7.36 (m, 3H), 7.30 (dd, J = 6.6, 
3.0 Hz, 2H), 7.17 – 7.13 (m, 4H), 3.74 (p, J = 7.2 Hz, 1H), 3.02 – 2.80 (m, 5H), 2.06 
(s, 3H), 1.24 (d, J = 6.9 Hz, 6H); 13C NMR (125 MHz, CDCl3) δ (ppm): 206.73, 
195.99, 147.45, 139.72, 134.39, 129.35, 129.12, 127.60, 127.23, 126.66, 49.49, 49.02, 
37.44, 33.65, 30.31, 23.94, 23.91; HRMS (ESI) calcd for C21H24O2SNa+ [M + Na+] 
363.1389, found 363.1407; HPLC (Chiralpak IC, i-propanol/hexane = 20/80, flow 
rate 1.0 mL/min, λ = 254 nm): tR (major) = 11.3 min, tR (minor) = 16.9 min, ee = 97%; 
[α]25D = -64.2 (c = 1.23 in DCM). 
 
 
(R)-S-phenyl 3-(4-(allyloxy)phenyl)-5-oxohexanethioate (6-6dc) (50.4 mg, 71% 
yield); 1H NMR (500 MHz, CDCl3) δ (ppm): 7.41 – 7.34 (m, 2H), 7.33 – 7.27 (m, 2H), 
7.17 – 7.11 (m, 2H), 6.89 – 6.83 (m, 2H), 6.05 (ddt, J = 17.2, 10.5, 5.3 Hz, 1H), 5.40 
(ddd, J = 17.2, 3.1, 1.5 Hz, 1H), 5.28 (ddd, J = 10.5, 2.6, 1.3 Hz, 1H), 4.51 (dt, J = 5.3, 
1.4 Hz, 2H), 3.71 (p, J = 7.2 Hz, 1H), 3.00 – 2.77 (m, 4H), 2.04 (s, 3H); 13C NMR 
(125 MHz, CDCl3) δ (ppm): 206.70, 195.90, 157.48, 134.59, 134.37, 133.28, 129.35, 
129.11, 128.34, 127.55, 117.58, 114.84, 68.79, 49.60, 49.12, 37.15, 30.35; HRMS 
(ESI) calcd for C21H22O3SNa+ [M + Na+] 377.1182, found 377.1191; HPLC 
(Chiralpak IC, i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR 








(R)-S-phenyl 3-(3-methoxyphenyl)-5-oxohexanethioate (6-6ec) (49.2 mg, 75% 
yield); 1H NMR (500 MHz, CDCl3) δ (ppm): 7.39 – 7.37 (m, 3H), 7.32 – 7.30 (m, 2H), 
7.23 (dd, J = 8.8, 7.7 Hz, 1H), 6.82 (d, J = 7.8 Hz, 1H), 6.77 (dd, J = 3.8, 1.5 Hz, 2H), 
3.80 (s, 3H), 3.74 (p, J = 7.2 Hz, 1H), 3.01 – 2.80 (m, 4H), 2.06 (s, 3H); 13C NMR 
(125 MHz, CDCl3) δ (ppm): 206.51, 195.84, 159.78, 144.13, 134.40, 129.69, 129.40, 
129.15, 127.55, 119.62, 113.38, 112.18, 55.19, 49.32, 48.87, 37.84, 30.36; HRMS 
(ESI) calcd for C19H20O3SNa+ [M + Na+] 351.1025, found 351.1009; HPLC 
(Chiralpak IC, i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR 
(major) = 25.2 min, tR (minor) = 27.1 min, ee = 97%; [α]25D = -69.5 (c = 0.96 in 
DCM). 
 
(R)-S-phenyl 3-(4-(benzyloxy)phenyl)-5-oxohexanethioate (6-6fc) (63.1mg, 78% 
yield); 1H NMR (500 MHz, CDCl3) δ (ppm): 7.44 – 7.42 (m, 2H), 7.39 – 7.37 (m, 5H), 
7.34 – 7.29 (m, 3H), 7.15 (d, J = 8.6 Hz, 2H), 6.93 (d, J = 8.6 Hz, 2H), 5.04 (s, 2H), 
3.72 (p, J = 7.2 Hz, 1H), 3.00 – 2.78 (m, 4H), 2.05 (s, 3H); 13C NMR (125 MHz, 
CDCl3) δ (ppm): 206.68, 195.90, 157.69, 136.99, 134.72, 134.37, 129.36, 129.13, 
128.54, 128.39, 127.92, 127.55, 127.45, 114.97, 70.00, 49.60, 49.12, 37.15, 30.36; 




HRMS (ESI) calcd for C25H24O3SNa+ [M + Na+] 427.1338, found 427.1324; HPLC 
(Chiralpak IC, i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR 




(R)-S-phenyl 3-(furan-2-yl)-5-oxohexanethioate (6-6gc) (49.0mg, 85% yield); 1H 
NMR (500 MHz, CDCl3) δ (ppm): 7.40 – 7.38 (m, 3H), 7.37 – 7.34 (m, 2H), 7.32 (dd, 
J = 1.8, 0.8 Hz, 1H), 6.28 (dd, J = 3.2, 1.9 Hz, 1H), 6.07 (d, J = 3.2 Hz, 1H), 3.86 (p, 
J = 6.9 Hz, 1H), 3.06 – 2.97 (m, 2H), 2.92 – 2.83 (m, 2H), 2.11 (s, 3H); 13C NMR 
(125 MHz, CDCl3) δ (ppm): 206.21, 195.64, 155.15, 141.47, 134.41, 129.45, 129.18, 
127.46, 110.23, 105.73, 46.54, 46.20, 31.38, 30.16; HRMS (ESI) calcd for 
C16H16O3SNa+ [M + Na+] 311.0712, found 311.0716; HPLC (Chiralpak IC, 
i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 16.2 min, 
tR (minor) = 39.8 min, ee = 98%; [α]25D = -43.7 (c = 1.13 in DCM). 
 
(R)-S-phenyl 5-oxo-3-(thiophen-2-yl)hexanethioate (6-6hc) (46.3 mg, 76% yield); 
1H NMR (500 MHz, CDCl3) δ (ppm): 7.40 – 7.38 (m, 3H), 7.35 – 7.33 (m, 2H), 7.16 
(d, J = 5.0 Hz, 1H), 6.92 (dd, J = 5.0, 3.5 Hz, 1H), 6.88 (d, J = 3.2 Hz, 2H), 4.09 (p, J 
= 6.9 Hz, 1H), 3.08 – 2.99 (m, 2H), 2.98 – 2.86 (m, 2H), 2.10 (s, 3H); 13C NMR (125 
MHz, CDCl3) δ (ppm): 206.07, 195.59, 145.90, 134.41, 129.46, 129.18, 127.41, 




126.76, 124.54, 123.66, 49.87, 49.58, 33.14, 30.35; HRMS (ESI) calcd for 
C16H16O2S2Na+ [M + Na+] 327.0484, found 327.0488; HPLC (Chiralpak IC, 
i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 14.6 min, 
tR (minor) = 23.0 min, ee = 97%; [α]25D = -56.5 (c = 1.05 in DCM). 
 
 
(R)-S-phenyl 3-methyl-5-oxohexanethioate (6-6ic) (36.9 mg, 78% yield); 1H NMR 
(500 MHz, CDCl3) δ (ppm): 7.40 (br, 5H), 2.68 (ddd, J = 8.5, 6.3, 2.7 Hz, 1H), 2.58 
(ddd, J = 12.4, 11.4, 5.9 Hz, 3H), 2.40 – 2.34 (m, 1H), 2.13 (s, 3H), 1.03 (d, J = 6.1 
Hz, 3H); 13C NMR (125 MHz, CDCl3) δ (ppm): 207.50, 196.46, 134.38, 129.37, 
129.16, 127.73, 49.55, 30.30, 29.65, 27.01, 19.79; HRMS (ESI) calcd for 
C13H16O2SNa+ [M + Na+] 259.0763, found 259.0761; HPLC (Chiralpak ID, 
i-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 10.4 min, 
tR (minor) = 9.5 min, ee = 97%; [α]25D = -5.7 (c = 0.90 in DCM). 
 
(R)-S-phenyl 3-methyl-5-oxoheptanethioate (6-6jc) (35.1 mg, 70% yield); 1H NMR 
(500 MHz, CDCl3) δ (ppm): 7.40 (br, 5H), 2.71 – 2.66 (m, 1H), 2.63 – 2.52 (m, 3H), 
2.45 – 2.33 (m, 3H), 1.04 (dd, J = 12.8, 6.6 Hz, 6H); 13C NMR (125 MHz, CDCl3) δ 
(ppm): 210.22, 196.53, 134.42, 129.38, 129.18, 127.81, 49.68, 48.28, 36.37, 27.15, 
19.90, 7.71; HRMS (ESI) calcd for C14H18O2SNa+ [M + Na+] 273.0920, found 




273.0920; HPLC (Chiralpak IC, i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 




(R)-S-4-chlorophenyl 5-oxo-3-phenylhexanethioate (6-6ae) (48.6 mg, 73% yield); 
1H NMR (500 MHz, CDCl3) δ (ppm): 7.35 – 7.30 (m, 4H), 7.24 – 7.20 (m, 5H), 3.76 
(p, J = 7.2 Hz, 1H), 2.98 (qd, J = 15.1, 7.2 Hz, 2H), 2.87 (qd, J = 16.9, 7.1 Hz, 2H), 
2.06 (s, 3H); 13C NMR (125 MHz, CDCl3) δ (ppm): 206.46, 195.34, 142.30, 135.81, 
135.60, 129.38, 128.70, 127.36, 127.04, 125.95, 49.40, 48.92, 37.80, 30.37; HRMS 
(ESI) calcd for C18H17O2ClSNa+ [M + Na+] 355.0530, found 355.0547; HPLC 
(Chiralpak IC, i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR 




(R)-S-2-methoxyphenyl 5-oxo-3-phenylhexanethioate (6-6ag) (52.6 mg, 80% yield); 
1H NMR (500 MHz, CDCl3) δ (ppm): 7.30 (td, J = 8.4, 1.6 Hz, 1H), 7.26 – 7.11 (m, 
6H), 6.86 (dd, J = 14.6, 7.9 Hz, 2H), 3.73 – 3.65 (m, 4H), 2.94 – 2.73 (m, 4H), 1.95 (s, 
3H); 13C NMR (125 MHz, CDCl3) δ (ppm): 206.59, 195.06, 159.08, 142.54, 136.53, 




131.61, 128.56, 127.36, 126.82, 121.00, 115.74, 111.51, 55.84, 49.12, 48.83, 37.87, 
30.29; HRMS (ESI) calcd for C19H20O3SNa+ [M + Na+] 351.1025, found 351.1035; 
HPLC (Chiralpak ID, i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): 
tR (major) = 15.4 min, tR (minor) = 17.3 min, ee = 98%; [α]25D = -66.4 (c = 1.15 in 
DCM). 
 
(R)-S-3,4-dimethoxyphenyl 5-oxo-3-phenylhexanethioate (6-6ah) (50.9 mg, 71% 
yield); 1H NMR (500 MHz, CDCl3) δ (ppm): 7.31 – 7.28 (m, 2H), 7.21 (dd, J = 10.9, 
4.4 Hz, 3H), 6.86 (d, J = 2.5 Hz, 2H), 6.76 (s, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 3.76 (p, 
J = 7.1 Hz, 1H), 3.00 – 2.80 (m, 4H), 2.05 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
(ppm): 206.53, 196.85, 150.22, 149.15, 142.46, 128.60, 127.60, 127.38, 126.90, 
118.37, 117.23, 111.49, 55.92, 55.84, 49.11, 48.92, 37.82, 30.32; HRMS (ESI) calcd 
for C20H22O4SNa+ [M + Na+] 381.1131, found 381.1140; HPLC (Chiralpak IA, 
i-propanol/hexane = 10/90, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 20.0 min, 
tR (minor) = 22.2 min, ee = 96%; [α]25D = -70.3 (c = 0.95 in DCM). 
 
(R)-S-phenyl 2-(3-oxocyclopentyl)ethanethioate (6-6kc) (29.1 mg, 62% yield); 1H 
NMR (500 MHz, CDCl3) δ (ppm): 7.43 – 7.40 (m, 5H), 2.85 – 2.75 (m, 2H), 2.75 – 
2.65 (m, 1H), 2.51 (dd, J = 18.3, 7.7 Hz, 1H), 2.36 – 2.15 (m, 3H), 1.94 (dd, J = 18.4, 
9.8 Hz, 1H), 1.70 – 1.61 (m, 1H); 13C NMR (125 MHz, CDCl3) δ (ppm): 217.75, 
195.86, 134.40, 129.56, 129.27, 127.36, 48.58, 44.37, 38.16, 33.97, 29.12; HRMS 




(ESI) calcd for C13H14O2SNa+ [M + Na+] 257.0607, found 257.0609; HPLC 
(Chiralpak IC, i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR 
(major) = 27.0 min, tR (minor) = 32.6 min, ee = 80%; [α]25D = -73.0 (c = 0.86 in 
DCM). 
 
(R)-S-phenyl 3-(4-bromophenyl)-5-oxohexanethioate (6-6lc). (55.5 mg, 74% yield); 
1H NMR (500 MHz, CDCl3) δ (ppm): 7.44 – 7.38 (m, 5H), 7.31 – 7.29 (m, 2H), 7.11 
(d, J = 8.2 Hz, 2H), 3.73 (p, J = 7.2 Hz, 1H), 3.01 – 2.77 (m, 4H), 2.06 (s, 3H); 13C 
NMR (125 MHz, CDCl3) δ (ppm): 206.05, 195.59, 141.49, 134.36, 131.74, 129.49, 
129.19, 127.30, 120.75, 48.99, 48.69, 37.12, 30.35; HRMS (ESI) calcd for 
C18H17O2BrSNa+ [M + Na+] 399.0025, found 399.0036; HPLC (Chiralpak IC, 
i-propanol/hexane = 20/80, flow rate 1.0 mL/min, λ = 254 nm): tR (major) = 9.8 min, 
tR (minor) = 14.7 min, ee = 97%; [α]25D = -87.3 (c = 0.93 in DCM) 
 
6.4.7 Condition Optimization for Decarboxylation of MAHTs and Enones 
 
Table 6.7 Optimization of the reaction conditionsa 
 
 
Entry Solvent Yield (%)b ee(%)c Entry Solvent Yield (%)b ee(%)c
1 DCM 65 90 10 IPA 44 84 




2 DCE 56 88 11 CH3CN 52 57 
3 Toluene 54 92 12 DMF <10 - 
4 Xylenes 52 90 13 1,4-Dioxane 53 98 
5 CF3Ph 52 84 14 THF 76 97 
6 Anisole 63 95 15 CPME 76 96 
7 Anisole <10 - 16 Et2O 76 93 
8 EA 68 95 17e THF 81 97 
9 EAd <10 -     
a Reactions were conducted with trans-4-Phenyl-3-buten-2-one 6-5a (0.2 mmol), MAHT 6-2c (0.24 
mmol), catalyst 6-VII (0.04 mmol) in the solvent (1.0 mL) at RT for 24 h. b Isolated yield. c 
Determined by HPLC analysis. d 0oC. e MAHT 6-2c (0.5 mmol). 
 
6.4.8 Mechanistic Investigations 
 
490.6 mg (2.5 mmol) of malonic acid half thioester (MAHT) 6-2c was placed 
into a 50 mL flask and 5.0 mL of acetonitrile was added. When the MAHT 6-2c has 
dissolved, 6.0 mL D2O was added and the solution was stirred for 6 hours under 
nitrogen. The solvent was removed under vaccum and the process was repeated two 
more times to yield 473.2 mg (95% yield) of the product d-6-2c.190 1H NMR (500 
MHz, CDCl3) δ (ppm): 7.46 – 7.42 (m, 5H), 3.70 (s, 0.2H); 13C NMR (125 MHz, 




190 See Ref. 88c.  




To a solution of cinnamaldehyde 6-1a (66.1 mg, 62.9 uL, 0.5 mmol) in CH3CN 
(2.5 mL) was added catalyst 6-VI (64.0 mg, 0.1 mmol) at 0 °C. After 40 min, d-6-2c 
(249.0 mg, 1.25 mmol) was added in one portion. Then, TEA (126.2 mg, 173.9 uL, 
1.25 mmol) was added dropwise at 0 °C. The resulting reaction mixture was kept 
stirring at 0°C for 24 h. The crude product was purified by silica gel flash 
chromatography, eluted by hexane/EtOAc = 10:1 to afford the desired product 
d-6-3ac as white solid (89.1 mg, 62% yield). 1H NMR (500 MHz, CDCl3) δ(ppm): 
7.60 (dd, J = 6.4, 3.2 Hz, 2H), 7.40 – 7.32 (m, 5H), 7.28 (t, J = 7.4 Hz, 1H), 7.16 (d, J 
= 7.6 Hz, 2H), 5.74 (dd, J = 11.2, 4.0 Hz, 1H), 3.23 – 3.14 (m, 1H), 2.88 (dd, J = 17.7, 
5.0 Hz, 0.49H), 2.59 – 2.49 (m, 1H), 2.04 – 1.97 (m, 0.49H); 13C NMR (125 MHz, 
CDCl3) δ (ppm): 169.48, 141.54, 133.27, 131.79, 129.16, 129.05, 128.61, 127.47, 
126.38, 86.34, 86.30, 86.26, 86.22, 37.36, 37.27, 37.17, 36.31. 
 
6.4.9 Methodology Application 
Synthesis of 3,4-Dihydro-2H-pyran-2-one (enol lactone) 6-13191 
 
m-CPBA (28.5 mg; 0.165 mmol) was added to a solution of 6-3ac (42.7 mg, 0.15 
mmol) in CH2Cl2 (5.0 mL) at 0 °C with stirring. The mixture was stirred at 0 °C for 
10 min and the reaction was quenched by adding saturated aq Na2SO3 (5 mL) and 
NaHCO3 (30 mL). The mixture was extracted with CH2Cl2 (3 × 20 mL) and the 
combined organic layers were dried with MgSO4. Filtration and evaporation of the 
solvent gave a residue which was purified by silica gel column chromatography 
(hexane–EtOAc = 3:1) to afford a mixture of two diastereomers. Then, the mixture 
was added into 1.0 mL CCl4. The reaction mixture was refluxed for overnight. The 
                                                              
191  a) Ochiai, M.; Nishide, K.; Node, M.; Fujita, E. Chem. Lett. 1981, 283; b) Shimizu, H.; Fukuda, S.; Sugiyama, 
S.; Satoh, T. Synthesis 2009, 8, 1323.  




crude product was purified by silica gel column chromatography (hexane–EtOAc = 
20:1) to afford the desired product 6-13 as a colourless oil (14.6 mg, 56% overall 
yield, 92% ee). 1H NMR (500 MHz, CDCl3) δ = 7.35 (dd, J = 10.2, 4.6 Hz, 2H), 7.30 
– 7.26 (m, 1H), 7.24 – 7.19 (m, 2H), 6.68 (dd, J = 6.0, 1.8 Hz, 1H), 5.44 (dd, J = 5.9, 
4.1 Hz, 1H), 3.83 – 3.79 (m, 1H), 2.98 (dd, J = 16.0, 6.9 Hz, 1H), 2.74 (dd, J = 15.9, 
8.3 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ = 167.29, 141.65, 141.16, 129.09, 127.52, 
126.82, 109.39, 37.31, 36.73; HRMS (EI) calcd for C11H10O2 174.0681, found 
174.0682; HPLC (Chiralpak AD-H, i-propanol/hexane = 2/98, flow rate 1.0 mL/min, 
λ = 254 nm): tR (minor) = 12.7 min, tR (major) = 14.1 min, ee = 92%; [α]25D = -20.1 (c 
= 0.51 in DCM). 
 
Synthesis of δ-lactone 6-14 
 
Compound 6-3ac (227.0mg, 0.8 mmol) was added to a suspension of Raney Ni 
(1.0 g) in absolute EtOH (10 mL). The mixture was stirred for overnight at room 
temperature, before the Raney Ni was removed by filtration through a celite pad. Then 
the catalyst was washed with absolute EtOH (3 × 10 mL) and the filtrate was 
concentrated under reduced pressure. The crude product was purified by silica gel 
column chromatography (hexane–EtOAc = 10:1) to afford the intermediate γ-ester 
aldehyde as a colourless oil (142.1 mg, 81% yield). 1H NMR (500 MHz, CDCl3) δ = 
9.65 (d, J = 1.6 Hz, 1H), 7.32 – 7.27 (m, 2H), 7.25 – 7.18 (m, 3H), 4.06 – 4.02 (m, 
2H), 3.73 (p, J = 7.4 Hz, 1H), 2.87 – 2.74 (m, 2H), 2.72 – 2.59 (m, 2H), 1.15 (t, J = 
7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ = 200.67, 171.44, 142.35, 128.67, 127.19, 
126.97, 60.44, 49.32, 40.84, 36.16, 13.99; HRMS (EI) calcd for C13H16O3 220.1099, 
found 220.1108.  




Sodium borohydride (5.7 mg, 0.15 mmol) was added into a solution of 
compound γ-ester aldehyde (22.0 mg, 0.10 mmol) in MeOH (1.0 mL) at 0oC. The 
reaction mixture was stirred at RT for 30 min. Then water (0.5 mL) was added to 
quench this reaction. The mixture was extracted with CH2Cl2 and the combined 
organic layers were dried with MgSO4. Filtration and evaporation of the solvent gave 
a residue which was purified by silica gel column chromatography (hexane–EtOAc = 
4:1) to yield a colourless oil. Then this colourless oil was directly dissolved in 5.0 mL 
CHCl3, followed by adding trifluoroacetic acid (38.3 uL, 0.50 mmol). The reaction 
mixture was stirred at room temperature for 1 hour and the reaction was quenched by 
adding saturated NaHCO3 (10 mL). The mixture was extracted with CH2Cl2 (3 × 20 
mL) and the combined organic layers were dried with MgSO4. Filtration and 
evaporation of the solvent gave a residue which was purified by silica gel column 
chromatography (hexane–EtOAc = 4:1) to afford the product δ-lactone 6-14 as a 
colourless oil (13.5 mg, 77% yield, 92% ee). 1H NMR (500 MHz, CDCl3) δ = 7.29 
(dd, J = 10.3, 4.7 Hz, 2H), 7.22 – 7.18 (m, 1H), 7.17 – 7.13 (m, 2H), 4.43 (ddd, J = 
11.4, 4.7, 4.2 Hz, 1H), 4.35 – 4.29 (m, 1H), 3.20 – 3.14 (m, 1H), 2.85 (ddd, J = 17.6, 
6.0, 1.6 Hz, 1H), 2.57 (dd, J = 17.6, 10.6 Hz, 1H), 2.11 (dqd, J = 13.9, 4.0, 1.6 Hz, 
1H), 1.97 (dtd, J = 14.2, 10.5, 4.9 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ = 170.61, 
142.75, 128.95, 127.20, 126.42, 68.58, 37.45, 37.41, 30.28; HRMS (EI) calcd for 
C11H12O2 176.0837, found 176.0834; HPLC (Chiralpak AS-H, i-propanol/hexane = 
30/70, flow rate 0.6 mL/min, λ = 254 nm): tR (major) = 32.7 min, tR (minor) = 39.5 
min, ee = 92%; [α]25D = -10.8 (c = 1.00 in DCM). 
 
Synthesis of (-)-Paroxetine 
 
CHO



















To a solution of 4-fluorocinnamaldehyde 6-1m (300.1 mg, 2.0 mmol,) in DCM 
(5.0 mL) was added catalyst 6-VI (238.8 mg, 0.4 mmol) at 0 °C. After 40 min, 
malonic acid half thioester 6-2c (981.1 mg, 5.0 mmol) was added in one portion. Then, 
TEA (695.6 uL, 5.0 mmol) in 5.0 mL DCM was added dropwise via syringe at 0 °C. 
The resulting reaction mixture was kept stirring at 0°C for 24 h. The crude product 
was purified by silica gel flash chromatography, eluted by hexane/EtOAc = 10:1 to 
afford the desired product 6-3mc as a white solid (436.2 mg, 72% yield, 91% ee).1H 
NMR (500 MHz, CDCl3) δ = 7.59 (dd, J = 6.2, 2.8 Hz, 2H), 7.39 – 7.33 (m, 3H), 7.13 
(dd, J = 8.5, 5.3 Hz, 2H), 7.04 (t, J = 8.6 Hz, 2H), 5.72 (dd, J = 11.2, 4.1 Hz, 1H), 
3.18 (ddd, J = 12.3, 8.4, 4.5 Hz, 1H), 2.87 (ddd, J = 17.6, 5.0, 2.1 Hz, 1H), 2.57 – 
2.46 (m, 2H), 1.97 (dd, J = 25.7, 11.8 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ = 
169.19, 162.98, 161.02, 137.33, 137.30, 133.35, 131.68, 129.21, 128.70, 127.96, 
127.90, 116.05, 115.88, 86.23, 37.38, 36.80, 36.42; HRMS (EI) calcd for C17H15FO2S 
302.0777, found 302.0771; HPLC (Chiralpak IC, i-propanol/hexane = 20/80, flow 
rate 1.0 mL/min, λ = 254 nm): tR (minor) = 23.4 min, tR (major) = 25.8 min, ee = 91%; 
[α]25D = -78.2 (c = 1.51 in DCM). 
 
Compound 6-3mc (302.36mg, 1.0 mmol) was added to a suspension of Raney Ni 
(0.3 g) in absolute MeOH (5.0 mL). The mixture was stirred for 10 hours at room 
temperature, before the Raney Ni was removed by filtration through a celite pad. Then 
the catalyst was washed with absolute MeOH (3 × 10 mL) and the filtrate was 
concentrated under reduced pressure. The crude product was purified by silica gel 
column chromatography (hexane–EtOAc = 6:1) to afford the compound 6-15 as a 
colourless oil (156.1 mg, 70% yield). 1H NMR (300 MHz, CDCl3) δ = 9.64 (t, J = 1.5 
Hz, 1H), 7.23 – 7.12 (m, 2H), 7.03 – 6.94 (m, 2H), 3.78 – 3.68 (m, 1H), 3.58 (s, 3H), 




2.88 – 2.71 (m, 2H), 2.71 – 2.56 (m, 2H); 13C NMR (75 MHz, CDCl3) δ = 200.26, 
171.75, 163.29, 160.04, 138.10, 138.06, 128.77, 128.66, 115.68, 115.40, 51.62, 49.37, 
40.62, 35.30; HRMS (EI) calcd for C12H13FO3 224.0849, found 224.0841. 
 
 
Sodium borohydride (11.3 mg, 0.3 mmol) was added into a solution of 
compound 6-15 (44.8 mg, 0.20 mmol) in MeOH (2.0 mL) at 0 oC. The reaction 
mixture was stirred at 0 oC for 10 min. Then water (1 mL) was added to quench this 
reaction. The mixture was extracted with CH2Cl2 and the combined organic layers 
were dried with MgSO4. Filtration and evaporation of the solvent gave a residue 
which was purified by silica gel column chromatography (hexane–EtOAc = 3:1) to 
afford the product 6-16 as a colourless oil (39.4 mg, 87% yield, 94% ee). 1H NMR 
(500 MHz, CD3OD) δ = 7.25 – 7.22 (m, 2H), 7.02 – 6.99 (m, 2H), 3.54 (s, 3H), 3.42 
(ddd, J = 11.0, 6.9, 5.3 Hz, 1H), 3.37 – 3.32 (m, 1H), 3.31 – 3.24 (m, 1H), 2.70 (dd, J 
= 15.2, 6.4 Hz, 1H), 2.59 (dd, J = 15.2, 9.0 Hz, 1H), 1.94 – 1.87 (m, 1H), 1.82 – 1.76 
(m, 1H); 13C NMR (125 MHz, CD3OD) δ = 174.28, 163.98, 162.05, 140.78, 140.76, 
130.34, 130.28, 116.14, 115.96, 60.47, 51.93, 42.30, 39.88, 39.27; HRMS (EI) calcd 
for C12H15FO3 226.1005, found 226.0999; HPLC (Chiralpak OB-H, 
i-propanol/hexane = 10/90, flow rate 0.8 mL/min, λ = 254 nm): tR (major) = 11.1 min, 








6.4.10 X-ray Crystallographic Analysis 
Table 6.8 Crystal data and structure refinement for 6-3ac. 
Empirical formula  C17 H16 O2 S 
Formula weight  284.36 
Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 8.9700(6) Å a= 90°. 
 b = 6.0133(4) Å b= 95.276(2)°. 
 c = 28.3443(18) Å g = 90°. 
Volume 1522.39(17) Å3 
Z 4 
Density (calculated) 1.241 Mg/m3 
Absorption coefficient 0.211 mm-1 
F(000) 600 
Crystal size 0.54 x 0.50 x 0.36 mm3 
Theta range for data collection 0.72 to 27.47° 
Index ranges -7<=h<=11, -7<=k<=7, -36<=l<=36 
Reflections collected 10737 
Independent reflections 6647 [R(int) = 0.0233] 
Completeness to theta = 27.47° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9280 and 0.8946 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6647 / 196 / 404 
Goodness-of-fit on F2 1.029 
Final R indices [I>2sigma(I)] R1 = 0.0708, wR2 = 0.1707 
R indices (all data) R1 = 0.0850, wR2 = 0.1821 
Absolute structure parameter 0.09(11) 
Largest diff. peak and hole 0.545 and -0.246 e.Å-3 





Figure 6.2 X-ray crystal structure of 6-3ac 
 
Table 6.9 Crystal data and structure refinement for 6-6lc. 
Empirical formula  C18 H17 Br O2 S 
Formula weight  377.29 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 5.6074(6) Å a= 90°. 
 b = 14.7841(16) Å b= 90°. 
 c = 20.027(2) Å g = 90°. 
Volume 1660.2(3) Å3 
Z 4 
Density (calculated) 1.509 Mg/m3 
Absorption coefficient 2.606 mm-1 
F(000) 768 
Crystal size 0.56 x 0.24 x 0.10 mm3 
Theta range for data collection 2.03 to 27.50° 
Index ranges -7<=h<=7, -18<=k<=19, -26<=l<=24 
Reflections collected 11718 
Independent reflections 3802 [R(int) = 0.0359] 




Completeness to theta = 27.50° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7806 and 0.3232 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3802 / 0 / 200 
Goodness-of-fit on F2 1.016 
Final R indices [I>2sigma(I)] R1 = 0.0290, wR2 = 0.0599 
R indices (all data) R1 = 0.0320, wR2 = 0.0608 
Absolute structure parameter 0.018(7) 
Largest diff. peak and hole 0.613 and -0.289 e.Å-3 
 
 
Figure 6.3 X-ray crystal structure of 6-6lc. 
 
